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1 
                                            INTRODUCTION 
 Anaemia is one of the common blood disorders. It refers to the reduction in red 
blood cell count, haemoglobin contents, packed cell volume. Basically it is a condition 
when the haemoglobin content of blood decrease below normal level1. 
 Generally, Anaemia occurs because of decrease in the production of RBC, 
increased destruction of RBC and excess loss of blood from the body. Iron deficiency 
anaemia is the most common type of anaemia. It develops due to inadequate availability 
of iron for haemoglobin synthesis. Causes of Iron deficiency anaemia are loss of blood, 
decreased intake of iron, poor absorption of iron from intestine, increase in demand for 
iron in conditions like growth and pregnancy. Iron deficiency anaemia is the most 
common form of nutritional deficiency affecting adults in rural as well as urban area. In 
different age group who are subjected to numerous stress which affects their health and 
well being1. 
 The WHO estimates that more than 1/3rd of the world population is Anaemic, of 
which Iron deficiency anaemia is the most common and serious problem of public health 
significance. In India Prevalence of Anaemia is the highest in the world but within the 
country prevalence rates differ substantially between different regions2. 
 Globally, Anaemia affects 1.62 million people which corresponds to 24.8% of the 
Population. The highest prevalence is in preschool-age children (47.4%) and the lowest 
prevalence in men (12.7%). However, the population group with the greatest number of 
individuals affected is non-pregnant women (468.4 million/30.2%)3. 
 National Family Health Survey has reported anaemia prevalence of 56.2 percent 
in women of 15-49 yr and 24.3 percent in men aged 15-49 yr. Iron deficiency is the most 
common cause of anaemia in the world affecting 30% of the world's population 
equivalent to 500 million people4. 
 Prevalence of anaemia in rural populations in Tamil nadu is as high as 52%. This 
could be explained due to lack of awareness in these individuals5. 60-70% of Indian 
adolescent girls are anaemic. In children and young adults particularly in deprived socio-
economic group, the prevalence of iron deficiency anaemia is 5% and 10% respectively6. 
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 In Siddha system of medicine, Anaemia is compared to Pandu noi. According to 
our text, Pandu noi has 5 types. In which, the symptoms of Pitha Pandu coincides with the 
symptoms of Iron deficiency anaemia. (Paleness of the tongue, fatigue, dyspnoea, 
giddiness, oral ulcer)7. According to the Siddha Medicine, when the normal equilibrium 
of the three humors (Vatham, Pitham, Kabam) is deranged, disease occurs. In Pandu noi, 
the Pitham and Kapam is deranged. 
 The preparation "Valendraphola Chooranam" mentioned in the Siddha text,        
“Gunapadam mooligai vaguppu" is indicated for Pandu. The drug Valendrapholam is 
bitter in taste8. The bitter taste has the property of neutralising pitham and kapam, thereby 
it helps in treating Pandu. 
 The previous studies of Valendrapholam shows the property of antioxidant, 
immuno-modulator, astringent, sedative. 
 Hence the author have selected Valendraphola Chooranam for Pandu. 
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AIM: 
To evaluate the safety and efficacy of Valendraphola Chooranam for Haematinic  
activity  in the management of Pandu (Anaemia). 
 
OBJECTIVE: 
Primary objective: 
To evaluate the Haematinic activity of “Valendraphola Chooranam” for “Pandu” 
(Anaemia) in preclinical studies. 
 
Secondary objective: 
Biochemical analysis. 
To evaluate the efficacy of Valendraphola Chooranam [Commiphora myrrha] in 
the management of Pandu [Anaemia]. 
High performance thin layer chromatography. 
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MATERIALS AND METHODS 
STANDARD OPERATIVE PROCEDURE:  
COLLECTION AND AUTHENTICATION OF RAW DRUG: 
               The raw drug was procured from Ramasamy chetty shop, Paris, Chennai, and 
authenticated by competent authority in Department of Gunapadam, National Institute of 
Siddha, Chennai. 
INGREDIENTS: 
Valendrapholam (Commiphora myrrha) 
PURIFICATION PROCESS9:  
Purification of Valendrapholam:  
The raw drug was purified by boiled in the vinegar.   
PREPARATION OF THE MEDICINE8:  
 The raw drug was purified and then dried and pulverized by an electric grinder 
into fine powder. And then it was sieved by using a fine silk cloth (vasthrakayam). The 
powder was stored in a clean, dry, air tight glass container.  
LABELLING : 
Name of the Preparation : Valendraphola Chooranam  
Quantity of the drug  : 14 gm   
Dose     : 1 gm bid 
Adjuvant/Vehicle   : Luke warm water 
Indication    : Pandu 
Date of manufacturing : The drug was prepared in two batches. 
                                                              23/05/2012, 20/08/2012 
Date of expiry   : 3 months from the date of manufacture. 
                        
5 
    thnyªâunghs« 
    Commiphora myrrha 
 
     (BEFORE PURIFICATION)                                    (AFTER PURIFICATION)  
 
      
                              
 
 
                                 
 
VALENDRAPHOLA CHOORANAM 
                     
 
6 
                                      REVIEW OF LITERATURE 
GUNAPADAM ASPECT 
   thnyªâunghs«8  
ntWbga®            : F§FkÔg«, FªJU, ÛW, btŸis¥nghs«,                                      
btŸsh¤ânghs« 
ga‹gL« cW¥ò : ãá‹ 
Rit   : if¥ò     
j‹ik  : bt¥g« 
ãÇî   : fh®¥ò. 
brŒif : 
 bt¥gK©lh¡» 
nfhiHaf‰¿ 
UJî©lh¡» 
gá¤Ô¤ö©o  
mf£L thŒtf‰¿ 
Fz« : 
 “Niyfa nuhf« brh¿fu¥gh‹ F‹k Äit 
 Miyth Æ‹nfhšnghš MF§fh© - Úyr¡fu 
 thsbkd¤ njh‰WKiy khjunr! - thnyªâu 
 nghsª jidbaL¡F« nghJ.” 
 ïjdhš Ñšão¥ò, ïis¥ò nehŒ, fu¥gh‹, F‹k«, Njf¡f£L, 
Njf¥gh©L, gh©L, ïiu¥ò, kªj«, thŒ¥ò© KjÈait ÔU«. 
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வாnல திரேபாள  ேச   ம   க  : 
ப ரசவ ரஷாமி த மா திைர10: 
அள   : 1 மா திைர, 2 ேவைள 
த   வ யாதி : ப ரசவ த தி க   , உதிர க ைட தைடய றி   
                      ெவள ப    , எ வ த  ப ண ைய   வர ெவா டா . 
 சா ப ர ெம  10:      
அள   : 2 கடைல ப ரமாண , 5 நா . 
       த   வ யாதி : தி க    மாத வ ல    கால தி  உ டா     
                     வய  வலி ணமா  . ச தான சி தி  டா  . 
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 BOTANICAL ASPECT 
VALENDRAPHOLAM11 
 
BOTANICAL NAME: Commiphora myrrha 
VERNACULAR NAMES12:  
 ENG        : Myrrh 
 SANS     : Gandha-rasaha 
 HINDI     : Bola 
TEL                   : Balintra-polamu  
KAN       : Bola 
 
SCIENTIFIC CLASSIFICATION: 
Kingdom   : Plantae 
Order    : Sapindales 
Family    : Burseraceae 
Genus    : Commiphora 
Species   : myrrha 
Botanical name: Commiphora myrrha 
HABITAT:  
“Indigenous to North-Eastern Africa.” It is collected in Southern Arabia, 
Abyssinia, Persia, Siam and sold in Indian Bazaars. Myrrh of commerce is obtained from 
the resinous exudation of  the tree Commiphora myrrha. There are at least two or three 
varieties, two of them being known as ‘Karam’ and ‘Mutiya’. 
PARTS USED:   
Gum from the bark of the tree. 
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CHEMICAL CONSTITUENTS: 
 Myrrhol  
Myrrhic acid  
Calcium phosphate, Carbonate  
Cumic aldehyde 
Eugenol 
Meta-cresol 
Pinene 
di-pentene  
Limonene 
ACTIONS: 
 Stimulant 
 Expectorant 
 Emmenogogue  
 Astringent 
USES: 
 It is useful in dyspepsia and mixed with molasses or preferably with iron and 
vegetable bitters it is given in amenorrhoea, chlorosis. 
 It is a good stomachic and laxative. 
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                                     PHYSICAL PROPERTIES 
Materials and Methods 
The Physical properties of Valendraphola Chooranam were analysed in the 
following procedure. It was done at Sri Ramachandra University, Chennai. 
pH at 10% of aqueous solution: 
Five grams of Valendraphola Chooranam was weighed accurately and placed in 
clear 100 ml beaker. Then 50 ml of distilled water was added to it and dissolved well. 
After 30 minutes it was then applied in to pH meter at standard buffer solution of 
4.0,7.0,9.2. (Trial drug I,Table 2) 
Ash Values 
The Ash values measures inorganic constituents present in the raw drug. A high 
ash content explains its unsuitable nature to be used as a drug. (Trial drug I, Table 2) 
Total Ash 
A little of extract was taken in a silica crucible previously ignited, cooled and 
weighed. It was incinerated by gradually increasing the heat not exceeding dull red heat 
(450°C) until free from carbon, cooled and weighed. The percentage of ash 
was calculated with reference to air-dried drug. The procedure was repeated to get the 
constant weight.   (Trial drug I, Table 2)  
Water soluble ash 
The total ash was boiled with 25 ml water and filtered through ash less filter paper 
(Whatmann 4.1). It was followed by washing with hot  water .The  filter paper  was dried  
and ignited in the silica crucible, cooled and the water insoluble ash was weighed. The 
water-soluble ash can be calculated by subtracting the water insoluble ash from the total 
ash. (Trial drug I, Table 2) 
Acid insoluble ash 
 The total ash obtained was boiled for 5 minutes with 25 ml of (10% w/v) dilute 
hydrochloric acid and filtering through ash less filter paper (Whatmann 4.1). the filter 
paper was ignited in the silica crucible, cooled and insoluble ash was weighed. (Trial drug 
I, Table 2). 
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HIGH PERFORMANCE THIN LAYER CHROMATOGRAPHY 
The HPTLC of Valendraphola Chooranam was done at Sri Ramachandra 
University, Chennai.  
HPTLC Fingerprint - RH1 
SAMPLE PREPARATION 
100 mg of extract was weighed and dissolved in 70% methanol to get a 
concentration of 10 mg/ml concentration this is then used for injection.  
CHROMATOGRAPHIC CONDITION FOR HPTLC FINGER PRINT                  
(Trial drug I, Graph 1) 
 
SampleName   :   Valendraphola Chooranam 
Sample-ID                   :  111 
Stationary phase :   Silica gel F 254 
Mobile phase  :   n-Hexane: Ethyl acetate: Formic acid 60:40:2.5 ml) 
Scanning wavelength :  254,298,489 nm 
Sample concentration :  20 mg/ml 
Injecting volume :  5, 10 µl  
Development mode :  Ascending mode 
 
Significance of HPTLC fingerprinting in Standardisation 
Standardisation of traditional medicine has become mandatory in the present 
national and international scientific scenario, as they have to stand competing with 
stringent regulatory methods and also clinically. HPTLC is one of the versatile 
chromatographic methods presently available for the rapid analysis of herbal drugs due to 
several reasons. Firstly the time required for the demonstration of the most of the 
characteristic constituents of a drug is very quick and short. Secondly, in addition to 
qualitative detection, HPTLC also provides semi-quantitative information on the major 
active constituents of a drug, thus enabling an assessment of drug quality. Thirdly the 
fingerprint obtained is suitable for monitoring the identity and purity of drugs and for 
detecting adulteration and substitution. Hence in order to check the identity, purity and 
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standardise the quantity of active principles in the herbal extracts a HPTLC fingerprint of 
the ingredient medicinal plant used in the formulation has been obtained.       
The distribution of phyto-constituents in a plant depends on various factors such 
as soil, time of collection period of storage, etc. So, it is necessary to standardize the 
extract being used for pharmacological studies. HPTLC serves as a convenient tool for 
finding out the distribution pattern of phyto constituents which is unique to each plant. 
The HPTLC finger-printing profile establishes the identity and purity of the raw drug 
being used. It helps in the authentification of the plant material.  
Chromatographic Conditions 
The finger printing has been done using the following chromatographic 
conditions. Chromatography was performed on a10x10 cm pre activated HPTLC silica 
gel 60F 254 plate. Samples were applied to the plate as 6mm wide band with an 
automatic TLC applicator Linomat 5 with N2 flow (CAMAG, Switzerland), 8mm from 
the bottom. Densitometric scanning was performed on CAMAG scanner III. The plates 
were pre-washed by methanol and activated at 600 C for 5 minutes prior to 
chromatography. The slit dimension was kept at 5 minutes x 0.45 minutes and 20 minutes 
scanning speed was employed. The mobile phase was chosen after running each plant in 
different mobile phases of varying polarity (Toluene, Toluene: Ethyl acetate and Ethyl 
acetate: Methanol) and 10 ml of mobile phase was used per chromatography. Linear 
ascending development was carried out in 20 cm x 10-em twin glass chamber saturated 
with the mobile phase. 
Chromatographic Analysis 
The hydro alcoholic extracts of the plants have been prepared at a concentration of 
10 mg/10 ml in alcohol and were spotted using CAMAG Linomat 5 applicator. The 
method was optimized by selecting appropriate mobile phase for respective plant extracts 
and developed in a twin trough chamber, 20 x 10 cm at 25°C. The plates were dried by 
hair dryer. The developed plates were scanned at appropriate wavelength using CAMAG 
TLC scanner 3 and photo-documented using CAMAG REPROSTAR 3. 
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Inference  
HPTLC fingerprint of RH -1 shows four peaks at Rf values 0.25, 0.31, 0.41 & 
0.95.  The peak correspond to the Rf value 0.31 has maximum peak area of 7256.5. At 
this stage it is difficult to confirm the individual components present in the extract, but 
from our lab experience on phytochemical analysis, we suggest that the major peaks 
found in the fingerprint may be acidic glycosides / resins. Since, in the present 
chromatographic conditions, the above mentioned components will be eluted easy.  
 
 
254 nm                       366nm                        366 nm                       white light 
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BIO -CHEMICAL ANALYSIS OF VALENDRAPHOLA CHOORANAM 
  
The biochemical analysis of the Valendraphola Chooranam was carried out in the 
Biochemistry lab, National Institute of Siddha, Chennai. 
S.No EXPERIMENT OBSERVATION INFERENCE 
1.         Appearance of sample Light yellow in 
colour 
 
2. Solubility: 
a. A little(500mg) of the sample 
was shaken well with distilled water. 
b. A little(500mg) of the sample 
was shaken well with con. HCl/Con. 
H2So4 
Sparingly soluble 
 
 
Absence of Silicate 
3. Action of Heat: 
   A small amount(500mg) of the 
sample was taken in a dry test tube and 
heated gartly at first and then strong. 
 
 No white fumes 
evolved  
 
 
Absence of Carbonate 
 
4. Flame Test: 
  A small amount(500mg) of the sample 
was made into a paste with con. HCl in 
a watch glass and introduced into non-
luminous part of the Bunsen flame. 
 No Bluish green 
flame appeared. 
Absence of Copper 
5. Ash Test: 
   A filter paper was soaked into a 
mixture of sample and dil. cobalt nitrate 
solution and introduced into the Bunsen 
flame and ignited. 
Yellow colour 
flame appeared. 
Absence of sodium 
 
15 
Preparation of Extract: 
5gm of Valendraphola Chooranam was weighed accurately and placed in a 250ml 
clean beaker and added with 50ml of distilled water. Then it was boiled well for about 10 
minutes. Then it was cooled and filtered in a 100ml volumetric flask and made up to 
100ml with distilled water. 
S.No EXPERIMENT OBSERVATION INFERENCE 
 I.Test For Acid Radicals   
1.  Test For Sulphate: 
a. 2ml of the above prepared extract 
was taken in a test tube to this added 2ml 
of 4% dil ammonium oxalate solution 
b. 2ml of the above prepared extracts 
was added with 2ml of dil-HCl was added 
until the effervescence ceases off. Then 
2ml of dil.Barium chloride solution was 
added. 
         Cloudy 
appearance present 
 
 
   Absence of 
Sulphate 
 
 
 
2. Test For Chloride: 
  2ml of the above prepared extract was 
added with dil. HCl till the effervescence 
ceases. Then 2ml of dil.silver nitrate 
solution was added. 
No cloudy 
appearance. 
  Absence of 
Chloride 
3. Test For Phosphate: 
  2ml of the extract was treated with 2ml 
of dil.ammonium molybdate solution and 
2ml of con.HNo3. 
 Yellow 
appearance present 
   Absence of 
Phosphate 
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.  
Test For Carbonate: 
    2ml of the extract was treated with 2ml 
dil. Magnesium sulphate solution 
No Cloudy 
appearance. 
  Absence of 
carbonate 
5. Test For Nitrate: 
  1gm of the substance was heated with 
copper turning and concentrated H2So4 
and viewed the test tube vertically down. 
 
No Brown gas 
evolved. 
 
   Absence of 
Nitrate 
6. Test For Sulphide: 
  1gm of the substance was treated with 
2ml of con. HCL 
No Rotten Egg 
Smelling gas. 
   Absence of 
Sulphide 
7. Test For Fluoride & Oxalate: 
  2ml of extract was added with 2ml of dil. 
Acetic acid and 2ml dil.calcium chloride 
solution and heated. 
No Cloudy 
appearance 
      Absence of 
fluoride and 
oxalate 
8. Test For Nitrite: 
  3drops of the extract was placed on a 
filter paper, on that-2 drops of dil.acetic 
acid and 2 drops of dil.Benzidine solution 
was placed. 
No Characteristic 
changes 
   Absence of 
Nitrite 
9. Test For Borate: 
  2 Pinches(50mg) of the substance was 
made into paste by using dil.sulphuric 
acid and alcohol (95%) and introduced 
into the blue flame. 
No Bluish green 
colour flame. 
   Absence of 
borate 
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 II. Test For Basic Radicals   
1. Test For Lead: 
        2ml of the extract was added with 
2ml of dil.potassium iodine solution. 
No yellow 
Precipitate 
obtained. 
Absence of Lead 
2. Test For Copper: 
     One pinch (50mg) of substance was 
made into paste with con.HCl in a watch 
glass and introduced into the non-
luminuous part of the flame. 
No Blue colour 
flame 
No Blue colour 
precipitate formed. 
 
  Absence of 
copper 
 
 
3. Test For Aluminium: 
  To the 2ml of extract, dil.sodium 
hydroxide was added in 5 drops to excess. 
NoYellow colour 
appeared. 
   Absence  of 
aluminium 
4. Test For Iron: 
a. To the 2ml of extract,2ml of 
dil.ammonium solution was added. 
b. To the 2ml of extract 2ml  
thiocyanate solution and 2ml  of con 
HNo3 was added 
 
blood red colour 
appeared. 
 
 
 
presence of Iron 
 
 
5. Test For Zinc:  
      To 2ml of the extract, dil.sodium 
hydroxide solution was added in 5 drops 
to excess and dil.ammonium chloride was 
added.  
 
No White 
precipitate was  
formed 
 
Absence of Zinc 
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6. Test For Calcium:  
      2ml of the extract was added with 2ml 
of 4% dil.ammonium oxalate solution  
 No Cloudy 
appearance and 
white precipitate 
was obtained 
 
   Presence of 
calcium 
7. Test For Magnesium:  
         To 2ml of extract dil.sodium 
hydroxide solution was added in drops to 
excess. 
 
White precipitate 
was  obtained 
 
   Absence of 
Magnesium 
8. Test For Ammonium: 
  To 2ml of extract 1 ml of Nessler's 
reagent and excess of dil.sodium 
hydroxide solution are added. 
 
  No Brown colour 
appeared 
 
     Absence of 
ammonium 
9. Test For Potassium:  
   A pinch(25mg) of substance was treated 
of with 2ml of dil.sodium nitrite solution 
and then treated with 2ml of dil.cobalt 
nitrate in 30% dil.glacial acetic acid. 
 
No Yellowish 
precipitate was 
obtained. 
 
   Absence of 
Potassium 
10. Test For Sodium: 
    2 pinches(50mg) of the substance was 
made into paste by using HCl and 
introduced into the blue flame of Bunsen 
burner. 
 yellow colour 
flame appeared 
    Absence of 
sodium 
11. Test For Mercury:  
   2ml of the extract was treated with 2ml 
of dil.sodium hydroxide solution.  
No yellow 
precipitate was 
obtained 
   Absence of 
mercury 
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12. Test For Arsenic:  
   2ml of the extract was treated with 2ml 
of dil.sodium hydroxide solution. 
 
No brownwish red 
precipitate was 
obtained 
 
    Absence of 
arsenic 
 III. Miscellaneous   
1.
  
Test For Starch:  
  2ml of extract was treated with weak 
dil.iodine solution  
 
No blue colour 
developed 
 
      Absence  
of starch 
2.
  
Test For Reducing Sugar:  
    5ml of Benedict's qualitative solution 
was taken in a test tube and allowed to 
boil for 2 minutes and added 8 to 10 drops 
of the extract and again boil it for 2 
minutes. The colour changes are noted. 
 
Brick red colour 
not developed 
 
   Absence of  
reducing sugar 
3.
  
Test For The Alkaloids: 
a) 2ml of the extract was treated with  2ml 
of dil.potassium iodide solution. 
b)  2ml of the extract was treated with  
2ml of dil.picric acid. 
c)  2ml of the extract was treated with 2ml 
of dil.phosphotungstic acid. 
 
. 
  
Yellow colour 
developed 
 
- 
 
   Presence  
of Alkaloids 
4.
  
Test For Tannic Acid:  
  2ml of extract was treated with 2ml of 
dil.ferric chloride solution  
 No black 
precipitate was 
obtained 
    Absence  
of Tannic acid 
20 
5.
  
Test For Unsaturated Compound: 
  To the 2ml of extract 2ml of 
dil.Potassium permanganate solution was 
added.  
 
Potassium 
permanganate was 
not decolourised 
 
     Absence  
of unsaturated 
compound  
6.
  
Test For Amino Acid: 
    2 drops of the extract was placed on a 
filter paper and dried well. 20ml of  
Biurette reagent was added. 
 
violet colour 
developed 
 
       Presence  
of amino acids 
7. 
 
Test For Type Of Compound: 
    2ml of the extract was treated with 2 ml 
of dil.ferric chloride solution.  
No green colour 
developed 
 
 
No red colour 
developed 
 
No violet colour 
developed 
 
 
No blue colour 
developed 
Absence of oxy 
quinole 
pinephrine and 
pyro catechol 
Anti pyrine, 
Aliphatic amino 
acids and 
meconic acid are 
absent  
Apomorphine 
salicylate and 
Resorcinol are 
absent 
Morphine, 
Phenol cresol 
and hydro 
uinone are 
absent 
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TOXICITY STUDY 
 ACUTE AND SUB ACUTE TOXICITY STUDY OF VALENDRAPHOLA 
CHOORANAM IN RODENTS 
Animals:  
 Mice of either sex weighing 25-30g and rats weighing 210-240g were obtained 
from the animal house of Vels University. The animals were used with the approval of the 
Institute Animal Ethics Committee and obtained from Vels University, Chennai. They 
were fed with a balanced standard pellet diet and maintained under standard laboratory 
conditions, providing 24-280C temperature, standard light cycle (12 h light, 12 h dark) 
and water ad libitum. Animals were kept in cages with raised floors of wide mesh to 
prevent coprophagy. Animal welfare guidelines were observed during the maintenance 
period and experimentation. The rats were randomly assigned to control and different 
treatment groups, six animals per group. (Approval number: XIII/VELS/PCOL 
/38/2000/CPCSEA/IAEC/08.08.2012). The animals were acclimatized for one week 
under laboratory conditions.  
ACUTE TOXICITY STUDY-OECD 425 GUIDELINES 
 Acute oral toxicity test for the Valendraphola Chooranam was carried out as per 
OECD Guidelines 425. As with other sequential test designs, care was taken to ensure 
that animals are available in the appropriate size and age range for the entire study. The 
test substance was administered in a single dose by gavage using a stomach tube or a 
suitable intubation cannula. The fasted body weight of each animal was determined and 
the dose was calculated according to the body weight. After the substance has been 
administered, food was withheld for a further 2 hours in mice. The animals were observed 
continuously for the first  
4 h and then each hour for the next 24 h and at 6 hourly intervals for the following 48 h 
after administering of the test drug, to observe any death or changes in general behaviour 
and other physiological activities. Single animals are dosed in sequence usually at 48 h 
intervals. However, the time interval between dosing was determined by the onset, 
duration, and severity of toxic signs. Treatment of an animal at the next dose was delayed 
until one was confident of survival of the previously dosed animal. 
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Observation of toxicity signs:  
General behaviour, respiratory pattern, cardiovascular signs, motor activities, 
reflexes, change in skin and fur, mortality and the body weight changes were monitored 
daily. The time of onset, intensity, and duration of these signs, if any, was recorded.  
ACUTE TOXICITY STUDY 
 Acute oral toxicity test for the Valendraphola Chooranam was carried out as per 
OECD Guidelines 425. Animals were observed individually after dosing at least once 
during the first 30 minutes, periodically during the first 24 hours, with special attention 
given during the first 4 hours, and daily thereafter, for a total of 14 days, except where 
they need to be removed from the study and humanly killed for animal welfare reasons or 
are found dead.  
 All observations are systematically recorded and Observations include changes in 
skin and fur, eyes and mucous membranes, and also respiratory, circulatory, autonomic 
and central nervous systems, and somatomotor activity and behaviour pattern. Attention 
was directed to observations of tremors, convulsions, salivation, diarrhoea, lethargy, sleep 
and coma. The principles and criteria summarised in the Humane Endpoints Guidance 
Document taken into consideration. Animals found in moribund condition and animals 
showing severe pain or enduring signs of severe distress was humanely killed. When 
animals were killed for human reasons or found dead, the time of death was recorded. 
SUB-ACUTE TOXICITY  
 In a 28-days sub acute toxicity study, twenty four rats of either sex (3+3)  were 
divided into four groups of 6 rats each. Group I that served as normal control was 
administered with distilled water (p.o.) while groups II, III and IV were administered 
daily with the Valendraphola Chooranam (p.o.) for 28 days at a dose of 0.1, 0.25 and 0.5 
g/kg respectively. The animals were then observed daily for gross behavioural changes 
and any other signs of subacute toxicity. The weight of each rat was recorded on day 0 
and weekly throughout the course of the study, food and water consumption per rat was 
calculated. At the end of the 28 days they were fasted overnight, each animal was 
anaesthetized with diethylether, following which they were then dissected and blood 
samples were obtained by cardiac puncture into heparinised tubes. The blood sample 
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collected from each rat was centrifuged with 3000 X g at 4oC for 10 min to separate the 
serum and used for the biochemical assays.  
Hematological and blood biochemical analyses:  
 At the end of the study, all animals were kept fasted for 16-18 h and then 
anesthetized with anesthetic ether on the 28th day. Blood samples for hematological and 
blood chemical analyses were taken from retro orbital vein. Heparinized blood samples 
were taken for determining complete blood count (white blood cell count, differential 
white blood cell count, platelet count, red blood cell count, hematocrit, and hemoglobin) 
by semiautomated hematology analyzer. The serum from non-heparinized blood was 
carefully collected for blood chemistry and enzyme analysis (glucose, blood urea nitrogen 
(BUN), creatinine, total protein, albumin, total and direct bilirubins, serum glutamate-
oxaloacetate transaminase (SGOT), serum glutamate pyruvate transaminase (SGPT), and 
alkaline phosphatase (ALP)) were automatically determined using autoanalyzer. 
Necropsy:  
 All rats were sacrificed after the blood collection. The positions, shapes, sizes and 
colours of internal organs were evaluated. The Spleen, Testes, Pancreas, Lung, Liver, 
Brain, Heart, Stomach, Intestine, Bone, Ovary, and Kidney tissues were excised from all 
rats to visually detect gross lesions, and weighed to determine relative organs’ weights 
and preserved in 10% neutral formalin for histopathological assessment. The tissues were 
embedded in paraffin, and then sectioned, stained with haematoxylin and eosin and were 
examined microscopically. 
STATISTICAL ANALYSIS  
Values were represented as mean ± SEM. Data were analysed using one-way 
analysis of variance (ANOVA) and group means were compared using the Tukey-Kramer 
Multiple Comparisms Test using Graph Pad Instat-V3 software. P values < 0.05 were 
considered significant. (Trial drug I, Table 4 – Table 11)  
RESULTS  
In the acute toxicity study at the dose level of 5 g/kg moderate toxic symptoms 
like alertness, grooming, touch response, writhing and hypnosis was observed. Hence the 
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next lower dose was tried and confirmed the non toxic response to test drug 
Valendraphola Chooranam. Hence for the further study the one tenth, one fifth and one  
twentieth of the tolerable dose was selected for the further sub acute toxicity evaluation.  
In the sub acute toxicity study, Animals were not shown any significant toxic 
clinical signs during the dosing period of 28 days. All animals from control and all the 
treated dose groups survived throughout the dosing period of 28 days.  
Results of body weight determination of animals of control and different dose 
groups exhibited comparable body weight gain throughout the dosing period of 28 days. 
During dosing period, the quantity of food consumed by animals from different dose 
groups was found to be comparable and normal with that of control animals. 
Ophthalmoscopic examination of animals in control and test product treated 
groups did not reveal any major and remarkable abnormality. Urine analysis data of 
control group and treated group of animals determined in week 4 did not reveal any 
abnormalities. 
 Comparison of organ weights of treated animals with respective control animals 
on day 28 kidney weight was slightly increased at middle dose treated group and was 
found to be comparable.  
Gross pathological examination of animals in control as well as the treated groups 
did not reveal any abnormalities. The increase or decrease in the values obtained was 
within normal biological and laboratory limits.  
An increase in total RBC count and Hb was obtained for animals in the dose 
group of 250 and 500 mg/kg (P<0.01). Results of Biochemical investigations conducted 
on days 28 no significant changes in the values of different parameters studied when 
compared with control; however, the values obtained were within normal biological and 
laboratory limits.  
 
CONCLUSION 
 Based on these findings, no toxic effect was observed upto 500mg/kg of 
Valendraphola Chooranam via oral route over a period of 28 days. So, it can be 
concluded that the Valendraphola Chooranam can be prescribed for therapeutic use in 
human with the dosage recommendations of upto 500 mg/kg. body weight p.o. 
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HISTOPATHOLOGY SLIDES 
                          
  BONE       BRAIN 
                       
  HEART      INTESTINE 
 
                      
  KIDNEY       LIVER 
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  LUNG                 OVARY 
 
                      
  PANCREAS      SPLEEN 
 
                      
  STOMACH      TESTIS 
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    PHARMACOLOGICAL STUDY 
            HAEMATINIC  ACTIVITY OF VALENDRAPHOLA CHOORANAM 
MATERIALS AND METHODS 
Drug material 
 The suspension of Valendraphola Chooranam was stored in a refrigerator until 
use. The suspension was further diluted with 2% CMC to get 200mg/ml stock solution 
and used in this study. 
Animals 
Male albino rats (150-180g) were used for the study. The rats were housed in 
wire-mesh cages with a 12 h light/dark cycle. They had continuous access to fod and 
water during the entire period of experimentation. 
(APPROVAL NUMBER: XIII/VELS/PCOL/38/2000/CPCSEA/IAEC/08.08.2012) 
 EVALUATION OF HAEMATINIC ACTIVITY  
 Six rats were kept as normal control group (Group 1), while 24 rats were made 
anaemic by oral intubations of phenylhydrazine (10 mg/kg body weight) daily for 8 days. 
Rats that developed anaemia with haemoglobin concentration <14 g/dl were recruited for 
the study. Anaemic rats were randomly divided into 5 groups (2 to 6) and treated as 
follows:        
Group 1: received distilled water (1 ml) daily (normal control) 
Group 2: received 2% CMC (1 ml) daily (anaemic control) 
Group 3: received oral single dose of the Valendraphola Chooranam 100 mg/kg 
body  weight/day  
Group 4: received oral single dose of the Valendraphola Chooranam 200 mg/kg 
Group 5: received oral single dose of the Valendraphola Chooranam 400 mg/kg  
Group 6: received oral single dose of the heamatinic syrup 2ml/kg body 
weight/day.  
The treatment was continued for 2 weeks.  
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Haematological investigation 
 Blood collected from the retro orbital vein of experimental animals after an 
overnight fast and after 1 and 2 weeks of treatment with Valendraphola Chooranam, was 
used for the determination of red blood cell count (RBC), haemoglobin (Hb) 
concentration and packed cell volume (PCV). The mean cell volume (MCV), mean cell 
haemoglobin (MCH) and the mean cell haemoglobin concentration (MCHC) were 
calculated. 
STATISTICAL ANALYSIS 
Experimental data was analysed using analysis of variance (ANOVA) and 
Dunnet’s ‘t’ test to determine significant differences between means. The statistical 
analysis system (INSTAT-V3) package was used for this analysis. (Trial drug I, Table 12 
– Table 14, Chart 1 -  3) 
RESULTS AND DISCUSSION 
 This study aimed to evaluate the effect of Valendraphola Chooranam on the 
haemolytic anaemia induced by phenylhydrazine in albino rats. There was a significant 
(p<0.05) increase in the mean Hb concentration recorded for rats in the test group 
200mg/kg of Valendraphola Chooranam relative to that observed in the control group 
(15.64 ± 0.59 g/dl).  
 After one week of treatment, the mean total red blood cell count of rats in each of 
the Valendraphola Chooranam test groups (5.16±0.24, 5.28±0.18, 5.11±0.21X 106/μL) 
were observed compared with those in the control group (4.12±0.28X 106/μL), but these 
differences were not significant (P>0.05). There was an increase in the PCV of rats in all 
the Valendraphola Chooranam treatment groups relative to that of the rats in the control 
group. The increase was significant (p < 0.05) for rats in high dose group (49.46 ± 
2.48%), compared with control group. There was a slight increase observed in the mean 
MCV values of rats in all the drug treated groups but it was statistically not significant 
compared to control group.  
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 Rats in low dosed test group were observed to have decrease mean MCH values 
(p<0.05). There was a non-significant (p>0.05) decrease in the mean MCHC values of 
rats in all the test groups.  
After 14 days of Valendraphola Chooranam treatment significantly increased 
almost all the parameters towards normal. Hb level was 17.10±0.68, 17.15±0.56, 
18.56±0.54g/dl respectively in 100, 200 and 400 mg/kg Valendraphola Chooranam 
treated groups. In the same manner, the RBC count was rapidly increased to 4.81±0.34 at 
Valendraphola Chooranam mid dose treated group (P<0.05). The mean RBC and Hb 
concentration of rats were increased, especially for rats administered the higher doses. 
Mean MCV values were also increased, while MCH and MCHC values decreased.  
CONCLUSION 
 Iron deficiency adversely affects the cognitive performance, behaviour, and 
physical growth of infants, preschool and school-aged children. The ideal antianaemic 
regimen should be safe, cheap, well tolerated by children and able to achieve a high cure 
rate. Iron preparations available used in treatment of iron deficiency anaemia has much 
adverse effect. In this study, the test drug Valendraphola Chooranam justifies and 
supports the traditional use in the treatment of anaemia. 
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      DISEASE ASPECT 
SIDDHA ASPECT 
btS¥ò nehŒ13 
ntWbga® :   bt©ik nehŒ, gh©L. 
ïašò : 
 ïa‰if Ãw«kh¿, clš btS¤J, f©izí« ef¡f©izí« Ú¡»¥ 
gh®¡»‹ FUâÆ‹¿ btS¤âU¡F«. 
nehŒ njh‹W« tÊ : 
 FUâÆ‹ t‹iikia¡ Fiw¡f¡ Toa c¥ò, òË¥òŸs bghU£fis 
ÄFâahf¡ bfhŸtjhY«, Ru«, ngâ, thªâ, Ñšthí KjÈa nehŒfS¡F  
c£gLjyhY«, FUâia msî flªJ btËah¡F« bgU«ghL, FUâaHš 
nehŒ, FUâ¡ fÊ¢rš, KisnehŒ (_y«), FUâthªâ, KjÈait 
V‰gLjyhY« bt£L¥ g£L ÄFâahf¡ FUâ btË¥gLjyhY« ïªnehŒ 
c©lhF«. m‹¿í« e¢R¤j‹ikíila kUªJfis ehssî¡F ÄŠá 
c©gjhY«, òifÆiy, bt‰¿iy¥ gh¡F, k©, rh«gš, âUÚW, f‰óu« 
KjÈaitfis mo¡fo bfhŸtjhY« ïªnehŒ tU«. 
K‰F¿fŸ : 
 czî KjÈa ntWghLfshš, Ô¡F‰w« ÄFªJ, FUâÆ‹ Ãw¤ijí«, 
viliaí« bfL¤J, cl‰F nt©oa C£l¤ijí« bfhlhkš, cliy 
btS¡f¢ brŒí«.  á¿J bjhiyî el¡»D« fhš XŒªJ nghjš, bgU_¢R 
th§fš, czÉš ÉU¥gÄ‹ik, thŒFkl£š, jiyR‰wš, f© ïUsš mo¡fo 
ka¡fkhjš, kh®ò Jo¤jš, clš ïis¤jš c©lhF«. 
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nehŒ v©: 
 F‰w¤jhš tUtd eh‹F«, eŠrhš tUtd x‹W« To IªjhF«.   
1. tË (thj¥) gh©L   
2. Ô (ã¤j¥) gh©L    
3. Ia (fg¥) gh©L    
4. K¡F‰w« (âÇnjhõ) gh©L   
5. eŠR (Él¥) gh©L,  
    k©Q‹ btS¥ò (gh©L) nehŒ x‹WsJ v‹W« áy® TWt®. 
tË btS¥ò nehŒ : 
 Ú®nt£if, gá m‰W, FUâ ehs§fŸ fW¥gh», gugu¤J¡ fhQ«. f© 
át¡F«, clš btS¤J å§F«. czÉ‰ Rit a¿ahik, tÆW bghUkš 
c©lhF«. 
mHš btS¥ò nehŒ : 
  “thbk‹w nkÅbayh kŠr Ë¤J 
   kfhbtS¥ò c©lh» kªj¡ f©zhª 
  jhbk‹w jhfbkhL _®¢ir ahF« 
   jÅthÆš ÄsFngh‰ whD iw¡F« 
  nebk‹w beŠRKŸ jhD K©lhŒ 
   beU¡»na _¢RK£ lJnt ahF§ 
  nfhbk‹w »W»W¤J thŒif¥ ghF§ 
   »s®ã¤j gh©Lbtd¡ Twyhnk” 
 
 eh, if, fhšfŸ btS¤J, f© gh®it k§F«. Ú®nt£ifnahL ka¡f«, 
beŠir ïW¡»¥ ão¤jJ nghš _¢R K£LtnjhL jiy »W»W¡F«. 
 FË®¢á jU« bghUŸfËš ÉU¥ò, thŒ ò©zhjš. 
32 
Ia btS¥ò nehŒ : 
 njhš Äf btS¤J eu«òfŸ òil¡F«.  eh c¥ò if¤jš, thªâahjš, 
ka¡fkiljš, ïL¥ò nehjš, nkš_¢R tUjš, clš t‹ik FiwªJ kh®ò 
Jo¤jš, mo¡fo clš KGikí« CJ«. 
eŠR btS¥ò nehŒ : 
 clš btS¡F«. Ú® nt£if, RitÆ‹ik, thªâ, É¡fš, 
bgU_¢brÇjš, clš KGikí« å§F«. 
K¡F‰w btS¥ò nehŒ : 
 nkš_¢R tUjš, clš t‹ik FiwªJ kh®ò Jo¤jš, mo¡fo clš 
KGikí« CJ«. 
k©Q‹ btS¥ò nehŒ : 
 ï~J áW FHªijfS«, áWtaâdU«, fUî‰wtU«, k©, rh«gš, 
br§fš, âUÚW, fU¥óu« ïitfË‹ ÛJ jÅ¤j ï¢ir bfh©L, msî flªJ 
c©gjhš fhQ« nehahF«. brÇahik, thªâ, clš bkÈªJ, FUât‰¿, 
btS¤J å§» kh®ò Jo¡F«.  
F‰w« KjÈa ntWghLfŸ : 
 mHš (ïuŠáj ã¤jK«) bkÈªJ, Ãw¤âY« vilÆY« FiwªJ, 
Ô¡F‰w¤ij¥ bgU¡F«.  mjdsthf k‰iwa F‰w§fS« j‹ÅiyÆš âÇªJ, 
guîfhÈ‹ t‹ikia¡ bfL¤J nehia c©lh¡F«. 
eho : 
 “jhdKŸs nr¤JkªjhÅË»š .................... 
 ............................................................................... 
 ......................................................... gh©Lnuhf«” 
 
 “ïlkhd nr¤Jk¤â‰ ã¤jeho 
 vGªjQ»š gh©lhF«” 
 “c©lhnah nr¤Jk¤âš thjeho 
 fyªâLnkš gh©L ãw¡Fªjhnd” 
 “thj¤âš ÓjŠnr®ªjhš gh©L©lhnk” 
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MODERN ASPECT 
ANAEMIA 
              Anaemia is defined as a reduction of haemoglobin levels below the normal 
values for the different age and sex groups14.  
              The normal values of haemoglobin for different age groups accepted by WHO 
are as follows14: 
 Children (6 months to 6 years) :11 g/dL and above 
         (6 years to 14 years) :12 g/dL and above 
 Adult males    :13 g/dL and above 
 Adult females (non pregnant) :12 g/dL and above 
 Adult females (pregnant)  :11 g/dL and above 
                In full health there is no racial variation in haemoglobin. In India any 
haemoglobin level below 12 g/dL in adult males and 11.5 g/dL in adult females should be 
diagnosed as anaemia and investigated. In general, reduction of haemoglobin is 
associated with a fall in erythrocyte count and Packed cell volume(PCV)14. 
Causes of Anaemia15: 
Decreased or ineffective marrow production 
               Inadequate iron, B12 or folate, trace elements(zinc, cobalt) 
               Hypoplasia of bone marrow 
               Infiltration by malignant cells.  
Peripheral causes(increased RBC destruction or loss) 
               Blood loss 
               Haemolysis 
               Hypersplenism 
 
Classification of anaemia15: 
Classification of anaemia based on RBC Morphology: 
              Normocytic anaemia 
              Macrocytic anaemia 
              Microcytic anaemia 
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IRON DEFICIENCY ANEMIA14: 
              Microcytic hypochromic anaemia occurring in India is mostly due to iron 
deficiency. In India and other developing countries, Iron deficiency anaemia far out 
numbers all the other types of anaemias put together, as it constitutes 90-95% of the total. 
Iron deficiency anaemia is one of the most widespread diseases all over the world.  
              Iron deficiency is prevalent in 30-50% of the adolescent and young adult women 
due to their unsatisfactory food habits and moderate or heavy blood loss during 
menstruation.  
              Even though iron deficiency is mainly caused by inadequate iron intake in food, 
Iron deficiency anaemia is not exclusively a disease of the poor. Food fadism and other 
diseases which cause blood loss account for the majority of anaemia cases occurring in 
the rich.  
 
Causes of Iron deficiency anemia16: 
 
Defective Intake: 
              In children, psychiatric patients, patients having anorexia due to any cause. 
 
Defective absorption:  
              Gastrectomy 
              Gastrojejunostomy 
 
Excessive demand: 
              Growing children 
              Females during reproductive period of life. 
 
Excessive loss: 
              Bleeding piles  
              Menorrhagia in females 
              Recurrent blood donation 
              Long standing haematuria 
              Drugs including Aspirin. 
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Clinical features16 
 
Symptoms: 
              Weakness 
              Fatigue 
              Lassitude 
              Lustreless hair 
              Palpitation 
              Breathlessness 
              Giddiness 
              Tingling 
              Numbness 
              Insomnia 
              Lack of concentration 
              Angular stomatitis 
 
Signs: 
              Pallor 
              Dry skin 
              White sclera 
              Koilonychia 
Investigations: 
  Hb 
  HCT/PCV 
  MCV 
  MCH 
  MCHC 
  Peripheral smear study 
  Serum iron 
  TIBC 
 Serum ferritin. 
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CLINICAL STUDY 
The study was conducted on patients with Pandu [Anaemia] patients satisfying the 
inclusion criteria.  
The study was conducted at the OPD/IPD of Ayothidoss Pandithar Hospital of the 
National Institute of Siddha, Tambaram sanatorium, Chennai-47. 
Sample size:  
The sample size was 20 patients. 
SUBJECT SELECTION:  
Inclusion criteria:  
Age    : 20-60 yrs  
 Sex     : Both male and female  
Weight   : 35-85 kgs  
            Patient having symptoms of 
Fatigue 
Lassitude 
Dyspnoea on exertion 
Giddiness 
Headache 
Insomnia 
Palpitation 
Poor appetite 
Any of the above 4 clinical symptoms 
Patient who are willing to provide blood sample for lab investigation.  
 Patient who are willing to attend OPD once in 7 days.  
 Patient who are willing to be admitted in the hospital for 30 days.  
Patient willing to sign the informed consent stating that he/she will 
conscientiously stick to the treatment during 30 days but can opt out of the trial of his/her 
own conscious discretion. 
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Exclusion criteria: 
Pregnancy and lactation 
Cardiac diseases  
Known case of Cirrhosis and Chronic Renal Failure 
Patient receiving Anti-tuberculosis drugs 
Hypo/hyperthyroidism 
Chronic blood loss 
Any other serious illness 
 
Withdrawal criteria: 
Development of any adverse reaction  
Occurrence of any other serious illness 
Non co-operation of the patient 
 
TRIAL DRUG AND DURATION 
Drug   :Valendraphola Chooranam -1 gm, bid with luke warm water, after food.                                                             
Duration of the treatment: 30 days. 
CONDUCT OF THE STUDY: 
Pandu patients satisfying inclusion and exclusion criteria were admitted to the 
trial. Informed consent was obtained from the patients. Routine investigations like Blood 
test, peripheral smear study, urine test  were carried out before and after the trial 
treatment. For in patients the drug was administered daily. For out patients the trial drug 
was issued for seven days course. They were advised to visit the OPD once in 7 days. At 
each visit they were clinically assessed.  
CLINICAL OBSERVATION: 
For the clinical study of “Valendraphola Chooranam” on Pandu, 20 patients were 
selected.   
Among 20 patients,17(85 %) were  female, 3(15%) were  male.  
According to age wise distribution 20% were in 20-30years, 40% were in 31-
40years,   25% were in 41-50 years and 15% were in 50-60 years. 
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Among 20 patients, All were affected from pallor, 17 patients were affected from 
breathlessness, 18 patients were affected from tiredness, 12 patients were affected from 
giddiness, 18  patients were affected from anorexia, 13  patients were affected from pica 
and 16 patients were affected from palpitations. 
From the clinical study 10% of patients relieved from pallor, 76.47% of patients 
relieved from breathlessness, 83.33% of patients relieved from tiredness, 83.33% of 
patients relieved from giddiness and 83.33% of patients relieved from anorexia, 69.23%  
patients were relieved from pica and 81.25%  patients were relieved from palpitations and 
no adverse effects were observed during trial period. 
16 (80%) Patients had significantly improved in the Hb levels after treatment. 
The following investigations were done before and at the end of the treatment.        
§ Blood sample (Hb, TC, DC, ESR, HCT/PCV, MCV, MCH, 
MCHC, and smear study, Sugar (F, PP), AEC, T.cholesterol, RFT 
and LFT) 
§ Urine test (Albumin, Sugar, Deposits) 
§ Motion test (ova, cyst, albumin) 
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DISCUSSION 
 The drug Valendraphola Chooranam was selected to evaluate the Haematinic 
activity in the management of Pandu (Anaemia). 
The literary evidence from Gunapadam mooligai vaguppu strongly supports the 
Haematinic activity of the drug. 
 
Bio-chemical analysis: 
The biochemical analysis of the drug reveals the presence of iron, calcium, 
alkaloid and amino acids. 
Iron17: 
           It is a component of haem which is required for the formation of haemoglobin and 
hence it compensates the blood loss. It helps in the transport of Oxygen and may be 
useful in preventing  hypoxia, which is one of the cause for anemia. 
             Hence the iron increases the haemoglobin concentration, thereby it reduces the 
anaemia.               
Calcium18:  
             Calcium plays a very important role in the body. It is necessary for normal 
functioning of nerves, cells, muscle, and bone. Hence it is considered as a nutritive 
supplement for treating Anaemia. 
Toxicological studies: 
Based on Sub acute toxicity Study, no toxic effect was observed upto 500 mg/kg 
of Valendraphola Chooranam via oral route over a period of 28 days. So, it can be 
concluded that the Valendraphola Chooranam can be prescribed for therapeutic use in 
human with the dosage recommendations of upto 500 mg/kg. body weight p.o. 
Pharmacological studies: 
 In this study, the test drug Valendraphola Chooranam justifies and supports the 
haematinic activity and traditional use in the treatment of anaemia. 
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Clinical observation: 
    10% of patients relieved from pallor, 76.47% of patients relieved from 
breathlessness, 83.33% of patients relieved from tiredness, 83.33% of patients relieved 
from giddiness and 83.33% of patients relieved from anorexia, 69.23%  patients were 
relieved from pica and 81.25%  patients were relieved from palpitations and no adverse 
effects were observed during trial period. 
16 (80%) Patients had significantly improved in the Hb levels after treatment. 
Bio-statistics: 
              Statistically, the paired ‘t’ test shows statistical significance for the Hb levels and 
associated symptoms before and after the treatment.(p<0.0001)  
Siddha Aspect19: 
Í¨Å  : ¨¸ôÒ 
¾ý¨Á : ¦ÅôÀõ 
À¢Ã¢×  : ¸¡÷ôÒ 
 
 ¨¸ôÒ Í¨Å «§Ã¡º¸ò¨¾ ¿£ìÌõ. À¢ò¾õ, ¸Àõ Å¢¸üÀò¾¢¨É º¡ó¾¢ 
¦ºöÔõ. 
 ¦ÅôÀ Å£Ã¢ÂÁ¡ÉÐ ¸Àò¨¾ ¿£ìÌõ, ¾¨ÄîÍüÈø, ¿¡ÅÈðº¢, §¾¸Å¡ð¼õ, 
Å¢¨ÃÅ¢ø ¦ºÃ¢ôÀ¢ò¾ø ¬¸¢Â ¸¡Ã¢Âí¸¨Ç ¦ºöÔõ. 
 ¸¡÷ôÒ Í¨ÅÂ¡ÉÐ «º£Ã½õ, ÅÂ¢üÚô ¦À¡ÕÁø, §º¡¨¸ ¬¸¢ÂÅü¨È 
¿£ìÌõ, ¾£ÀÉò¨¾Ôõ, ¦ºÃ¢ô¨ÀÔõ, ¿üÍ¨Å¨ÂÔõ ¯ñ¼¡ì¸¢, ¦¸ð¼ ÁÄò¨¾ì 
¸Æ¢ôÀ¢òÐ, ¸Àò¾¡ø ¯ñ¼¡É §¸Î¸¨Ç ¿£ìÌõ. 
 ±É§Å À¢ò¾õ, ¸Àõ, þÅüÈ¢ý ÌüÈí¸Ç¡ø ±üÀÎõ À¡ñÎ §¿¡Â¢¨É 
¨¸ôÒ, ¦ÅôÀõ, ¸¡÷ôÒ Å£Ã¢ÂÓ¨¼Â ãÄ¢¨¸¸¨Ç ¦¸¡ñÎ ÁÕòÐÅõ ¦ºöÂ 
¿üÀÄ¨É «Ç¢ìÌõ7. 
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                                   SUMMARY  
 The drug Valendraphola Chooranam was selected to evaluate the Haematinic 
activity in the management of Pandu (Anemia). 
The literary evidence from Gunapadam mooligai vaguppu strongly supports the 
Haematinic activity of the drug. 
The qualitative and quantitative analysis were done at Biochemistry lab, National 
Institute of Siddha and Sri Ramachandra University, Chennai respectively. The 
biochemical analysis of the drug reveals the presence of iron, calcium, alkaloid and amino 
acids. The result ensures the Haematinic activity of the Valendraphola Chooranam was 
due to the presence of active phytoconstituents of the drug. 
High Performance Thin Layer Chromatography was done at Sri Ramachandra 
University, Chennai.  
The pre-clinical evaluation (acute & repeated oral toxicity study) of the drug was  
carried out as per OECD guideline in Vels college of Pharmacy, Chennai. The result 
shows the safety of the drug for human administration. 
The Preclinical Pharmacological study was carried out in animal model in Vels 
college of Pharmacy, Chennai. The result shows that the drug has significant Haematinic 
effect. 
As per the Siddha literature and modern science reviews and research articles, the 
trial drug has potent Haematinic effect. 
20 Patients were recruited for clinical trial.  The trial drug Valendraphola 
chooranam at the dose of 1 gm, b.i.d was given to the patient for 7 days and patients were 
asked to visit op once in 7 days for 30 days. Clinical assessment and prognosis was noted 
at each visit. 
From the clinical study, after the course of treatment, 16 (80%) of the patients had 
significant increase in the Hb levels after treatment.  
10% of patients relieved from pallor, 76.47% of patients relieved from 
breathlessness, 83.33% of patients relieved from tiredness, 83.33% of patients relieved 
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from giddiness and 83.33% of patients relieved from anorexia, 69.23%  patients were 
relieved from pica and 81.25%  patients were relieved from palpitations and no adverse 
effects were observed during the trial period. 
Statistically, the paired ‘t’ test shows statistical significance for the Hb levels and 
associated symptoms before and after the treatment.(p<0.0001) 
The drug Valendraphola Chooranam has 
§ Haematinic Activity 
§ No side effects 
§ No undoing effects 
§ Encouraging clinical results.  
 From the clinical study and the statistical analysis, it was proved that the drug 
Valendraphola Chooranam was statistically significant on Haematinic activity in the 
management of Pandu (Anemia). 
 
 
 
 
 
 
 
 
 
 
 
43 
CONCLUSION 
The literature evidence of the plant shows that it has Haematinic activity. 
 
The safety studies (acute toxicity and repeated oral toxicity studies) conducted 
revealed that the trial drug Valendraphola Chooranam is safe. There were no 
abnormalities found in blood investigation and histo-pathological examination. Hence it 
can be reasonably assumed that the drug is safe for human use. 
 
The pharmacological study conducted in animal model shows significant 
Haematinic activity. 
 
Clinical study reveals the therapeutic efficacy of the trial drug by showing, 
increasing in Hb levels significantly. There was improvement in clinical symptoms after 
treatment. 
 
There were no adverse reactions complained during the clinical trial. 
 
Hence, the drug VALENDRAPHOLA CHOORANAM can be used in the 
management of Pandu (Anaemia). 
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INTRODUCTION 
             Bronchial asthma is one of the major health issues in many developing countries, 
causing great concern and stress among the victims20. Asthma is a disease which dates 
back atleast to the time of Hippocrates, who noted a condition of "deep and heavy 
breathing". The Greeks had labelled this condition as 'Asthma', the meaning of which was 
panting21. 
 Most of the individuals develop severe exacerbation of asthma by several 
triggering agents including increasing air pollution, urbanization, stress, deforestation. 
Home factors that can lead to exacerbation include dust, house mites, animal danders, 
cockroach allergens. The situation is complicated by poor access to medical services and 
poor health education among the affected population22. 
 In many countries the prevalence of asthma is increasing, particularly in the 
second decade of life where this disease affects 10-15% of population. There is also a 
geographical variation with asthma being common in more developed countries. Long 
term follow up in developing countries suggests that the disease may become more 
frequent as individuals become more westernised23. 
 An estimated 300 million people in the world currently have asthma and there 
may be additional 100 million persons asthma by the year 2025. It has been reported that 
there are approximately 15-20 million asthmatics24. Asthma is a heterogeneous disease 
and genetic and environmental factors such as viruses, occupational exposures and 
allergens contribute to its situation and continuance25. Studies of occupational asthma 
suggest that a high percentage of the work force, perhaps upto 20% may become 
asthmatic if exposed to potent sensitizers23. 
 India contributes to 10% of the global burden of asthma having around 2.4 crore 
of its population being asthmatic26. 
 According to the "The Global Asthma Report 2011", published by the 
International Union Against Tuberculosis and Lung disease and International study of 
Asthma and Allergies in childhood: Asthma is the most common chronic disease among 
children and over 23.5 crore people around the world was affected by it which accounts 
for 1 in every 250 deaths globally26.  
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 In Siddha system of medicine, Eraippu noi is compared to Bronchial Asthma. 
Siddha medicine means medicine that is perfect. Siddha medicine is claimed to revitalize 
and rejuvenate dysfunctional organs that cause the disease and to maintain the ratio of 
vatham, pitham and kabam. According to the Siddha medicine, diet and lifestyle play a 
major role not only in health but also in curing diseases27. 
 Immunomodulating agents are useful in the treatment of asthma by inhibiting the 
antigen-antibody (AG-AB) reaction and thereby inhibiting the release of inflammatory 
mediators28. 
 The preparation "SINGATHI CHOORANAM" is mentioned in the Siddha text 
"Agasthiyar mani ennum Vaithiya Chinthamani Venba 4000"29. The preparation contains 
Karkadagasingi, Siruthekku, Chukku, Milagu, Thippili, Kadukkai, Thandrikkai, 
Aamanakku ver, Kandankathari ver, Jatamanjil, Indhuppu. In this Siruthekku, Thippili, 
Karkadagasingi has Anti-inflammatory effect, Chukku has immunomodulatory effect, 
Kadukkai has Anti-histaminic activity, Kandankathari ver has Anti-allergic activity. 
 According to Siddha system of medicine, Eraippu occurs as a result of 
derangement of  kabam7. The ingredients of this medicine contains Chukku, Milagu, 
Thippili, Kadukkai which acts as rejuvenators. Most of the ingredients have Kaarppu 
suvai, veppa veeriyam and kaarppu pirivu, Kaarppu suvai neutralises the kabam and 
thereby it may help reducing the exacerbation of attacks. 
 Hence the author have selected the medicine "SINGATHI CHOORANAM" for 
treating Eraippu. 
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AIM: 
To evaluate the safety and efficacy of “Singathi Chooranam” for bronchodilator 
activity in the management of  Eraippu [Bronchial Asthma]. 
 
OBJECTIVE: 
 
Primary objective: 
To evaluate the bronchodilator  activity of “Singathi Chooranam”  in preclinical 
studies. 
 
Secondary objective: 
 Biochemical analysis. 
 
To evaluate the efficacy of  “Singathi chooranam” for bronchodilator activity 
in the management of Eraippu [Bronchial Asthma]. 
 
High Performance Thin Layer Chromatography  
 
Atomic Absorption Spectrophotometer. 
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MATERIALS AND METHODS  
STANDARD OPERATIVE PROCEDURE  
COLLECTION AND AUTHENTICATION OF THE RAW DRUGS 
The raw drug was procured from Ramasamy chetty shop, Paris, Chennai and 
authenticated by competent authority of Department of Gunapadam, National Institute of 
Siddha, Chennai. 
INGREDIENTS29: 
  Purified Karkadagashigi (Rhus succedanea) 
            Purified Siruthekku (Clerodendrum serratum) 
Purified Amanaku Ver (Ricinus communis) 
Purified Kandangattari Ver (Solanum surratense) 
Purified Jadamanjil (Nardostachys grandiflora) 
Purified Chukku (Zingiber officinale) 
Purified Milagu (Piper nigrum) 
Purified Thippili (Piper longum) 
Purified Kadukkai (Terminalia chebula)  
Purified Thantrikkai (Terminalia bellirica) 
Purified Indhuppu (Sodium chloride impura) 
 All are in equal proportions. 
 
PURIFICATION PROCESS : 
 
Purification of Karkadagashingi30: 
The raw drug was purified by roasted in the almond oil. 
Purification of Siruthekku30:  
The raw drug was purified by removed the outer layer and cut into small pieces. 
Finally the pieces are dried in the sunlight. 
48 
Purification of Amanaku ver30: 
The raw drug was washed well in water. 
Purification of Kandangattari ver30: 
The raw drug was washed well in water. 
Purification of Jadamanjil30: 
 The raw drug was purified by dried in the sunlight. 
Purification of Chukku9: 
The raw drug was purified by soaked in the limestone water and the outer layer 
was removed. 
Purification of Milagu9: 
The raw drug was soaked in buttermilk for 1hour 15 minutes and then roasted the 
drug. 
Purification of Thippili9: 
 The raw drug was purified by soaked in the lemon juice. 
Purification of Kadukkai9: 
The raw drug was purified by removed the seeds. 
Purification of Thantrikkai9: 
The raw drug was purified by removed the seeds.  
Purification of Indhuppu31: 
The raw drug was purified by soaked in goat’s urine for 3 nazhigai (72 minutes) 
and dried in the sunlight. 
PREPARATION OF THE MEDICINE29:  
The raw drug was purified and pulverized  by an electric grinder into fine powder, 
separately. And then it was sieved by using a fine silk cloth (vasthrakayam). The fine 
powder was  mixed with milk and backed in a backing pan (pittaviyal method). Then it 
was dried and ultra filtered by a cotton cloth and made into fine powder again. The 
powder was stored in a clean, dry air tight glass container.  
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LABELLING:  
Name of the preparation : Singathi Chooranam  
Quantity of the drug   : 14 gm 
Dose     : 1 gm, bid 
Adjuvant/ vehicle   : Luke warm water 
Indication    : Eraippu [Bronchial Asthma] 
Date of manufacturing : The drug was prepared in two batches. 
                                                                         14/06/2012, 04/09/2012. 
Date of expiry   : 3 months from the date of manufacture. 
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     ÄsF                                             jh‹¿   
         (Piper nigrum)                     (Terminalia bellirica) 
                    
 
              fL¡fhŒ                                         R¡F 
         (Terminalia chebula)                                 (Zingiber officinale)  
                    
 
  â¥ãÈ        rlhkhŠá   
       (Piper longum)                             (Nardostachys grandiflora)    
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          f®¡flfá§»                                  Mkz¡F 
       (Rhus succedanea)                                    (Ricinus communis)   
                                   
 
   f©l§f¤âÇ     f©Lghu§» 
          (Solanum surattense)                              (Clerodendrumserratum) 
                                               
 
                                             ïªJ¥ò 
         (Sodium chloride impura)                          (Sodium chloride impura) 
              (Before purification)                             (After purification) 
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SINGATHI CHOORANAM 
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REVIEW OF LITERATURE 
GUNAPADAM ASPECT8  
                      f®¡flfá§» (Rhus succedanea, Linn.) 
ntWbga® : f®¡flfá§», f‰fhlfá§». 
Rit : Jt®¥ò, j‹ik: bt¥g«,  ãÇî : fh®¥ò. 
brŒif : Jt®¥ã, cukh¡», clYukh¡», brÇ¥ò©lh¡», nfhiHaf‰¿, 
bt¥gK©lh¡»,  
Fz« : 
 “f®¡flf á§» fg§fhr« <isbahL 
 K¡fš »uhÂ KâÇiu¢rš - bgh¡bfdnt 
 fhL»‹w ngâiaíŠ rhL« mÇitaiu¡ 
 TLâw§ bfhL¡F§ TW.” 
ïjdhš Ia¤jhY©lhF« ïUkš, r‰W¡To¡ fÊí« Ãz¡fÊ¢rš nehŒ, 
FUâ¡ fÊ¢rÈY©lhF« fL¥ò, <is, tÆ‰¿iu¢rš ïitfŸ Ú§F«. 
f©Lghu§» (Clerodendrum serratum (Linn) Moon) 
ntWbga® : áWnj¡F 
ga‹gL« cW¥òfŸ:  nt® 
Rit : if¥ò, Jt®¥ò,  j‹ik : bt¥g«,  ãÇî : fh®¥ò. 
brŒif : bt¥gK©lh¡», jhJbt¥gf‰¿ 
Fz« : 
 “f©Lgh u§»baDŠ áWnj¡ F©nlš, 
  fhby§nf ã¤jbk§nf fgªjh bd§nf 
 bjh©Lbjh£L¤ bjhl®Rthr fhr bk§nf 
  Rubk§nf bt¿ba§nf bjhÅneh ba§nf 
 Ä©LòÇ ÕerÚ®¡ nfhit ba§nf 
  btËÚU© Ùbu§nf Éw‰fh by§nf 
 m©Lghl¢ ÓjRu§ fL¥ò bk§nf 
  aHiyaf nehba§nf aiwF ånu!”    
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 ïjdhš K¡F‰w«, ïiu¥ãUkš, cŸbt¥ò, bt¿ nehŒ (ig¤âa«), Ru«, 
_¡»š K‹Ú®¡nfhit, ã‹ Ú®¡nfhit, eh£g£l tËnehŒ, FË® fhŒ¢rš, 
clštÈ, c£fhªjš, kd¤ jLkh‰w« ÔU«. 
Mkz¡F (Ricinus communis) 
ntWbga® :  Vu©l«, á¤âu«, jy%g«. 
ga‹gL« cW¥ò : nt® 
Rit : if¥ò,   j‹ik : bt¥g«,    ãÇî : fh®¥ò. 
brŒif : thjkl¡» 
Fz« : 
 “thj¤ bjhl¡if tubth£lh k‰go¡F¡ 
 fhj¤J¡ f¥gh‰ foínk - Nj¤ij¥ 
 ngu©l¥ gªâ¡F« ngâ¡F nehŒ¡f£il 
 nau©l bk‹gâÅna”   - nju‹ bt©gh 
bghUŸ : 
 fÊ¢riy c©lh¡» tË¡F‰w¤ij vHbth£lhk‰wL¡F«. 
             f©l§f¤âÇ (Solanum surattense, Burm.f.) 
ga‹gL« cW¥òfŸ :   nt® 
Rit : fh®¥ò,  j‹ik : bt¥g«,  ãÇî : fh®¥ò 
brŒif : nfhiHaf‰¿, áWÚ®¥bgU¡», mf£LthŒtf‰¿.  
Fz« : 
 “ntÇiyó fhŒgHk› É¤Jkj‹ g£ilíÄ› 
 ñÇ ÈU¡f cl‰fd¥ò« - ÚuhŒ 
 tU«Õe r§faŠR thrKªj§ fhnj 
 mU§f©l§ f¤jÇí sh®”    
clÈ‹ Únu‰w«, _¡»š Ú® ghŒjš, <is (fa«), ïiu¥ò ïit ngh«. 
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rlhkhŠá (Nardostachys grandiflora, DC.) 
ntWbga® :  rlhkhá, #lkhŠá, igrhá, roiy, khÄá, ójnráÃ 
ga‹gL« cW¥òfŸ :   nt® 
Rit : (g¢irÆš) ïÅ¥ò (fhŒªjã‹) fh®¥ò,  j‹ik : bt¥g«, ãÇî : fh®¥ò. 
brŒif :bt¥gK©lh¡», ïátf‰¿, áWÚ®¥bgU¡», nfhiHaf‰¿ 
Fz« : 
 “F£lŠ áyªâÉl« nfhu òuhz Ru« 
 c£od§fhš ngâf©nzhŒ x£oUkš - brh£ou¤j 
 ã¤jÄiu¥ ngF« bgU§nfhiu v‹Wiu¡FŠ 
 R¤jrlh khŠáiy brhš”  
ïj‰F áyªâ eŠR, giHaRu«, c£NL, thŒî, fÊ¢rš, f©nzhŒ, 
ïUkš, FUâaHš, ïiu¥ò Ú§F«. 
 
R¡F (Zingiber officinale, Rosc.) 
ntWbga® : mU¡f‹, M®¤uf«, fLg¤âu«, R©o brh©o, ehfu«, Él_oa   
                        mÄ®j« 
ga‹gL« cW¥òfŸ:  »H§F (cy®ªjJ) 
Rit : fh®¥ò,   j‹ik :  bt¥g«,   ãÇî : fh®¥ò. 
brŒif :  bt¥gK©lh¡», gá¤Ô¤ö©o, mf£LthŒtf‰¿ 
Fz« : 
 “Niykªj« beŠbrÇ¥ò njhlnk¥ g«kHiy 
 _y« ïiu¥ãUkš _¡FÚ® - thyfg 
 njhlkâ rhu bjhl®thj F‹kÚ®¤ 
 njhl«M k«ngh¡FŠ R¡F” 
 R¡»dhš, brÇahik, kh®bgÇ¢rš, òËna¥g«, bt¥g«, ÑœthŒ nehŒ, 
ïiu¥ò, ïUkš, fÊ¢rš, Únu‰w«, F‹k«, tÆ‰W¥ãr«, fhJ¡ F¤jš, KfnehŒ, 
jiy nehŒ, FiytÈ, gh©L, tÆ‰W¡ F¤jš, IaRu« ngh«. 
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 ÄsF (Piper nigrum. Linn) 
ntWbga® :  fÈid, f¿,fha«, âu§fš, ÄÇaš, khr«, kiyahË 
ga‹gL« cW¥òfŸ: gH« 
Rit : if¥ò, fh®¥ò,   j‹ik :  bt¥g«,  ãÇî : fh®¥ò. 
brŒif : fhwY©lh¡», mf£LthŒtf‰¿, Kiwbt¥gf‰¿, bt¥g K©lh¡», 
e¢rÇ 
Fz« : 
 “ÓjRu« gh©L ány¤k§ »uhÂF‹k« 
 thj« mUáã¤j« kh_y« - XJr‹Å 
 ahrkgÞ khu« ml‹nkf« fhrÄit 
 ehr§ f¿Äs»dhš.” 
 FË®Ru«, gh©L, nfhiH, F‹k«, thí, RitÆ‹ik, bt¿, _y«, 
ïUkš, brÉtÈ, brÇahik ïit nghF«. 
 
          â¥ãÈ (Piper longum) 
ntWbga® : fhk‹, FlhÇ, nfhiHaf‰¿, fid, fÈÅ, itnj», m«ò 
ga‹gL« cW¥òfŸ :  fhŒ, mÇá 
Rit :  ïÅ¥ò,  j‹ik - j£g«,  ãÇî - ïÅ¥ò. 
               cy®ªjJ - fh®¥ò,  j‹ik - bt¥g«,  ãÇî - ïÅ¥ò. 
brŒif :bt¥gK©lh¡», mf£Lthítf‰¿ 
Fz« : 
 “<is ÆUk Èiu¥ò¥ gr¥ãÂfŸ 
 khs bthÊahkš th£Lnk - ahSKiw 
 gh§fh a¿ªJbrŒå® g©oj¤ij¥ g©ojnu 
 nt§ifthŒ¥ gh‹fiz bkŒ”   (nju‹ bt©gh) 
<is, ïUkš, ïiu¥ò, c¥ãr« KjÈa ãÂfis¥ ngh¡f¤ j¡fthW 
â¥ãÈia Msnt©oajh«. 
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fL¡fhŒ (Terminalia chebula) 
ntWbga® :  mKj«, tdJ®¡», nuh»Â, étÃfh, étªâ, mÇj», m«ik. 
ga‹gL« cW¥ò :  njhš 
Rit : K¡»a Rit - Jt®¥ò, m¤Jl‹ á¿J - ïÅ¥ò, òË¥ò, fh®¥ò, if¥ò 
j‹ik :bt¥g«  ãÇî :  ïÅ¥ò 
Fz« : 
 “jhil fG¤j¡» jhY F¿ÆÉl¥ 
 Õil áÈgjK‰ ngâKl« - Milba£lh¤ 
 öyÄo ò©thj nrhÂfh khiyÆu© 
 lhyÄo ngh«tÇ¡fh ahš.” 
 fL¡fhÆdhš f‹d«, fG¤J, eh, M©F¿, ï›Él§fËš nehŒfŸ, 
fhyo¥ò‰WnehŒ, mâöy«, ïo¥ò©, thjnrhÂj«, fhkhiy, jhtu, 
r§fkÉl§fŸ ïit ngh«. 
 
jh‹¿ (Terminalia bellirica (Gaertn.) Roxb.) 
ntWbga® : 
 m«gy¤â, vÇf£gy«, fªjf£gy«, TÈ¤JUk«, fsªö‹¿, ójthrf« 
ga‹gL« cW¥òfŸ: ïiy, gH«, Éiu 
Rit :  Jt®¥ò   j‹ik :  bt¥g«    ãÇî : ïÅ¥ò 
brŒif :Jt®¥ã, nfhiHaf‰¿, kyÄs¡», cukh¡». 
Fz« : 
 “áyªâÉl« fhÄa¥ò© ÓHhd nkf§ 
 fyªJtU« thjã¤j§ fhnyh - ly®ªJlÈš 
 C‹¿¡fhŒ bt¥g Kâuãª J§fu¡Fª 
 jh‹¿¡fhŒ ifÆbyL¤ jhš.” 
 ïjdhš áyªâeŠR, M©F¿¥ò©, btŸis, FUâaHš nehŒ, tË Ô 
F‰w§fshš tU« nehŒfŸ ngh«. 
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ïªJ¥ò (Sodium chloride impura)31 
ntWbga®fŸ : 
 irªjt«, áªöu«, kâT®ik, kâí¥ò, Äªjh¢brhš, rªâuD¥ò 
 
R¤â : 
ïjid¡ fhoÆš _‹W ehŸ Cw¥ngh£L, NÇabdhËÆš cy®¤â vL¡f¢ 
R¤âahF«. 
ïjid¡ fho mšyJ btŸsh£L ÚÇš _‹w ehÊif k¤â¤J btŒÆÈš 
cy®¤â¡ bfhŸs ïJ R¤âahF«. 
brŒif : 
 kyfhÇ, gá¤Ô¤ö©o, mf£LthŒtf‰¿, áWÚ®¥bgU¡» 
 
Fz« : 
 “br‹Å¡f©zh g‰ù® brÉfîŸf© l«fgnehŒ 
 rªÃah r§fhrª jhfÄiu¥ - ò‹Åu¤j 
 _yŠ áyªâeË _ofPŠ Nij tÈ 
 NyŠ áijíÄªjh‰ brhš” 
 
 m£lF‹k«, kªj«, má®¡fu«, fgã¤j«, ky¡f£L, fhÄa nehŒ, fu¥gh‹, 
IanehŒ, ne¤âufhr«, jhf«, Rthr«, ïu¤j _y« KjÈa ãÂfŸ Ú§F«. 
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nrU« kUªJfŸ 
f‰flfá§» nrU« kUªJfŸ  
âÇgyhâ Nuz«10: 
msî                :  âÇfo¥ ãukhz«  mDghd« : nj‹    
ÔU« nehŒfŸ :  Ójs r«gªjkhd <is, ïUkš, fhr« 
f©lfhÇ¡ »Uj«10: 
msî                :  2 - 3 nj¡fu©o 
ÔU« nehŒfŸ :  ciskªij, Rthrfhr«, <is, ïUkš, ra« 
áWnj¡F nrU«  kUªJfŸ  
â¥ãÈ ïny»a«10: 
msî     : R©il¡fhŒ¥ ãukhz« 
ÔU« nehŒfŸ :  <is, ïUkš, fhr«, ra«, thªâ 
Mlhnjhil¢ Nuz«30: 
Msî    : 1/4 njhyh,    mDghd« : ghš 
ÔU« nehŒfŸ :  Ójs r«gªj¤jhY©lhd Rthrfhr« 
jhËrhâ Nuz«32: 
msî     :  1 - 2 »uh«,    mDghd« :  nj‹     
ÔU«nehŒfŸ  :  fgnehŒ - 96, ïUkš, bjh©il¡ f£L 
f©l§f¤âÇ nt® nrU« kUªJfŸ  
kfh áŠrhâ ïny»a«29:  
msî     : 1 - 2 nj¡fu©o 
ÔU«nehŒfŸ  : F‹k«, gh©L, nrhig, Rthrfhr« 
N¤âu migahâ ny»a«29: 
mDghd«   : fL¡fhŒ FoÚ® 
ÔU«nehŒfŸ : Niy, Rthrfhr«, gh©L, F‹k« 
kfu Rj®rz¢ Nuz«30: 
msî    : 1/2 njhyh,   mDghd« : btªÚ® 
ÔU«nehŒfŸ : fgRu«, Rthrfhr«, fhkhiy 
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rlhkhŠáš nrU« kUªJfŸ  
_j©l ny»a«10: 
msî     :  fH‰á¡ bfh£il ãukhz« 
ÔU« nehŒfŸ : Rthr«, rõa«, fhr«, Ú®¡nfhit, Niy 
ïyt§fhâ Nuz«30: 
msî     :  1/2 njhyh 
ÔU« nehŒfŸ : ïiu¥ò, ka¡f«, Ru«, ïUkš 
öJis¡ »Uj«10: 
msî     : 1 - 2 nj¡fu©o 
ÔU« nehŒfŸ : <is, ïUkš, Rthr«, ïu¤j fhr« 
R¡F nrU« kUªJfŸ  
r¤â¡rhuiz¡ »Uj«30: 
msî     :  1/2 - 1 fu©o 
ÔU« nehŒfŸ : fhr«, Rthrfhr«, Ru« 
rîgh¡»a R©o29: 
msî     : R©ilasî 
ÔU« nehŒfŸ : ra«, m¡»Åkªj«, fhr«, Rthr« 
âuh£rhâ¢ Nuz«32: 
msî     : 1 - 2 »uh«,   mDghd« :  nj‹ 
ÔU« nehŒfŸ : ïUkš, Rthrfhr«, gh©L 
ÄsF nrU« kUªJfŸ  
Rthr FnlhÇ Nuz«10: 
msî    : âÇfo¥ ãuhkhz«,     mDghd« : nj‹, ïŠá¢rhW 
ÔU«nehŒfŸ : <is, ïUkš, nfhiH thªâ 
Éšthâ ïny»a«10: 
msî     : gh¡fsî 
ÔU« nehŒfŸ : F‹k«, fhr«, <is, ïUkš 
fhr Fyhªjf kh¤âiu10 : 
mDghd«  : Kiy¥ghš, ïŠá¢rhW 
ÔU«nehŒfŸ : Rthr«, fhr«, <is 
 
61 
â¥ãÈ nrU« kUªJfŸ 
ïuhk knfRu« FËif33: 
msî    : F‹¿bail   
ÔU«nehŒfŸ : ra«, <is, F‹k«, Ia« 
â¥ãÈ Nuz«10: 
msî   : âÇfo¥ ãukhz«,   mDghd« : nj‹ 
ÔU«nehŒfŸ:  ïUkš, <is, Rthrfhr« 
gŠrnfhy »Uj«10: 
msî    : 2 - 3 nj¡fu©o,  mDghd« : f‰f©L bgho 
ÔU«nehŒfŸ : <is, ïUkš, brÇahik 
fL¡fhŒ nrU« kUªJfŸ 
kAh kjdfhnkRu ïny»a«30: 
msî    : fH‰á¡fhŒ ãukhz« 
ÔU«nehŒfŸ : <is, ïUkš, Niy 
nkf áªjhkÂ bkGF30: 
msî    : R©il¡fhasî  
ÔU«nehŒfŸ : F‹k«, Rthrfhr«, ïáî 
jhgtdy¢ Nuz«29: 
mDghd«    : gR beŒ 
ÔU« nehŒfŸ : r‹Å, Rthrfhr«, ra«, ïUkš 
jh‹¿¡fhŒ nrU« kUªJfŸ  
fšahz »Uj«30: 
msî   : 1 fu©o 
ÔU«nehŒfŸ : Ru«, rõa«, Rthrfhr« 
tšyhiu beŒ32: 
msî    : 1 - 2 nj¡fu©o 
ÔU«nehŒfŸ : <is, ïiu¥ò, Rthrfhr« 
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ïªJ¥ò nrU« kUªJfŸ  
Mlhnjhil¡ »Uj«10: 
msî    :1 nj¡fu©o 
ÔU«nehŒfŸ : beŠRtÈ, fg¢á¡fyhš c©lhd ïiu¥ò, Rthrfhr« 
MWKf¢ brªöu«10: 
msî    : 1/2 - 1 F‹¿bail   mDghd« : nj‹ 
ÔU«nehŒfŸ : Ru«, <is, rõa«, fhr« 
kfh m¡»Å Fkhu‹29: 
msî    : 1 - 2 
ÔU«nehŒfŸ : Rthrfhr«, 13 tif r‹Å, thj F‹k«, Niy 
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BOTANICAL ASPECTS34 
f®¡flfá§» 
BOTANICAL NAME :  Rhus succedanea Linn 
VERNACULAR NAME                                 
 ENG  : Galls 
SANS  : Karkatashring 
HINDI  : Kakarsingi 
TEL  : Karkatakashrungi 
MAL  : Karkatasringi 
CLASSIFICATION12 
Kingdom : Plantae  
Class  : Dicotyledons 
Subclass : Polypetalae 
Series  : Disciflorae 
Order  : Sapindales  
Family  : Anacardiaceae  
Subfamily : Anacardioideae  
Genus  : Rhus (syn. Searsia) 
 Species : R.succedanea 
BOTANICAL DESCRIPTION : Leaves alternate, pinnate, 15-23 cm long, with or 
without terminal leaflet 4-5 pairs, lanceolate, acuminate, sub-opposite, coriaceous, 7-12 
cm long. Characteristic Galls are produced on leafy branches. Flowering: March-May; 
Fruiting: June-October. 
PARTS USED : Leaf galls 
PHYSICAL CONSTANTS : Foreign matter – Not more than 2%; Total ash- Not more 
than 7%; Acid- insoluble ash- Not more than 0.2%; Alcohol- soluble extractive- Not less 
than 30%; Water- soluble extractive- Not less than 30%.  
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CHEMICAL CONSTITUENTS : Resin, pistacienoic acids A and B, tannins, β-
sitosterol, α-piene, β-piene,dl-limonene, dihydroqercetin. 
PHARMACOLOGICAL ACTIVITIES : Expectorant, antispasmodic, antibacterial, 
antiinflammaory, antiallergic, antimicrobial, antifungal. 
SUPPORTIVE JOURNAL ARTICLES35: 
 Rhus Succedanea shown significant effect on constrictor response of histamine, 
acetylcholine and serotonin on smooth muscles. 
     f©Lghu§» 
BOTANICAL NAME :  Clerodendrum serratum(Linn)  
VERNACULAR NAME   
 ENG  : Beetle Killer 
SANS  : Bharngi, Barbara 
HINDI  : Bharangi 
TEL  : Gantu sharag 
MAL  : Cerutekku 
CLASSIFICATION12 
Kingdom  :Plantae 
Class   :Dicotyledons 
Subclass  :Gamopetalae 
Series   :Bicarpellatae 
Order   :Lamiales 
Family   :Verbenaceae 
Genus   :Clerodendrum 
Species  :C.serrata 
BOTANICAL DESCRIPTION : Perennial herbs or shrubs, 0.9-2.4 m high. Leaves 
sessile or nearly so, opposite or sometimes ternate, passing upwards into bracts, narrowly 
obovate-oblong or sub-elliptic, acute or acuminate, usually coarsely and sharply serrate. 
Flowers many, blue-purple or white, arranged in dichotomous cymes, the whole forming 
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a lax, subpyramidal panicle. Drupes 6 mm long, broadly obovoid, rather succulent, dark-
purple when ripe. 
PARTS USED : Root 
CHEMICAL CONSTITUENTS : Serratagenic acid, queretaroic acid, Ferulic    acid, 
scutellarein baicalein. 
PHARMACOLOGICAL ACTIVITIES: Antihistaminic, bronchoconstrictor, 
antiallergic, antiasthmatic, antibiotic, stomachic.  
SUPPORTIVE JOURNAL ARTICLES36 : 
Icosahydropicenic acid (IHPA), a new pentacyclic triterpenoid saponin was first 
time isolated from the roots of Clerodendrum Serratum (L) Moon (Verbenaceae). IHPA, 
at the dose of 100mg/kg, showed significant protection of mast cell degraualtion 
(59.62%) as compared to standard sodium cromoglycate (64.48%). The compound also 
revealed significant inhibitory activity on histamine—induced goat tracheal chain 
preparation. The study provides scientific basis for its clinical use in the treatment of 
asthma. 
                            Mkz¡F 
BOTANICAL NAME :  Ricinus communis 
VERNACULAR NAME                                  
ENG  : Castor, Castor oil plant              
SANS  : Yeranda 
   HINDI  : Erandi 
 TEL  : Erandamu  
 MAL  : Avanakku 
CLASSIFICATION12  
      Kingdom : Plantae  
      Class  : Dicotyledons 
      Series  : Unisexuals 
Order  : Malpighiales  
Family  : Euphorbiaceae  
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Subfamily : Acalyphoideae  
Genus  : Ricinus  
Species : R.communis  
BOTANICAL DESCRIPTION : Tall annuals, sometimes shrubby or tree-like. 
Leaves alternate, broad, palmately 5-11-lobed, serrate. Flowers monecious, in terminal 
subpaniculate racemes, 30-60 cm long. Fruit a pickly capsule of three 2-valved cocci. 
Seeds oblong, testa crustaceous, variously coloured, mottled. 
PARTS USED  : Root  
PHYSICAL CONSTANTS : Root – Ash – Not more than 8.0%; Acid insoluble ash – 
Not more than 1.0%; Alcohol soluble extractive – Not less than 3.0%; Water soluble 
extractive – Not less than 9.0%. 
CHEMICAL CONSTITUENTS : Germanicol ester derivative and an unidentified     
triterpene; Inorganic material like potassium, sodium, magnesium, chloride, nitrate, iron,   
aluminium, manganese, calcium, carbonate and phosphate including gallotannins. 
PHARMACOLOGICAL ACTIVITIES : Anti-inflammatory, spasmogenic, 
purgative,   immunizing and spasmolytic. 
SUPPORTIVE JOURNAL ARTICLES37 : 
 The Methanolic Extract of Ricinus Communis root at a dose of 250 mg/kg p.o 
exhibited significant Anti inflammatory activity in carrageenin induced rat paw edema 
model and a higher dose of 500 mg/kg p.o  also exhibited significant activity in cotton 
pellet granuloma model in Wister Albino rats. 
f©l§f¤âÇ 
BOTANICAL NAME :  Solanum surattense, Solanum virginianum 
VERNACULAR NAME   
ENG  : Yellow-berried nightshade 
SANS  : Kanta-karika Nidegdhika 
HINDI  : Kateli 
TEL  : Nelamulaka, Vakudu 
MAL  : Kantankattiri 
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CLASSIFICATION12 
Kingdom : Plantae 
Class  : Dicotyledons 
Subclass : Gamopetalae 
Series  : Polemoniales 
Order  : Solanales 
Family  : Solanaceae 
Genus  : Solanum 
Species : S.xanthocarpum 
BOTANICAL DESCRIPTION : Procumbent or trailling herb or under shrub with many 
branches clothed with 10-15 mm long prickles. Leaves ovate or elliptic, sinuate or sub- 
pinnatifid, prickly. Flowers blue or violet-purple, in lateral cymes. Berries globose, 1.2-2 
cm in diameter, glabrous, yellow or whitish with green markings. Seeds glabrous, 
subreniform, 2-2.5 mm in diameter. 
PARTS USED : Whole plant 
PHYSICAL CONSTANTS : Total ash – 2.881%; Acid soluble ash- 0.645%; Water 
soluble extractive- 15.32%; Ethanol soluble extractive- 12.27%; Pet ether soluble 
extractive- 5.33%. 
CHEMICAL CONSTITUENTS : Carpesterol, gluco-alkaloid solanocarpine, 
solasodine, solasonine, solamargine, coumarins, scopolin, scopoletin, esculin and 
esculetin. 
PHARMACOLOGICAL ACTIVITIES : Antibiotic, antiinflammatory, analgesic, 
antifungal, diuretic, spasmolytic, antipyretic. 
SUPPORTIVE JOURNAL ARTICLES38 : 
Apigenin has shown anti allergic effect in ovalbumin induced asthma. 
Ova induced mice showed allergic airway reactions and included an increase in 
number of eosinophils in bronchoalveolar lavage fluid, an increase in inflammatory cell 
infiltration into lung around blood vessels and airways, airway luminal narrowing and 
development of airway hyper responsiveness. 
68 
Administration of Apigenin before last airway ova challenge resulted in a significant 
inhibtion of all asthmatic reactions. 
rlhkhŠá                                                                                                                             
BOTANICAL NAME : Nardostachys grandiflora DC, Nardostachys jatamansi DC   
VERNACULAR NAME                 
ENG  : Valerina root 
SANS  : Jatmansi 
HINDI  : Jatamansi 
TEL  : Jatamamsi 
MAL  : Manchi 
CLASSIFICATION12  
Kingdom : Plantae  
Order  : Dipsacales  
Family  : Valerianaceae  
Genus  : Nardostachys  
Species : N.grandiflora  
BOTANICAL DESCRIPTION : An erect perennial, aromatic herb, 10-70 cm high, 
with long, stout, woody greyish, rhizomatous, tail-like rootstock covered with reddish-
brown hairs or tufted fibrous remains of the petioles of withered radical leaves. Radical 
leaves 15-20 x 2.5 cm, longitudinally nerved, glabrous, narrowed into the petiole; cauline 
leaves 1 or 2 pairs, 2.5-7.5 cm, sessile, oblong or subovate. Flowers pale-white or pink, 
rosy in terminal corymbose cymes.  
PARTS USED : Rhizome 
CHEMICAL CONSTITUENTS : Actinidine, carotene,nardol, nardostachonol, 
isovaleric acid, valeranone, β-sitosterol, jatamansone, jatmansic acid, oroselol, oroselone. 
PHARMACOLOGICAL ACTIVITIES : Hypotensive, analgesic, tranquillising, 
antibacterial, antifungal, diuretic, antimicrobial, antiulcerogenic, antianxiety, 
bronchodilatory. 
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SUPPORTIVE JOURNAL ARTICLES35 : 
The alcoholic extract of rhizomes of Jatamansi exhibited bronchodialatory effects 
in guinea pig, induced by histamine. 
The extract also showed antispasmodic effect in experimental models on the 
isolated smooth muscles. 
  Extract of Nardostachys jatamansi shown significant effect on constrictor 
response of histamine, acetylcholine and serotonin on smooth muscles. 
        R¡F 
BOTANICAL NAME :  Zingiber officinale Rose 
VERNACULAR NAME                                  
 ENG  : Dried  Ginger 
SANS  : Nagaram 
HINDI  : Sonth   
TEL  : Sonthi 
MAL  : Chukku 
CLASSIFICATION12  
Kingdom : Plantae  
Division : Magnoliophyta 
Class  : Monocotyledon  
Order  : Zingiberales  
Family  : Zingiberaceae  
Genus  : Zingiber  
Species : Z.officinale  
BOTANICAL DESCRIPTION : Perenial herb; rhizome stout, tuberous with erect          
leafy stem, 10-25 x 1.5-3 cm, narrowed to the base, acute or acuminate; sheath 10-15 cm 
long. 
PARTS USED : Dried rhizome  
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PHYSICAL CONSTANTS : Dried rhizome – Total ash – Not more than 6%; Water 
soluble ash – Not less than 1.5%; Alcohol (90%) soluble extractive – Not less than 3%; 
Water soluble extractive- Not less than 10%. 
CHEMICAL CONSTITUENTS : β- sesquiphellandrene, gingerol, zingerone,   
shogaol, diarylheptenones, c, two diarylhepatonoids, Camphene, phellandrene, cineol, 
citral, borneol, zingiberene, gingerol, shogaol and gingediol.  
PHARMACOLOGICAL ACTIVITIES : Antiinflammatory, hypolipidaemic,                                                                                                                         
antiemetic, antiulcer, antiplatelet, antipyretic, antioxidant, antibacterial, antifungal, 
hypoglycaemic. 
SUPPORTIVE JOURNAL ARTICLES39 : 
Ginger suppresses prostaglandin synthesis through inhibition of cyclooxygenase- 
1 and cyclooxygenase-2.  Ginger also suppresses leukotriene biosynthesis by inhibiting 5-
lipoxygenase.  
 This pharmacological property distinguishes ginger from nonsteroidal anti-
inflammatory drugs. 
      ÄsF 
BOTANICAL NAME :  Piper nigrum Linn  
VERNACULAR NAME                                  
       ENG  : Black pepper, common pepper 
 SANS  : Maricha 
HINDI  : Kalimirch 
 TEL  : Miriyalu 
MAL  : Kurumulaku 
CLASSIFICATION12  
Kingdom : Plantae  
Division : Magnoliophyta  
Class  : Dicotyledons  
Subclass : Magnoliidae 
Order  : Piperales  
Family  : Piperaceae  
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Genus  : Piper  
Species : P.nigrum  
BOTANICAL DESCRIPTION : Fruits ovoid or globose, one seeded, bright red  
when ripe. Seeds globose, testa thin, perisperm hard and white. 
PARTS USED : Fruit 
PHYSICAL CONSTANTS : Total ash- Not more than 5.0%; Acid insoluble ash- Not 
more than 0.5%; Alcohol soluble extractive- Not less than 6.0%; Water soluble 
extractive- Not less than 6.0%. 
CHEMICAL CONSTITUENTS : Piperonal, piperine, piperoleine A&B, α-pinene, 
sabiene, β-pinene, myrcene, p-cymene, pellitonine, piperettine, piperonal,alamine, 
arginine. 
PHARMACOLOGICAL ACTIVITIES: Antioxidant, sedative, analgesic, muscle 
relaxant, antipyretic, antiinflammatory, antifungal, antimicrobial, antiulcer, antibacterial.                                                                                     
SUPPORTIVE JOURNAL ARTICLES40 :  
To evaluate the anti-asthmatic activity of Piper nigrum on acetylcholine induced 
contraction of goat tracheal chain preparation. The aqueous extract of Piper nigrum fruits 
at the doses of 380 mcg/ml and 640 mcg/ml significantly inhibited acetylcholine induced 
bronchoconstriction of isolated goat trachea. Thus the present study revealed that the 
aqueous extract of fruit of Piper nigrum has significant anti-asthmatic potential.  
  
â¥ãÈ 
BOTANICAL NAME : Piper longum Linn    
VERNACULAR NAME                                  
ENG  : Indian long pepper, Long pepper 
 SANS  : Pippali 
HINDI  : Pipli 
 TEL  : Pipallu 
MAL  : Tippali 
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CLASSIFICATION12  
Kingdom : Plantae  
Division : Magnoliophyta  
Class  : Dicotyledons 
Order  : Piperales  
Family  : Piperaceae  
Genus  : Piper  
Species : P.longum  
BOTANICAL DESCRIPTION : Fruits ovoid, yellowish orange, sunk in fleshy   
spike. 
PARTS USED : Fruit 
CHEMICAL CONSTITUENTS : Piperlongumine and piperlonguminine; Piperine 
and sesamin; Sesquiterpene hydrocarbon, caryophyllene, piperine, pipernonaline and 
piperundecalidine; Sylvatin, sesamin and diaeudesmin. 
PHARMACOLOGICAL  ACTIVITIES : Antibacterial, antiinflammatory, 
antimalarial, antitubercular, insecticidal, antispasmodic, cough-suppressor, 
immunostimulatory, anthelmintic, antinarcotic, antiulcerogenic. 
SUPPORTIVE JOURNAL ARTICLES41 : 
The extracts of the fruits of piper longum  (100 µg Ml-1) significantly (p<0.01) 
inhibited the histamine induced contraction of isolated Guinea pig ileum preparation. The 
extracts (50, 100, 200 mg kg-1)  showed the significant  (p<0.01) activity and increase in 
dose of extract increased the % protection in histamine induced bronchospasm and also 
showed significant  (p<0.01) activity in haloperidol induced catalepsy and passive paw 
anaphylaxis. 
     fL¡fhŒ                                               
BOTANICAL NAME :  Terminalia chebula Retz  
VERNACULAR NAME                                     
 ENG  : Chebulik myrobalan 
SANS  : Pathya, Haritaki 
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HINDI  : Hara  
TEL  : Karakkaya 
MAL  : Katukka 
CLASSIFICATION12 
Kingdom : Plantae  
Division : Magnoliophyta  
Class  : Magnoliopsida  
Order  : Myrtales  
Family  : Combretaceae  
Genus  : Terminalia  
Species : T.chebula  
BOTANICAL DESCRIPTION : Drupes ellipsoidal, obovoid or ovoid, yellow to 
orange-brown, sometimes tinged with red or black and hard when ripe, 3-5 cm long, 5 
ribbed on drying. Seeds hard, pale yellow. 
PARTS USED : Fruit 
PHYSICAL CONSTANTS : Foreign matter – Not more than 1%; Total ash – Not more 
than 5%; Acid insoluble ash – Not more than 5%; Alcohol soluble extractive – Not less 
than 40%; Water soluble extractive – Not less than 60%. 
CHEMICAL CONSTITUENTS : Anthraquinone glycoside, chebulinic acid, 
chebulagic acid, tannic acid, terchebin, tetrachebulin, vitamin C, arachidic, behenic, 
linolec, oleic, palmitic and stearic acids. 
PHARMACOLOGICAL ACTIVITIES : Antimicrobial, antifungal, antibacterial, 
antistress, sntispasmodic.             
SUPORTIVE JOURNAL ARTICLES42: 
 Terminalia chebula has been reported to exhibit, Anti tussie property, Anti 
histamine property. 
 The water and ethanolic extracts of the fruit on Guinea pig ileum, were found to 
have strong anti histaminic activity. 
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jh‹¿ 
BOTANICAL NAME :  Terminalia bellirica(Gaertn.) Roxb 
VERNACULAR NAME        
 ENG  : Belliric Myrobalan 
 SANS  : Vebeethaki 
HINDI  : Bhaira 
TEL  : Tandra 
 MAL  : Tanni, Tannikka 
CLASSIFICATION12 
Kingdom : Plantae  
    Division : Magnoliophyta  
    Class  : Magnoliopsida  
  Order  : Myrtales  
 Family  : Combretaceae  
 Genus  : Terminalia  
 Species : T.bellirica  
BOTANICAL DESCRIPTION : A large tree, upto 40 m high. Fruits globular, 1.5 – 
2.5 cm in diam, obscurely 5- angled when dry. 
PARTS USED : Fruit 
PHYSICAL CONSTANTS : Foreign matter – Not more than 2%; Total ash – Not more 
than 7%; Acid insoluble ash – Not more than 1%; Alcohol soluble extactive – Not less 
than 8%; Water soluble extractivev – Not less than 35%.  
CHEMICAL CONSTITUENTS : Chebulagic acid, ellagic acid, mannitol and 
rhamnose, β- sitosterol and bellericanin, palmitic, oleic and linoleic acids. 
PHARMACOLOGICAL  ACTIVITIES : Purgative,  antifungal,  antihistaminic, 
antiasthmatic, broncho-dilatory, anti-spasmodic antibacterial,   antistress. 
SUPPORTIVE JOURNAL ARTICLES43 : 
 The extract of terminalia bellirica fruit was found to possess antihistaminic effect 
on experimental asthma in Guinea –pigs. The anti asthmatic effect was confirmed by 
pollen-induced asthma in animals.  
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MINERALOGICAL ASPECT 
ïªJ¥ò (ROCK SALT) 
Halite, commonly known as Rock salt, is the mineral form of Sodium chloride44. 
VERNACULAR NAMES45: 
 ENG   :  Rock salt, Bay salt 
 SANS  :  Saindhava 
 HINDI :  Sendhalon 
 TEL  :  Saindhalavanam 
 MAL    :  Intu-uppu 
 GUJ  :  Sindhaluna 
OCCURENCE: 
 It occurs mostly in United states of America, Canada, New mexico, Islamabad, 
Pakistan, United kingdom44. 
 This is taken out from earth especially in the North West regions of Punjab and 
Sind(Pakistan)46. 
CHARACTERS44: 
 It is colourless or white but may also be light blue, purple, pink, red, orange, 
yellow or grey depending on the amount and the type of impurities. It is saline in taste. It 
commonly occurs with minerals such as sulfates, halides and borates. 
PHYSIOCHEMICAL PROPERTIES44: 
 Category                     - halide mineral 
 Chemical formula       - NaCl 
 Crystal symmetry       - Isometric hexoctahedral 
 Molar mass                 - 58.433 g/mol 
 Colour                 - colourless or white 
 Crystal system             - Cubic 
 Luster               - Vitreous 
 Streak               - White 
 Optical properties       - Isotropic 
 Refractive index          - 1.544 
 Solubility                     - water soluble 
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PURIFICATION46: 
 Rock salt was kept soaked in Vinegar (old rice fomented water) for three days and 
insolated to get purified and detoxified form. 
 The rock salt was kept soaked in Goat’s urine for three days and insolated to get 
purified form. 
ACTIONS45: 
 Carminative 
Stomachic 
Digestive 
Cathartic 
Emetic. 
USES45: 
 It is given in dyspepsia and other abdominal disorders. 
Apart from the medicinal uses it is used for managing ice and in the cooking 
purposes. 
 
 
 
 
 
 
 
77 
PHYSICAL PROPERTIES 
Materials and Methods 
The Physical properties of Singathi Chooranam were analysed in the following 
procedure. It was done at Sri Ramachandra University, Chennai. 
pH at 10% of aqueous solution: 
             Five grams of Singathi Chooranam was weighed accurately and placed in clear 
100 ml beaker. Then 50 ml of distilled water was added to it and dissolved well. After 30 
minutes it was then applied in to pH meter at standard buffer solution of 4.0,7.0,9.2. 
(Trial drug II, Table 2) 
Ash Values 
             The Ash values measures of the inorganic constituents present in the raw drug. A 
high ash content explains its unsuitable nature to be used as a drug. (Trial drug II,Table 2) 
Total Ash 
             A little of extract was taken in a silica crucible previously ignited, cooled and 
weighed. It was incinerated by gradually increasing the heat not exceeding dull red heat 
(450°C) until free from carbon, cooled and weighed. The percentage of ash 
was calculated with reference to air- dried drug. The procedure was repeated to get the 
constant weight. (Trial drug II, Table 2) 
Water soluble ash 
            The total ash was boiled with 25 ml water and filtered through ash less filter paper 
(Whatmann 4.1). It was followed by washing with hot  water .The  filter paper  was dried  
and ignited in the silica crucible, cooled and the water insoluble ash was weighed. The 
water-soluble ash can be calculated by subtracting the water insoluble ash from the total 
ash. (Trial drug II, Table 2) 
Acid insoluble ash 
            The total ash obtained was boiled for 5 minutes with 25 ml of (10% w/v) dilute 
hydrochloric acid and filtering through ash less filter paper (Whatmann 4.1).  The filter 
paper was ignited in the silica crucible, cooled and insoluble ash was weighed. (Trial drug 
II, Table 2) 
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HIGH PERFORMANCE THIN LAYER CHROMATOGRAPHY 
The HPTLC of Singathi Chooranam was done at Sri Ramachandra University, 
Chennai. 
HPTLC Fingerprint - RH1 
SAMPLE PREPARATION 
100 mg of extract was weighed and dissolved in 70% methanol to get a 
concentration of 10mg/ml concentration this is then used for injection.  
CHROMATOGRAPHIC CONDITION FOR HPTLC FINGER PRINT (Trial drug 
II, Graph 1) 
SampleName   :   Singathi chooranam 
Sample-ID                   :  105 
Stationary phase :   Silica gel F 254 
Mobile phase  :   n-Hexane: Ethyl acetate: Formic acid 60:40:2.5 ml) 
Scanning wavelength :  254,298,489 nm 
Sample concentration :  20 mg/ml 
Injecting volume :  5, 10 µl  
Development mode :  Ascending mode 
Significance of HPTLC fingerprinting in Standardisation 
Standardisation of traditional medicine has become mandatory in the present 
national and international scientific scenario, as they have to stand competing with 
stringent regulatory methods and also clinically. HPTLC is one of the versatile 
chromatographic methods presently available for the rapid analysis of herbal drugs due to 
several reasons. Firstly the time required for the demonstration of the most of the 
characteristic constituents of a drug is very quick and short. Secondly, in addition to 
qualitative detection, HPTLC also provides semi-quantitative information on the major 
active constituents of a drug, thus enabling an assessment of drug quality. Thirdly the 
fingerprint obtained is suitable for monitoring the identity and purity of drugs and for 
detecting adulteration and substitution. Hence in order to check the identity, purity and 
standardise the quantity of active principles in the herbal extracts a HPTLC fingerprint of 
all the ingredient medicinal plants used in the formulation has been obtained.       
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The distribution of phyto-constituents in a plant depends on various factors such 
as soil, time of collection period of storage, etc. So, it is necessary to standardize the 
extract being used for pharmacological studies. HPTLC serves as a convenient tool for 
finding out the distribution pattern of phyto constituents which is unique to each plant. 
The HPTLC finger-printing profile establishes the identity and purity of the raw drug 
being used. It helps in the authentification of the plant material.  
Chromatographic Conditions 
The finger printing has been done using the following chromatographic 
conditions. Chromatography was performed on a10x10 cm pre activated HPTLC silica 
gel 60F 254 plate. Samples were applied to the plate as 6mm wide band with an 
automatic TLC applicator Linomat 5 with N2 flow (CAMAG, Switzerland), 8mm from 
the bottom. Densitometric scanning was performed on CAMAG scanner III.The plates 
were pre-washed by methanol and activated at 600 C for 5 minutes prior to 
chromatography. The slit dimension was kept at 5 minutes x 0.45 minutes and 20 minutes 
scanning speed was employed. The mobile phase was chosen after running each plant in 
different mobile phases of varying polarity (Toluene, Toluene: Ethyl acetate and Ethyl 
acetate: Methanol) and 10 ml of mobile phase was used per chromatography. Linear 
ascending development was carried out in 20 cm x 10-em twin glass chamber saturated 
with the mobile phase.  
Chromatographic Analysis 
The hydro alcoholic extracts of the plants have been prepared at a concentration of 
10 mg/10 ml in alcohol and were spotted using CAMAG Linomat 5 applicator. The 
method was optimized by selecting appropriate mobile phase for respective plant extracts 
and developed in a twin trough chamber, 20 x 10 cm at 25°C. The plates were dried by 
hair dryer. The developed plates were scanned at appropriate wavelength using CAMAG 
TLC scanner 3 and photo-documented using CAMAG REPROSTAR 3. 
Inference  
HPTLC fingerprint of RH -1 shows four peaks at Rf values 0.25, 0.31, 0.41 & 
0.95.  The peak correspond to the Rf value 0.31 has maximum peak area of 7256.5. At 
this stage it is difficult to confirm the individual components present in the extract, but 
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from our lab experience on phytochemical analysis, we suggest that the major peaks 
found in the fingerprint may be acidic glycosides / resins. Since, in the present 
chromatographic conditions, the above mentioned components will be eluted easy.  
 
                          
254nm (No: 105 -13)           366nm (No: 105 -14)   366nm (No: 105 -15)    White light (No: 105 -16) 
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BIO -CHEMICAL ANALYSIS OF SINGATHI CHOORANAM  
 The biochemical analysis of the Singathi Chooranam was carried out in the 
Biochemistry lab, National Institute of Siddha, Chennai.  
 
S.No                   EXPERIMENT OBSERVATION INFERENCE 
1.         Appearance of sample Light yellow in 
colour 
 
2. Solubility: 
a. A little(500mg) of the sample 
was shaken well with distilled water. 
b. A little(500mg) of the sample 
was shaken well with con. HCl/Con. 
H2So4 
Sparingly soluble 
 
 
Absence of Silicate 
3. Action of Heat: 
   A small amount(500mg) of the 
sample was taken in a dry test tube and 
heated gartly at first and then strong. 
 
 No white fumes 
evolved  
 
 
Absence of Carbonate 
 
4. Flame Test: 
  A small amount(500mg) of the sample 
was made into a paste with con. HCl in 
a watch glass and introduced into non-
luminous part of the Bunsen flame. 
 No Bluish green 
flame appeared. 
Absence of Copper 
5. Ash Test: 
   A filter paper was soaked into a 
mixture of sample and dil. cobalt nitrate 
solution and introduced into the Bunsen 
flame and ignited. 
Yellow colour 
flame appeared. 
Presence of sodium 
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Preparation of Extract: 
5gm of Singathi Chooranam was weighed accurately and placed in a 250ml clean 
beaker and added with 50ml of distilled water. Then it was boiled well for about 10 
minutes. Then it was cooled and filtered in a 100ml volumetric flask and made up to 
100ml with distilled water. 
 
S.No EXPERIMENT OBSERVATION INFERENCE 
 I.Test For Acid Radicals   
1.  Test For Sulphate: 
a. 2ml of the above prepared extract 
was taken in a test tube to this added 2ml 
of 4% dil ammonium oxalate solution 
b. 2ml of the above prepared extracts 
was added with 2ml of dil-HCl was added 
until the effervescence ceases off. Then 
2ml of dil.Barium chloride solution was 
added. 
 Cloudy 
appearance present 
 
 
   Absence of 
Sulphate 
 
 
 
2. Test For Chloride: 
  2ml of the above prepared extract was 
added with dil. HCl till the effervescence 
ceases. Then 2ml of dil.silver nitrate 
solution was added. 
No cloudy 
appearance. 
  Presence of 
Chloride 
3. Test For Phosphate: 
  2ml of the extract was treated with 2ml 
of dil.ammonium molybdate solution and 
2ml of con.HNo3. 
 Yellow 
appearance present 
   Absence of 
Phosphate 
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4 
.  
Test For Carbonate: 
    2ml of the extract was treated with 2ml 
dil. Magnesium sulphate solution 
No Cloudy 
appearance. 
  Absence of 
carbonate 
5. Test For Nitrate: 
  1gm of the substance was heated with 
copper turning and concentrated H2So4 
and viewed the test tube vertically down. 
 
No Brown gas 
evolved. 
 
   Absence of 
Nitrate 
6. Test For Sulphide: 
  1gm of the substance was treated with 
2ml of con. HCL 
No Rotten Egg 
Smelling gas. 
   Absence of 
Sulphide 
7. Test For Fluoride & Oxalate: 
  2ml of extract was added with 2ml of dil. 
Acetic acid and 2ml dil.calcium chloride 
solution and heated. 
No Cloudy 
appearance 
      Absence of 
fluoride and 
oxalate 
8. Test For Nitrite: 
  3drops of the extract was placed on a 
filter paper, on that-2 drops of dil.acetic 
acid and 2 drops of dil.Benzidine solution 
was placed. 
No Characteristic 
changes 
   Absence of 
Nitrite 
9. Test For Borate: 
  2 Pinches(50mg) of the substance was 
made into paste by using dil.sulphuric 
acid and alcohol (95%) and introduced 
into the blue flame. 
No Bluish green 
colour flame. 
   Absence of 
borate 
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 II. Test For Basic Radicals   
1. Test For Lead: 
        2ml of the extract was added with 
2ml of dil.potassium iodine solution. 
No yellow 
Precipitate 
obtained. 
Absence of 
Lead 
2. Test For Copper: 
a. One pinch(50mg) of substance 
was made into paste with con. HClin a 
watch glass and introduced into the non-
luminuous part of the flame. 
No Blue colour 
flame 
No Blue colour 
precipitate formed. 
 
  Absence of 
copper 
 
 
3. Test For Aluminium: 
  To the 2ml of extract, dil.sodium 
hydroxide was added in 5 drops to excess. 
NoYellow colour 
appeared. 
   Absence  of 
aluminium 
4. Test For Iron: 
a. To the 2ml of extract,2ml of 
dil.ammonium solution was added. 
b. To the 2ml of extract 2ml  
thiocyanate solution and 2ml  of con 
HNo3 was added 
 
blood red colour 
appeared. 
 
 
 
Presence of Iron 
 
 
5. Test For Zinc:  
      To 2ml of the extract, dil.sodium 
hydroxide solution was added in 5 drops 
to excess and dil.ammonium chloride was 
added.  
 
No White 
precipitate was  
formed 
 
Absence of 
Zinc 
6. Test For Calcium:  
      2ml of the extract was added with 2ml 
of 4% dil.ammonium oxalate solution  
 No Cloudy 
appearance and 
white precipitate 
was obtained 
 
   Absence of 
calcium 
7. Test For Magnesium:  
         To 2ml of extract dil.sodium 
hydroxide solution was added in drops to 
excess. 
 
White precipitate 
was  obtained 
 
   Presence of 
Magnesium 
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8. Test For Ammonium: 
  To 2ml of extract 1 ml of Nessler's 
reagent and excess of dil.sodium 
hydroxide solution are added. 
 
  No Brown colour 
appeared 
 
     Absence of 
ammonium 
9. Test For Potassium:  
   A pinch(25mg) of substance was treated 
of with 2ml of dil.sodium nitrite solution 
and then treated with 2ml of dil.cobalt 
nitrate in 30% dil.glacial acetic acid. 
 
No Yellowish 
precipitate was 
obtained. 
 
   Absence of 
Potassium 
10. Test For Sodium: 
    2 pinches(50mg) of the substance was 
made into paste by using HCl and 
introduced into the blue flame of Bunsen 
burner. 
 yellow colour 
flame appeared 
    Presence of 
sodium 
11. Test For Mercury:  
   2ml of the extract was treated with 2ml 
of dil.sodium hydroxide solution.  
No yellow 
precipitate was 
obtained 
   Absence of 
mercury 
12. 
Test For Arsenic:  
   2ml of the extract was treated with 2ml 
of dil.sodium hydroxide solution. 
 
No brownwish red 
precipitate was 
obtained 
 
    Absence of 
arsenic 
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 III. Miscellaneous   
1.
  
Test For Starch:  
  2ml of extract was treated with weak 
dil.iodine solution  
 
No  blue colour 
developed 
 
      Absence  
of starch 
2.
  
Test For Reducing Sugar:  
    5ml of Benedict's qualitative solution 
was taken in a test tube and allowed to 
boil for 2 minutes and added 8 to 10 drops 
of the extract and again boil it for 2 
minutes. The colour changes are noted. 
 
Brick red colour 
not developed 
 
   Absence of  
reducing sugar 
3.
  
Test For The Alkaloids: 
a) 2ml of the extract was treated with  2ml 
of dil.potassium iodide solution. 
b)  2ml of the extract was treated with  
2ml of dil.picric acid. 
c)  2ml of the extract was treated with 2ml 
of dil.phosphotungstic acid. 
 
. 
  
Yellow colour 
developed 
 
- 
 
   Presence  
of Alkaloid 
4.
  
Test For Tannic Acid:  
  2ml of extract was treated with 2ml of 
dil.ferric chloride solution  
 No black 
precipitate was 
obtained 
    Presence  
of Tannic acid 
5.
  
Test For Unsaturated Compound: 
  To the 2ml of extract 2ml of 
dil.Potassium permanganate solution was 
added.  
 
Potassium 
permanganate was 
not decolourised 
     Absence  
of unsaturated 
compound  
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6.
  
Test For Amino Acid: 
    2 drops of the extract was placed on a 
filter paper and dried well. 20ml of  
Biurette reagent was added. 
 
violet colour 
developed 
 
   Presence  
of amino acids 
7. Test For Type Of Compound: 
    2ml of the extract was treated with 2 ml 
of dil.ferric chloride solution.  
No green colour 
developed 
 
 
No red colour 
developed 
 
No violet colour 
developed 
 
 
No blue colour 
developed 
Absence of oxy 
quinole 
pinephrine and 
pyro catechol 
Anti pyrine, 
Aliphatic amino 
acids and 
meconic acid 
are absent  
Apomorphine 
salicylate and 
Resorcinol are 
absent 
Morphine, 
Phenol cresol 
and hydro 
uinone are 
absent 
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 ELEMENTAL ANALYSIS USING ATOMIC ABSORPTION       
                                   SPECTROPHOTOMETER   
 The AAS of Singathi Chooranam was done at Sri Ramachandra University, 
Chennai. 
Elemental analysis using atomic absorption spectrophotometer 
In this method the sample, in the form of a homogeneous liquid, is introduced into 
a flame where thermal and chemical reactions create “free” atoms capable of absorbing, 
emitting or fluorescing at characteristic wavelengths.  
In Atomic Absorption Spectrophotometer (AAS) the majority of free atoms in the 
commonly used flames were in the ground state, but that the flames did not also have 
enough energy to excite these atoms.  A light source emitting a narrow spectral line of the 
characteristic energy is used to excite the free atoms formed in the flame.  The decrease in 
energy (absorption) is then measured. 
METHODOLOGY 
I. Microwave Digestion For Elemental Analysis 
Model Name: Multiwave3000 
Digestion Procedure: 
200mg of the given sample is placed in a digestion vessel, acid is added and the 
mixture is heated for several minutes. After the digestion, the samples are diluted to a 
specific volume. If too much sample is used in wet digestion, the reaction mixture can 
become violent. The samples are placed in digestion vessels that fit directly into digestion 
racks. There are several different acids or mixtures of acids used for digestion, the most 
common of which is concentrated Hydrochloric acid. The samples are heated slowly at a 
high temperature. After digestion, the samples are diluted to the appropriate volume with 
deionized H2O.  
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II. Elemental Analysis using Atomic Absorption Spectrophotometer 
The elemental analysis of digested samples have been determined by Atomic 
Absorption Spectrophotometer- Flame technique (AAS model 400 Perkin Elmer). 
Working standard solutions of Fe were prepared from stock standard solution of 1000 
ppm from MERCK.  Using blank solution to zero the instrument performs the 
Calibration.  The standards are then analyzed and their absorbance recorded.  A graph of 
Absorbance Vs Concentration is plotted.  Calibration of the instrument was repeated 
periodically during operation.  A blank reading was also taken and necessary correction 
was made during the calculation of concentration of various elements. 
The digested material was made upto 100 ml for analysis in an (AAS) atomic 
absorption spectrophotometer (Perkin Elmer). The results were calibrated using standard 
calibration curve. 
In AAS the wave Length(nm), Flame type, Lamp source and Calibration range 
(ppm) of different elements have been used, are listed in table. 
Instrumental conditions for elemental analysis 
Element Wavelength 
nm  
Light 
source 
Flame type 
Iron 386.0 HCL Air/Ac 
 
Air/Ac: Air-Acetylene; HCL: Hallow cathode lamp 
Elemental Analysis using Flame photometer 
 The analysis of Na of the digested samples have been determined by Flame photometer 
(Flame photometer 129- Systronics Make). (Trail drug II, Table 4) 
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                          TOXICITY STUDY 
ACUTE AND SUB ACUTE TOXICITY STUDY OF SINGATHI CHOORANAM 
IN RODENTS 
Animals  
Mice of either sex weighing 25-30g and rats weighing 210-240g were obtained 
from the animal house of Vels University. The animals were used with the approval of the 
Institute Animal Ethics Committee and obtained from Vels University, Chennai. They 
were fed with a balanced standard pellet diet and maintained under standard laboratory 
conditions, providing 24-280C temperature, standard light cycle (12 h light, 12 h dark) 
and water ad libitum.  
 Animals were kept in cages with raised floors of wide mesh to prevent 
coprophagy. Animal welfare guidelines were observed during the maintenance period and 
experimentation. The rats were randomly assigned to control and different treatment 
groups, six animals per group. The animals were acclimatized for one week under 
laboratory conditions.  
ACUTE TOXICITY STUDY-OECD 425 GUIDELINES 
Acute oral toxicity test for the Singathi Chooranam was carried out as per OECD 
Guidelines 425. As with other sequential test designs, care was taken to ensure that 
animals are available in the appropriate size and age range for the entire study. The test 
substance is administered in a single dose by gavage using a stomach tube or a suitable 
intubation cannula. The fasted body weight of each animal is determined and the dose is 
calculated according to the body weight. After the substance has been administered, food 
was withheld for a further 2 hours in mice. The animals were observed continuously for 
the first 4 h and then each hour for the next 24 h and at 6 hourly intervals for the 
following 48 h after administering of the test drug, to observe any death or changes in 
general behaviour and other physiological activities.  
Single animals are dosed in sequence usually at 48 h intervals. However, the time 
interval between dosing is determined by the onset, duration, and severity of toxic signs. 
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Treatment of an animal at the next dose was delayed until one is confident of survival of 
the previously dosed animal.  
Observation of toxicity signs: General behavior, respiratory pattern, cardiovascular 
signs, motor activities, reflexes, change in skin and fur, mortality and the body weight 
changes were monitored daily. The time of onset, intensity, and duration of these signs, if 
any, was recorded.  
SUB-ACUTE TOXICITY  
 In a 28-days sub acute toxicity study, twenty four rats of either sex were divided 
into four groups of 6 rats each. Group I that served as normal control was administered 
with distilled water (p.o.) while groups II, III and IV were administered daily with the 
Singathi Chooranam (p.o.) for 28 days at a dose of 100, 200 and 400 g/kg respectively. 
The animals were then observed daily for gross behavioural changes and any other signs 
of subacute toxicity.  
 The weight of each rat was recorded on day 0 and weekly throughout the course 
of the study, food and water consumption per rat was calculated. At the end of the 28 
days they were fasted overnight, each animal was anaesthetized with diethylether, 
following which they were then dissected and blood samples were obtained by cardiac 
puncture into heparinised tubes. The blood sample collected from each rat was 
centrifuged with 3000 X g at 4oC for 10 min to separate the serum and used for the 
biochemical assays.  
Hematological and blood biochemical analysis: 
 At the end of the study, all animals were kept fasted for 16-18 h and then 
anesthetized with anesthetic ether on the 28th day. Blood samples for hematological and 
blood chemical analyses were taken from retro orbital vein. Heparinized blood samples 
were taken for determining complete blood count (white blood cell count, differential 
white blood cell count, platelet count, red blood cell count, hematocrit, and hemoglobin) 
by semiautomated hematology analyzer.  
 The serum from non-heparinized blood was carefully collected for blood 
chemistry and enzyme analysis like glucose, Creatinine, Total protein, Albumin, Total 
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and Direct bilirubins, Serum glutamate-oxaloacetate transaminase (SGOT), Serum 
glutamate pyruvate transaminase (SGPT), and Alkaline phosphatase (ALP) were 
automatically determined using autoanalyzer. 
Necropsy:  
All rats were sacrificed after the blood collection. The positions, shapes, sizes and 
colors of internal organs were evaluated. The Spleen, Testes, Pancrea, Lung, Liver, Brain, 
Heart, Stomach, Intestine, Bone, Ovary, and Kidney tissues were excised from all rats to 
visually detect gross lesions, and weighed to determine relative organs’ weights and 
preserved in 10% neutral formalin for histopathological assessment. The tissues were 
embedded in paraffin, and then sectioned, stained with haematoxylin and eosin and were 
examined microscopically. 
Statistical analysis 
 Values were represented as mean ± SEM. Data were analysed using one-way 
analysis of variance (ANOVA) and group means were compared using the Tukey-Kramer 
Multiple Comparison test using Instat-V3 software. P values < 0.05 were considered 
significant.(Table 5 – Table 12) 
RESULTS  
 Animals were not shown any significant toxic clinical signs during the dosing 
period of 28 days. All animals from control and all the treated dose groups survived 
throughout the dosing period of 28 days and it was found one animal dead after 24days of 
treatment in high dose. Results of body weight determination of animals of control and 
different dose groups exhibited comparable body weight gain throughout the dosing 
period of 28 days.  
 During dosing period, the quantity of food consumed by animals from different 
dose groups was found to be comparable and normal with that of control animals. 
Ophthalmoscopic examination of animals in control and Singathi Chooranam treated 
groups did not reveal any major and remarkable abnormality. These tests conducted on 
the experimental animals at termination and recorded did not reveal any abnormalities. 
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Urine analysis data of control group and treated group of animals determined did not 
reveal any abnormalities.  
 Comparison of organ weights of treated animals with respective control animals 
on day 28 was found to be comparable. Gross pathological examination of animals in 
control as well as the treated groups did not reveal any abnormalities. The results of 
haematological investigations conducted on day 28, revealed, the increase or decrease in 
the values obtained was within normal biological and laboratory limits. Results of 
Biochemical investigations revealed the following significant changes in the values of 
different parameters were within normal biological and laboratory limits.  
CONCLUSION 
 From the results obtained in this study, no toxic effect was observed upto 
400mg/kg of Singathi Chooranam via oral route over a period of 28 days. So, it can be 
concluded that the Singathi Chooranam can be prescribed for therapeutic use in human with 
the dosage recommendations of upto 400mg/kg. body weight p.o. 
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HISTOPATHOLOGICAL SLIDES 
                              
  BONE              BRAIN 
                           
  HEART               INTESTINE 
                             
  KIDNEY                        LIVER 
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  LUNG       OVARY 
                          
  PANCREAS                                     SPLEEN  
                           
  STOMACH                TESTIS 
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PHARMACOLOGICAL STUDIES 
MATERIALS AND METHODS 
Drugs And Stock Solution  
 Drugs used were Histamine diphosphate (Sigma Chemical, USA) and 
Promethazine hydrochloride (Rhone – Poulenc, Mumbai). Histamine dihydrochloride was 
dissolved in distilled water and desired concentrations were prepared. The test drug 
Singathi chooranam concentration was 100 microgram per ml prepared by suspending 
with 2% CMC and then the volume was adjusted to 10 ml with normal saline for making 
the concentration of 100 μg/ml.in distilled water. 
Animals 
 Male albino guinea pig weighing 350– 400g was kept in fasting condition 18 
hours prior to commencement of experiment and given water ad libitum. It was housed 
under standard laboratory conditions of temperature (25 ± 2°C) and 12/12 hr light/dark 
cycle and then sacrificed by a blow to the head and exsanguinated as per CPCSEA 
recommended guidelines. (XIII/VELS/PCOL/39/2000/CPCSEA/IAEC/08.08.2012) 
IN-VITRO ANTIHISTAMINIC STUDY 
 Guinea pig was sacrificed and a segment from ileum (2 cm) was dissected from 
the terminal ileum and mounted in an organ bath containing Tyrode solution (10 ml) 
between two stainless steel hooks under 0.5 to 1 g initial tension. The lower hook was 
fixed at the bottom of the organ bath and upper one was connected to an isotonic 
transducer. The Tyrode solution composition (pH 7.4) was (concentration in gm/lit.) NaCl 
8.0, KCl0.2, CaCl2 0.2, MgCl2 0.1, NaHCO3 1.0, NaH2PO4 0.05, and Glucose1.0 
gm/liter.  It was continuously aerated and maintained at 37 ± 0.5ºC The equilibrium 
period was 60 min and the bath solution was refreshed every 15 min. After equilibrium 
period, a dose response curve for histamine in variant molar concentrations, by 
maintaining 45 min time cycle.  
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ANTIHISTAMINIC ACTIVITY 
 
 
BRONCHODILATOR STUDY 
 Animals were divided into four groups of six animals each. Each animal were 
served as its own control. Animals belonging to each group were subjected to a histamine 
aerosol (0.2% Histamine diphosphate in saline) using a glass nebuliser for 2 sec in an 
airtight Perspex chamber. Aerosolization of the solution was achieved via a compressed 
air line operating at a pressure of 8 Psi and a flow rate of 5ml/min. After exposure to the 
histamine aerosol, the animal showed signs of immediate immobilization and bouts of 
coughing. This was followed by shallow breathing symptoms, after which the animal 
collapsed, fell on its back and convulsed. The time taken by the animal to fall on its back 
after exposure to the aerosol was designated as the exposition time. The exposition time 
for each animal in all the four groups was noted.  
 Once the animal fell on its back, it was immediately taken out of the chamber and 
exposed to fresh air where the animal returned back to normal. After 1 hour the animals 
in the first three groups were administered orally 100, 200 and 400 mg/kg p.o, of Singathi 
chooranam respectively. While the fourth group of animals received 300µg/kg of 
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Promethazine by oral route. One hour later, the animals were reexposed to the aerosol and 
exposition time for each animal was noted. The difference in the exposition time before 
and after Singathi chooranam administration was taken as a measure of the protective 
effect. Percent protection afforded by the Singathi chooranam was calculated by the 
formula. 
     Eta-Etb 
       Percentage Protection = --------------x100 
        Etb 
Where ‘Eta’ is the mean exposition time after treatment with extract and ‘Etb’ is 
the mean exposition time before treatment with extract. 
STATISTICAL ANALYSIS 
 Ileum contractions induced by agonist were assumed as 100% and reductions 
induced by test drug calculated. Percentage of ileum contraction was expressed as mean ± 
SEM. Results were analyzed using one-way analysis of variance (ANOVA). Probability 
value less than 0.05 were considered as significant. (Trial drug II, Table 13 & 14, Graph 2 
& 3) 
RESULTS AND DISCUSSION 
 Bronchial asthma is characterized by wide spread narrowing of the bronchial tree 
due to contraction of smooth muscle and releases series of chemical mediators including 
histamine, leukotrienes etc. Histamine when inhaled has been shown to induce 
bronchoconstriction by direct H1 receptor activation and also by a neutrally mediated 
bronchoconstrictor effect via vagal reflexes. The mean increase in exposition time against 
histamine challenge was significantly (P<0.01) increased with increasing doses of 
Singathi chooranam and offered dose dependent protection 20.21% (200mg/kg) and 
26.06% (400mg/kg). Whereas known anti histaminic drug Promethazine hydrochloride 
(300µg/kg, p.o) also inhibited histamine induced bronchoconstriction in guinea pigs and 
offered 40.75% of protection against histamine challenge.  Histamine has shown to 
activate action potentials in the intrapulmonary vagal afferents. The inflammatory 
response is characterized by an increase in the numbers of eosinophils and mast cells, 
mucus hypersecretion, and activation of T cells. Several studies have shown that T-helper 
type (Th2) cells play a major role in the initiation and maintenance of allergic airway 
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inflammation and asthma through their increased production of Th2-type cytokines (IL-4, 
IL-5, and IL- 13). These inflammatory cytokines also produced in the bronchial tissue by 
mast cells, alveolar macrophages, and epithelial cells, play a significant role in the 
pathogenesis of airway inflammation. Histamine contracts the guinea pig ileum muscle of 
guinea pig. Guinea pig ileum is easier to handle and to prepare; it is also much more 
sensitive.  
 Therefore, the dose relative contractile responses of different agonists like ACh, 
histamine, 5hydroxytryptamine and bradykinin can be observed in isolated Guinea pig 
ileum. In the present study the isolated guinea pig ileum preparation; there is right side 
shift of Dose Response Curve of histamine in the presence of Singathi chooranam 
indicating Bronchodilation. Thus, the present study provides the experimental evidence 
for the presence of bronchodilator effect of Singathi Chooranam. 
CONCLUSION 
 Based on the results of the above study, it can be concluded that the Singathi 
chooranam possesses significant antihistaminic and bronchodilating activity. 
    
              
 
 
 
 
 
 
 
 
100 
   DISEASE ASPECT 
SIDDHA ASPECT 
                                   ïiu¥ò nehŒ13 
ntWbga®fŸ :   ïG¥ò nehŒ, Rthrfhr«, Rthr«, <is. Ru« 
ïašò : 
 ïªnehŒ ï‹d tif¤bjd¡ F¿¥ãl¡ Tlhjgo, xU fhuzKÄ‹¿ 
kh®ig tÈ¤J ïW¡»aJ ngh‹W ntjidia¤ jªJ, _¢ir btËÉlî«, cŸ 
ïG¡fî« Koahkš âzw¢ brŒí«.  m‹¿í«, btËahF« _¢R ÄFªj 
áuk¤njhL btËahtJl‹, FHš, ahœ, åiz KjÈa th¤âa§fË‹ xÈia¥ 
nghš xÈ¡F«.  nkY«, ïUkyhš kh®ãYŸs rËia btËah¡Ftj‰F ïa‰if 
KaÈD« m¡nfhiH btËahjš ïšiy. 
nehŒ tU« tÊ : 
 ïa‰ifahaikªj clÈD¡F, nt©lhj czî, braš 
KjÈaitfshš, t‹ik Fiwªj ÃiyÆš Ia¤ij ÄFâgL¤j¡ Toa 
czthY«, el¤ijahY«, òš, ó©L, mÇá, nfœtuF, KjÈaitfË‹ 
RizahY«, jd¡F cjthj eh‰w¥ bghUŸfis Kf®tjhY« ïªnehŒ ãw¡F«. 
nehÆ‹ K‰F¿fŸ : 
 j§fS¡F Mfh czî«, Mfh fh‰¿‹ kzK« g£lîl‹ _¡»š 
Ú®ghŒjš, J«kš tUjš, kh¥ò nehjš, kh®ig ïW¡»¡ f£oaJ nghy 
c©lhjš,  ïa‰if _¢R¤ j£Lglš, Éyh¥g¡f« tÈ¤J _¢R¤ âzwš. 
tiffŸ : 
tË ïiu¥ò nehŒ : 
 _¢R ÉLtj‰F nt©oa clš t‹ik ïšyhJ, ÉL« _¢R j‹tÈî 
FiwªJ vG«.  beŠáDŸ ahJ« ïšyhjJ ngh‹w X® cz®¢á njh‹W«. 
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Ia ïiu¥ò nehŒ : 
 kh®ig mil¥gJ nghš njh‹¿, _¢R btËÉl Koahkš Ä¡f 
ntjidia¥ ãw¥ã¤J th£L«.  ïG¥òŸs ntisÆš á¿J ïUkš thuhkY« 
rËí« btËahfkÈU¥ã‹, nehahsid _¢R btËÉl Koahkš jÉ¡f¡ brŒJ 
gL¡fî« ïU¡fî« brŒahJ. 
IatË ïiu¥ò nehŒ : 
 _¢ir rÇtu cŸ th§Ftj‰F« btËÉLtj‰F« ïayhkš É£LÉ£L 
_¢br¿jY« kyK« ÚU« f£o tÆW c¥ã bghUKjY« c©lh» cliy 
th£L«. 
K¡F‰w ïiu¥ò nehŒ : 
 ÉL« _¢R bgÇa khL ÉL« _¢ir bah¤âU¡F«.  kh®ig ïW¡»¡ 
f£oaJ nghy nehjš, mo¡fo ka¡f« c©lhjš. 
nkšneh¡F ïiu¥ò nehŒ : 
 nk‰T¿a ïiu¥ò nehŒfËš vitnaD«, kU¤Jt¤â‰F¡ f£L¥glhkš, 
Ú©lehŸ bjhl®ªJ nkš neh¡F¡fhš (cjhdthí) t‹ik ïHªJ _¢ir 
btËah¡f ïayhj nghJ, ãÂahs‹ _¢R¤âz¿, f© btËna K£o, thŒ 
cy®ªJ ngrKoahJ âif¤J gL¡if Ãiyahkš vGªJ thŒ âwªjJ nghy 
nkš neh¡», r‰W fh‰iw btËah¡» cŸËG¡f miyth‹.  m¢rka¤âš 
clnd jFªj kU¤Jt« brŒÆ‹ FzkilªJ ãiH¥gh‹.  ï‹nwš, âwªjthŒ 
âwªjgona ïU¡f, Kf§fW¤J ka¡FK‰W kuz¤ij milth‹. 
F‰w« KjÈa ntWghLfŸ : 
 Ia¡F‰w« j‹Åiy khWjyhY«, tË mšyJ Ô¡F‰w¤ijnaD« 
mšyJ m›ÉU F‰w¤ijnaD« jd¡F¤ Jiz¡bfh©L F¿Fz§fis¥ 
ãw¥ã¡F«.  clš ÃiyfËš (Mjhu§fËš) kh®ãlkhd mdhfj¤âš vG«, 
nkš neh¡F§fhš (cjhd‹) j‹ msÉš ÄFªJ Ã‰F«. 
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eho eil : 
 “jhdKŸs nr¤J kªjhÅs»a 
 ......................................... 
 .................. Rthr« ................. 
 gh§fhd thj¤âš nr¤Jk eho 
 gÇá¤jhš 
 .................................................... 
 ..................................................... 
 X§fhQ« .................... Rthrfhr«   .... (rjf eho) 
 c‰¿L kŒa eho nah§»na Jo¤J Ã‹wh‰ 
 g‰¿L« ïUk äis gj¿na Æis¥ò© lh¡»    (Fzthfl«) 
 
v¢áš (nfhiH rË) : 
 ïJ Eiu¤J msÉš ÄFªJ gSt‰W¡ fhÂ‹, tË (thj)¡ F‰w¤jhš 
tªjjhF«. 
 fW¤J, fod¥g£L òyhš kz¤Jl‹ fhÂ‹, Ia¡ (fg«) F‰w¤ij¡ 
F¿¡F«. 
 btS¤J¢ Óœ fyªjJ nghY« kŠrŸ Ãw¤njhL« fhÂ‹, mHš (ã¤j«) 
F‰w¤ij¡ fh£L«. 
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MODERN ASPECT 
BRONCHIAL ASTHMA15 
Asthma is defined as a chronic inflammatory disease of airways that is 
characterized by increased responsiveness of the tracheobronchial tree to a multiplicity of 
stimuli. It is manifested physiologically by a widespread narrowing of the air passages, 
which may be relieved spontaneously or as a result of therapy, and clinically by 
paroxysms of dyspnoea, cough, and wheezing. 
TYPES: 
 Extrinsic Asthma (Atopic asthma, Early onset asthma) 
 Intrinsic asthma (Non-atopic asthma, Late onset asthma) 
Other types: 
Ø Nocturnal asthma 
Ø Gastric asthma 
Ø Exercise induced asthma 
Ø Episodic asthma 
Ø Chronic asthma 
Ø Acute severe asthma (Status Asthmatics) 
Extrinsic asthma: 
 Onset is in childhood. 
 It occurs in atopic individuals who readily form IgE antibodies in response to 
allergens. 
Intrinsic asthma: 
 It can begin at any age, especially in late adulthood. 
There is no role for allergens in the production of the disease. 
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FACTORS PRECIPITATING ASTHMA: 
 Cold air  
 Tobacco smoke 
 Dust, acrid fumes 
 Emotional stress 
 Respiratory infections (viral, bacterial) 
 Exercise 
 Drugs 
  NSAIDS especially aspirin 
  β – blockers 
 Chemicals 
  Sulfiting agents like Na or K bisulfite, sulphur dioxide, etc. 
 Allergens 
  Ingested (fish, nuts, strawberries) 
  Inhaled (dust, pollen, house dust mite) 
  Food additives (tartrazine, metabisulfite preservatives, ajinomoto) 
 Occupational allergens 
  Grain-dust 
  Wood-dust 
CLINICAL FEATURES: 
            Dyspnoea 
            Wheeze 
            Chest pain 
            Cough with mild expectoration 
            Cough 
            Chest tightness 
COMPLICATIONS16: 
            Status Asthmaticus 
            Secondary Infection – Bronchitis, Tuberculosis 
            Emphysema of lungs 
            Right heart failure in late stages called chronic pulmonale. 
            Bronchiectasis 
            Pneumothorax 
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                                               CLINICAL STUDY 
The study was conducted on patients with Eraippu [Bronchial asthma] patients 
satisfying the inclusion criteria.  
The study was conducted at the OPD/IPD of Ayothidoss Pandithar Hospital of the 
National Institute of Siddha, Tambaram sanatorium, Chennai-47. 
Sample size:  
The sample size was 20 patients. 
SUBJECT SELECTION:  
Inclusion criteria:  
Age   : 15-65 yrs  
Sex   : both male and female  
Weight : 35-85 kgs  
            Patient having symptoms of 
Ø Wheezing  
Ø Dyspnoea 
Ø Cough 
Ø Cough with mild expectoration 
Ø Chest tightness 
Any of the 4 clinical symptoms 
Patient who are willing to provide blood for lab investigation.  
 Patients who are willing to attend OPD once in 7 days.  
 Patient who are willing to be admitted in the hospital for 30 days. 
Patient willing to sign the informed consent stating that he/she will 
conscientiously 
stick to the treatment during 30 days but can opt out of the trial of his/her own conscious 
discretion. 
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Exclusion criteria: 
Bronchiectasis 
Pleural effusion 
Pneumonia 
Tuberculosis 
Other type of asthma 
Any other serious illness 
Withdrawal criteria: 
Development of any adverse reaction  
 Occurence of any other serious illness 
Non co-operation of the patient 
TRIAL DRUG AND DURATION 
Drug   :Singathi chooranam -1gm, bid with luke warm water, after food.                                                             
Duration of the treatment: 30 days.  
CONDUCT OF THE STUDY: 
Eraippu patients satisfying inclusion and exclusion criteria were admitted to the 
trial. Informed consent was obtained from the patients. Routine investigations like Blood 
test, urine test, and PEFR were carried out before and after the trial treatment. For in 
patients the drug was administered daily. For out patients the trial drug was issued for 
seven days course. They were advised to visit the OPD once in 7 days. During each visit 
they were clinically assessed.  
CLINICAL OBSERVATION: 
For the clinical study of “Singathi Chooranam” on Eraippu, 20 patients were 
selected.   
Among 20 patients,11(55 %) were female, 9(45%) were male.  
According to age wise distribution 40%were in 20-30 years, 30% were in 31-40 
years and  30% were in 41-60 years. 
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Among 20 patients, All patients were affected from Wheezing, 20patients were 
affected from Dyspnoea, 15 patients were affected from Cough, 9 patients were affected 
from Expectoration and 17 patients were affected from Chest tightness. 
From the clinical study 85% of patients relieved from wheezing, 70% of patients 
relieved from dyspnoea, 60% of patients relieved from cough, 66.67% of patients relieved 
from expectoration and 88.23% of patients relieved from chest tightness and no adverse 
effects were observed during trial period. 
 16 (80%) patients had a significant improvement in the PEFR levels after the 
treatment. 
 The following investigations were done before and at the end of the treatment.     
§ Blood sample ( Hb, TC, DC, ESR, Sugar(F,PP), AEC, 
T.cholesterol,RFT, LFT)   
§ Peak Expiratory Flow Rate 
§ Urine test (Albumin, Sugar,Deposits) 
The following investigations were done before treatment.     
§ X-ray chest - PA view 
§ ECG  
§ Sputum AFB 
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DISCUSSION 
 The drug Singathi Chooranam was selected to evaluate the Anti-shistaminic and 
bronchodilator activity in the treatment of Eraippu. 
 The literary evidence from Agathiyar Mani ennum Vaidhiya Chinthamani Venba 
4000–part 1 strongly support the antihistsminic, bronchodilator activity of the drug. 
Bio-chemical analysis: 
             The biochemical analysis of the drug reveals the presence of sodium, 
magnesium, iron, chloride, alkaloids, tannic acid and amino acid.  
Magnesium47: 
 Magnesium is essential in muscle relaxation after contraction. Magnesium also 
plays a key role in the production of energy which is needed by the chest wall muscles 
and the diaphragm to perform the work of breathing.  
Magnesium promotes healthy lung function by acting as a bronchodilator, 
preventing the bronchial passages from going into spasm. Magnesium deficiency may 
increase vulnerabilty to allergies by increasing the release of histamine into the 
bloodstream, increasing allergic reactivity in general. 
Low dietary intake of magnesium is associated with an increased incidence of 
asthmatic symptoms, wheezing and reduced lung function.  
Magnesium sulfate has been shown to inhibit smooth muscle contraction, decrease 
histamine release from mast cells, and inhibit acetylcholine release. 
Sodium17: 
 Important for acid-base balance. 
 Required for normal cell permeability. 
 Sodium deficiency causes muscle cramps. 
 
109 
Iron48:  
 It is a component of haem which is required for the formation of haemoglobin. 
The function of hemoglobin is to carry the respiratory gases, oxygen and carbondioxide.  
Alkaloids49: 
 Alkaloids have the property of dilating the bronchial tubes allowing an increase in 
breathing. So, the alkaloids containing plants in Singathi chooranam may help to treat the 
Asthma. 
Tannic acid50: 
 It decreases the bronchial hyperreactivity, hence it helps to treat the Asthma. 
Amino acid51: 
 It is an important antioxidant that may influence susceptibility to Asthma. 
Toxicological studies: 
From the results obtained in this study, no toxic effect was observed upto 
400mg/kg of Singathi Chooranam via oral route over a period of 28 days. So, it can be 
concluded that the Singathi Chooranam can be prescribed for therapeutic use in human 
with the dosage recommendations of upto 400mg/kg. body weight p.o. 
Pharmacological studies: 
 Based on the results of the above study, it can be concluded that the Singathi 
chooranam possesses significant antihistaminic and bronchodilating activity. 
Clinical observation: 
              From the clinical study, after the course of treatment, 85% of patients relieved 
from wheezing, 70% of patients relieved from dyspnoea, 60% of patients relieved from 
cough, 66.67% of patients relieved from expectoration, 88.23% of patients relieved from 
chest tightness and no adverse effects were observed during trial period. 
 16(80%) of the patients had significant improvement in the PEFR after treatment.  
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Bio-statistics: 
              Statistically, the paired ‘t’ test shows statistical significance for the PEFR and 
symptoms before and after the treatment.(p<0.0001) 
Siddha aspect19: 
¸¡÷ôÒ Í¨ÅÂ¡ÉÐ ¸Àò¨¾ ºÁôÀÎòÐõ ¾ý¨ÁÔ¨¼ÂÐ. 
¨¸ôÒ Í¨ÅÂ¡ÉÐ À¢ò¾õ, ¸Àõ ¬¸¢ÂÅüÈ¢ý Å¢¸üÀò¨¾ º¡ó¾¢ ¦ºöÔõ.  
ÐÅ÷ôÒ Í¨ÅÂ¡ÉÐ ¸À À¢ò¾ò¨¾ §À¡ìÌõ. ¦ÅôÀõ Å£Ã¢Âõ ¸Àò¨¾ ¿£ìÌõ.  
¸À ÌüÈò¾¢É¡ø ²üÀÎõ þ¨ÃôÒ §¿¡Â¢¨É ¸¡÷ôÒ Í¨ÅÔ¨¼Â 
ãÄ¢¨¸¸Ç¡É ¸ñ¼í¸ò¾¢Ã¢, º¼¡Á¡ïº¢ø, ÍìÌ, ¸Îì¸¡ö, Á¢ÇÌ, ¨¸ôÒ 
Í¨ÅÔ¨¼Â ãÄ¢¨¸¸Ç¡É ¸ñÎÀ¡Ãí¸¢, Á¢ÇÌ, ÐÅ÷ôÒ Í¨ÅÔ¨¼Â 
ãÄ¢¨¸¸Ç¡É ¸÷ì¸¼¸º¢í¸¢, ¸ñÎÀ¡Ãí¸¢, ¾¡ýÈ¢ì¸¡ö Ó¾Ä¢Â Í¨ÅÔ¨¼Â 
ãÄ¢¨¸¸û º¢í¸¡¾¢ ÝÃ½ò¾¢ø §º÷óÐûÇ¾¡ø, þ¾É¡ø ÁÕòÐÅõ ¦ºöÂ ¿øÄ 
ÀÄ¨É «Ç¢ì¸¢ýÈÐ. 
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SUMMARY 
             The drug Singathi Chooranam was selected to evaluate the anti-histaminic and 
bronchodilator activity in the management of Eraippu (Bronchial asthma). 
             The literary evidence from Agathiyar mani ennum Vaidhiya Chinthamani Venba 
4000–part 1 strongly support the antihistaminic, bronchodilator activity of the drug. 
The qualitative and quantitative analysis were done at Biochemistry lab, National 
Institute of Siddha and Sri Ramachandra University, Chennai respectively. The 
biochemical analysis of the drug reveals the presence of sodium, magnesium, iron, 
chloride, alkaloids, tannic acid and amino acid. The results ensure the anti-histaminic and 
bronchodilator activity of the Singathi Chooranam was due to the presence of active 
phytoconstituents of the drug. 
High Performance Thin Layer Chromatography and Atomic Absorption 
Spectrophotometer was done at Sri Ramachandra University, Chennai.  
The pre-clinical evaluation (acute & repeated oral toxicity study) of the drug was 
carried out as per OECD guideline in Vels college of pharmacy, Chennai. The result 
shows safety of the drug for human administration. 
The Preclinical Pharmacological study was carried out in animal model in Vels 
college of pharmacy, Chennai. The result shows that the drug has significant anti-
histaminic and bronchodilator effect. 
As per the Siddha literature and modern science reviews and research articles, the 
trial drug has potent anti-histaminic and bronchodilator effect. 
20 Patients were recruited for clinical trial.  The trial drug Singathi chooranam at 
the dose of 1 gm, b.i.d was given to the patient for 7 days and patients were asked to visit 
op once in 7 days for 30 days. Clinical assessment and prognosis was noted at each visit. 
From the clinical study, after the course of treatment, 16(80%) of the patients had 
significant improvement in the PEFR after treatment.  
85% of patients relieved from wheezing, 70% of patients relieved from dyspnoea, 
60% of patients relieved from cough, 66.67% of patients relieved from expectoration, 
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88.23% of patients relieved from chest tightness and no adverse effects were observed 
during trial period. 
Statistically, the paired ‘t’ test shows statistical significance for the PEFR and 
associated symptoms before and after the treatment.(p<0.0001) 
 The drug Singathi chooranam has 
§ Anti-histaminic Activity 
§ Bronchodilator Activity 
§ No side effects 
§ No undoing effects 
§ Encouraging clinical results.  
From the clinical and the statistical analysis, it is proved that the drug Singathi 
Chooranam is statistically significant on antihistaminic and bronchodilator activity in the 
management of Eraippu (Bronchial asthma). 
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CONCLUSION 
The literature and research journal review of the plant shows that it has anti-
histaminic and bronchodilator activity. 
The safety studies (acute toxicity and repeated oral toxicity studies) conducted 
revealed that the trial drug Singathi Chooranam is safe. There were no abnormalities 
found in blood investigation and histo-pathological examination. Hence it can be 
reasonably assumed that the drug is safe for human use. 
The pharmacological study conducted in animal model shows significant Anti 
histaminic and Bronchodilator  activity. 
Clinical study reveals the therapeutic efficacy of the trial drug by showing, 
reduction in AEC levels and improvement in PEFR level significantly. There was 
improvement in other clinical symptoms after treatment. 
There were no adverse reactions complained during the clinical trial. 
Hence, the drug SINGATHI CHOORANAM can be used in the management of 
Eraippu (Bronchial Asthma) 
  
                TABLES FOR TRAIL DRUG-1 VALENDRAPHOLA CHOORANAM 
 
TRIAL DRUG I, TABLE 1: QUALITATIVE ANALYSIS 
 
 
 
                                                                                                                
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TRIAL DRUG I, TABLE 2: PHYSICAL PROPERTIES 
 
 
S.NO 
 
Characteristic test 
 
Results 
 
1. 
 
Ph 
 
4.6 
 
2. 
 
Ash Value 
 
0.94 
 
3. 
 
Water soluble ash 
 
0.03 
 
4. 
 
Acid insoluble ash 
 
0.05 
 
 
S.NO PARAMETERS RESULTS 
1. Phosphate  Absent 
2. Sulphate Absent 
3. Magnesium Absent 
4. Iron Present 
5 Aminoacids Present 
6. Starch Absent 
7. Flavonoids Absent 
8. Proteins Present 
9. Tannic acid Absent 
10. Glycosides Absent 
  
  
 TRIAL DRUG I, TABLE 3: Preliminary acid, basic radicals screening of      
                                                    Valendraphola chooranam. 
 
 
S.No. Constituents 
VC 
1. Calcium + 
2. 
Iron (Ferric) 
+ 
3. 
Iron (Ferrous) 
+ 
4. 
Chloride 
_ 
5. 
Phosphate 
_ 
6. 
Potassium 
_ 
7. 
Sodium 
_ 
8. 
Sulphate 
_ 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
GRAPH 1: HPTLC Profile 
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TRIAL DRUG I, CHART  1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
TRIAL DRUG I, CHART  2 
 
 
 
TRIAL DRUG I, CHART  3 
 
  
                 CLINICAL OBSERVATION 
 
 
TRIAL DRUG I, TABLE 15: AGE DISTRIBUTION 
 
   
 
 
 
 
 
 
 
 
 
S.NO AGE(YEARS) PERCENTAGE 
1. 20-30 4(20%) 
2. 31-40 8(40%) 
3. 41-50 5(25%) 
4. 51-60 3(15%) 
  
TRIAL DRUG I, TABLE 16: GENDER DISTRIBUTION 
 
 
S.NO GENDER NO OF PATIENTS PERCENTAGE 
1. MALE 3 15% 
2. FEMALE 17 85% 
 
 
 
 
 
15%
85%
Male
Female
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
TRIAL DRUG I, TABLE 17: IMPROVEMENT  SHOWING SIGNS AND 
SYMPTOMS BEFORE AND AFTER TREATMENT OF PANDU PATIENTS. 
 
S.NO SYMPTOMS 
NO. OF PATIENTS WITH SYMPTOMS 
 
BT 
AT Improvement 
Percentage No 
improvement Improvement 
1. Pallor 20(100%) 18(90%) 2(10%) (10%) 
2. Breathlessness 17(85%) 4(23.53%) 13(76.47%) (76.47%) 
3. Tiredness 18(90%) 3(16.67%) 15(83.33%) (83.33%) 
4. Giddiness 12(60%) 2(16.67%) 10(83.33%) (83.33%) 
5. Anorexia 18(90%) 3(16.67%) 15(83.33%) (83.33%) 
6. Pica 13(65%) 4(30.77%) 9(69.23%) (69.23%) 
7. Palpitations 16(80%) 3(18.75%) 13(81.25%) (81.25%) 
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BT          –  Before Treatment 
AT NOI  –  After Treatment No Improvement 
AT I         –  After Treatment Improvement 
 
 
 
 
 
  
IMPROVEMENT IN HB LEVELS 
 
   
S.NO 
OP/IP NO AGE SEX BT HB AT HB 
1 C81998 52 F 9 9.7 
2 C81264 39 F 6.4 7.8 
3 C75674 55 F 9.3 10.6 
4 C83901 25 F 8.4 9.1 
5 C82169 45 M 10 10 
6 C69781 36 F 7.4 8.9 
7 C91254 39 F 9.2 11.1 
8 C92794 33 F 8.6 11 
9 C91728 27 F 7.2 8.2 
10 C92876 40 F 8.2 8.9 
11 C92882 51 F 7.1 7.1 
12 C82212 28 M 8.6 9.8 
13 C93377 37 F 7.6 7.6 
14 C91376 37 F 8.3 9.3 
15 C94453 49 F 9.2 9.2 
16 C89619 38 F 9.6 10.8 
17 C94419 46 F 9 10.4 
S18 4248 48 F 8.5 10 
19 D000707 47 M 8.9 10 
20 C90994 28 F 6.1 7.6 
 
 
 
 
 
 
 
 
 
 
  
 
 
STATISTICAL ANALYSIS 
 
All collected data were entered into MS Excel software using different columns as 
variables and rows as patients. SPSS software was used to perform statistical analysis. Basic 
descriptive statistics include frequency distributions and cross-tabulations were performed. 
The quantity variables were expressed as Mean ± Standard Deviation and qualitative data as 
percentage. A probability value of <0.05 was considered to indicate as statistical significance. 
Paired ‘t’ test was performed for determining the significance between before and after 
treatment. 
 
 
 
Paired t test for Symptoms before and after treatment: 
 
Variable Obs Mean Std.dev t.value P value 
Before 
symptoms 
20 
 
5.10 
 
1.689 
 
10.353 P<0.0001 
After 
symptoms 
20 1.85 1.631 
 
For Symptoms, the mean±standard deviation before treatment is 5.10±1.689  and after 
treatment is 1.85±1.631, which is statistically significant(p<0.0001). 
 
  
Paired t test for Hb before and after treatment: 
 
Variable Obs Mean Std.dev t.value P value 
Before 
treatment 
20 
 
8.33 
 
1.0553 
 
-6.945 P<0.0001 
After 
treatment 
20 9.355 1.2041 
 
For Hb, the mean±standard deviation before treatment is 8.33±1.0553 and after treatment is 
9.355±1.2041, which is statistically significant(p<0.0001). 
 
 
 
 
TOXICOLOGY TABLES 
 
TRIAL DRUG I, TABLE 4: Dose finding experiment and its behavioural Signs of Toxicity 
No Dose mg/kg 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 
1 2000 + - - + - + - - - - - - - - - - - - -  - 
2 5000 + - - + - + + - - - - - + - - - - - - - 
1. Alertness 2. Aggressiveness 3. Pile erection 4. Grooming  5. Gripping  6. Touch Response 7. Decreased Motor Activity 8. Tremors 9. 
Convulsions 10. Muscle Spasm 11. Catatonia 12. Muscle relaxant 13. Hypnosis 14. Analgesia 15.Lacrimation 16. Exophthalmos 17. Diarrhoea 
18. Writhing 19. Respiration 20. Mortality 
 
 
TRIAL DRUG I, TABLE 5. Body wt (g) of rats exposed to Valendraphola Chooranam for 28days. 
Dose (mg/kg/day) 
Days 
1 7 14 21 28 
Control 122.65±4.22 124.13±5.10 126.10±4.12 128.52±7.02 128.62±5.21 
100 124.47±5.10 125.22±5.12 126.12±4.70 125.22±5.88 126.10±5.52 
250 124.18±4.42 128.17±5.75 124.18±5.12 125.18±6.00 126.17±6.10 
500 121.15±4.21 125.23±5.38 128.16±4.71 128.02±6.20 128.10±6.22 
Values are mean ± S.E.M. (Dunnet ’t' test). nsP>0.05; Vs Control N=6. 
 
TRIAL DRUG I, TABLE 6. Food intake of rats exposed to Valendraphola Chooranam for 28days. 
Dose (mg/kg/day) Days (gms/rats) 
1 7 14 21 28 
Control 47.05±2.32 45.12±2.52 54.41±2.31 55.11±2.66 57.52±3.16 
100 44.27±2.28 45.34±2.40 52.40±2.88 50.11±2.26 48.10±3.22 
250 45.13±2.14 42.82±2.54 44.42±2.64* 45.32±3.46 46.48±3.00 
500 44.41±2.45 45.48±2.55 42.32±2.57* 45.10±2.60* 45.44±3.18* 
Values are mean ± S.E.M. (Dunnet ’t' test). nsP>0.05; Vs Control N=6. 
 
 
TRIAL DRUG I, TABLE 7. Water (ml/day) intake of rats exposed to Valendraphola Chooranam for 28days. 
Dose (mg/kg/day) Days(ml/rat) 
1 7 14 21 28 
Control 50.22±2.45 52.44±3.12 55.28±3.10 52.14±3.18 51.12±3.45 
100 50.10±2.40 50.96±3.04 45.23±3.46 46.00±3.00 45.55±2.51 
250 47.27±2.84 40.18±3.34* 40.87±3.28* 42.32±2.48 42.10±3.20 
500 51.14±3.45 52.44±3.15 50.20±3.41 50.13±3.12 53.22±3.44 
Values are mean ± S.E.M. (Dunnet’t' test). *P<0.05; N=6. 
 
 
 
 TRIAL DRUG I, TABLE 8. Hematological parameters after 28days treatment with Valendraphola Chooranam. 
Parameter Control 100 mg/kg 250 mg/kg 500 mg/kg 
RBC (millions/cu.mm) 5.13±0.41 5.15±0.41 5.26±0.32 5.32±0.41 
Hb (g/dl) 13.01±0.28 13.83±0.98 14.0±1.1 14.12±1.0 
PCV (%) 42.11±1.05 44.5±4.1 44.0±2.5 45±1.1 
WBC(cells/cu.mm) 7375±440.17 8050±330.9 8325±417.3 8633±513.3 
Neutrophil (%) 45.22±4.10 42.42 ±2.5  45.24±3.0 45.27±3.2 
Lymphocytes (%) 40.22±2.26 42.10±2.13  42.15±2.40 44.10±4.1 
Eosinophil’s (%) 4.0±0.40 3.0±0.56 4.1±0.44 5.10±0.43 
Monocytes (%) 3.0±0.22 4.0±0.24* 4.0±0.3* 3.2±0.2 
Basophils (%) 0±0 0±0 0±0 0±0 
Platelets (105 cells/cu.mm) 1.52±0.05 1.86±0.09 1.89±0.12 2.1±0.14** 
MCV(Fl) 75.5±2.2 67.2±1.4 73.1±2.3 74.4±3.5 
MCHC (pg) 29.5±2.5 28.41±2.4 29.2±2.1 30.00±2.5 
Values are mean ± S.E.M. (Dunnet ’t' test). *P<0.05; **P<0.01. N=6. 
 
 
 
 
 
 
TRIAL DRUG I, TABLE 9. Effect of Valendraphola Chooranam biochemical (LFT, RFT, Lipid Profile) Parameters 
Values are mean ± S.E.M. (Dunnet ’t' test). nsP>0.05; Vs Control N=6. 
       Parameter Control 100 mg/kg 250 mg/kg 500 mg/kg 
Glucose (mg/dL) 85.04±5.17 78.66±5.50 76.20±7.25 74.16±6.88 
Total Bilirubin (mg/dL) 0.213±0.05 0.214±0.05 0.212±0.05 0.210±0.06 
Bilirubin direct (mg/dL) 0.1±0.04 0.1±0.05 0.1±0.04 0.1±0.05 
Creatinine (mg/dL) 0.90±0.05 0.88±0.05 0.91±0.03 0.93±0.03 
BUN (mg/dL) 18.05±1.56 18.00±1.29 17.26±1.73 17.14±1.64 
AST (IU/L) 132.4±7.32 127.2±6.12 126.1±6.10 124.2±5.18 
ALT (IU/L) 36.10±3.11 34.10±2.46 35.52±2.55 34.42±2.40 
ALP (IU/L) 75.32±4.43 70.16±4.12 66.30±4.36 67.44±4.22 
Total cholestrol (mg/dL) 56.86±5.77 57.61±5.68 55.84±5.21 59.61±4.88 
Total protein (g/dL) 8.30±0.28 7.44±0.24 7.58±0.75 7.56±0.76 
Albumin (g/dL) 2.62±0.05 2.64±0.06 2.72±0.06 2.80±0.05 
Urea(mg/dL) 55.32±1.60 54.41±3.50 55.12±2.38 54.75±2.16 
Uric acid (mg/dL) 1.6±0.12 1.6±0.18 1.6±0.16 1.5±0.14 
Na m.mol 142.70±5.15 141.2±5.00 141.45±5.20 141.22±5.12 
K m.mol 20.11±2.47 19.88±1.72 20.10±1.62 20.16±1.72 
Cl m.mol 102.16±4.11 102.33±5.14 104.44±5.82 100.04±5.10 
HDL(mg/dL) 13.00±1.14 13.31±1.45 13.10±1.42 13.46±2.00 
LDL(mg/dL) 43.12±2.23 44.55±3.54 42.21±3.23 43.10±3.24 
VLDL(mg/dl) 15.42±2.55 15.98±2.65 16.02±2.34 15.98±2.20 
Triglycerides (mg/dl) 85.24±3.00 85.26±2.22 86.23±3.24 88.36±2.72 
TRIAL DRUG I, TABLE-10 Urine Analysis 
Parameters 
Control 100 mg/kg 250 mg/kg 500 mg/kg 
Colour Yellow Yellow Yellow Yellow 
Transparency Clear Slightly turbid Slightly cloudy Slightly turbid 
Specific gravity 1.010 1.010 1.010 1.010 
PH >7.2 >8.0 >8.0 >9.0 
Protein Nil 3+ 3+ 3+ 
Glucose Nil Nil Nil Nil 
Bilirubin -ve -ve -ve -ve 
Ketones -ve +ve +ve +ve 
Blood Absent Absent Absent Absent 
Urobilinogen 
Normal Abnormal Abnormal Abnormal 
Pus cells 0-cells/HPF 1-cell/HPF 2-cells/HPF 1-cell/HPF 
RBCs Nil Nil 0-1cells/HPF Nil 
Epithelial cells Nil 1-cell/HPF Nil 1-cell/HPF 
Crystals Nil Nil Nil Nil 
Casts Nil Nil Nil Nil 
Others Bacteria seen Bacteria seen Bacteria seen Bacteria seen 
 
 
 
 
TRIAL DRUG I, TABLE 11. Effect of Valendraphola Chooranam on organ weight 
Dose (mg/kg) Control 100 mg/kg 250 mg/kg 500 mg/kg 
Heart(g) 0.70±0.05 0.67±0.11 0.66±0.09 0.69±0.04 
Liver(g) 4.42±0.42 4.29±0.39 4.82±0.62 4.77±0.55 
Lung(g) 0.71±0.04 0.72±0.05 0.72±0.05 0.69±0.4 
Spleen(g) 0.68±0.04 0.69±0.04 0.71±0.05 0.68±0.05 
Kidney(g) 1.09±0.3 1.01±0.04 1.96±0.2** 1.42±0.05 
Testis(g) 0.92±0.03 0.91±0.05 0.90±0.04 0.91±0.03 
Ovary(g) 0.04±0.01 0.04±0.02 0.04±0.01 0.04±0.02 
Brain 0.69±0.06 0.67±0.04 0.68±0.03 0.67±0.05 
Pancreas 1.44±0.08 1.48±0.09 1.50±0.10 1.51±0.12 
Uterus 0.78±0.08 0.82±0.09 0.81±0.06 0.82±0.05 
 
 
Values are mean ± S.E.M. (Dunnet’t' test). *P<0.05; **P<0.01 Vs Control N=6. 
 
 
PHARMACOLOGICAL TABLES 
TRIAL DRUG I, TABLE 12: Effect of Phenylhydrazine (10mg/kg, p.o. daily for 7 days) alone on Hematological parameters. 
Parameters 
 
Group 1 
(Normal) 
Group 2 
(Anemic) 
Group 3 
(Anemic) 
Group 4 
(Anemic) 
Group 5 
(Anemic) 
Group 6 
(Anemic) 
Hb (g/dl) 17.31 ± 0.46 11.2±0.27** 12.65±0.25** 12.14±0.38** 12.11±0.28** 12.05 ± 0.30** 
PCV (%) 50.12 ±1.51 38.55 ± 2.39** 40.12 ± 1.53* 42.12 ± 2.34 41.05 ± 2.04* 39.16 ± 2.72** 
RBC (x106/ml) 5.88 ± 0.17 4.50 ± 0.28** 4.53 ± 0.24** 4.75 ± 0.20* 4.44 ± 0.30** 4.52 ± 0.34** 
MCV (fl) 69.15 ± 2.67 81.35±3.4 85.46±6.11* 84.05±3.12 83.16±5.44 88.41± 3.61* 
MCH (pg) 21.74 ± 1.44 25.28±1.31 28.19±1.65* 30.12±1.10** 32.10±0.84** 30.24 ± 2.40** 
MCHC (g/dl) 35.64 ± 0.38 32.20±0.5 34.02±0.74 33.62±1.46 32.14±2.86 30.09 ± 2.22 
Values are ± S.E.M. (Dunnet’t' test). *P<0.05; **P<0.01 Vs Control N=6. 
TRIAL DRUG I, TABLE 13:Hematological parameter of rats after Seven days treatment with Valendraphola Chooranam. 
Parameters  
 
Group 1 
(Normal) 
Group 2 
(Anemic control) 
Group 3 
(100 mg/kg) 
Group 4 
(200 mg/kg) 
Group 5 
(400 mg/kg) 
Group 6 
(Heamatinic 
syrup) 
Hb (g/dl) 17.11 ±1.26** 11.31±1.1 13.64±0.48 14.55±1.22 15.64 ± 0.59* 19.54 ±1.41** 
PCV (%) 51.04 ±1.34** 40.10±2.6 43.21±2.29 45.25±2.37 49.46±2.48* 54.18 ±2.48** 
RBC (x106/ml) 5.16±0.21 4.12±0.28 5.16±0.24 5.28±0.18 5.11±0.21 6.55±1.00** 
MCV (fl) 75.17±2.36  74.2±2.5 78.20±1.8 75.4±2.6 76.30±4.1 75.33±2.52  
MCH (pg) 22.10±1.48*  28.1±1.42 22.24±1.5* 23.0±1.4 23.05±2.0 22.26±1.34*  
MCHC (g/dl) 34.24±1.28  31.15±1.18  28.64±1.8 29.79±1.5 31.2±1.7 33.17±1.4 
Values are mean ± S.E.M. (Dunnet’t' test). *P<0.05; **P<0.01 Vs Control N=6. 
TRIAL DRUG I, TABLE 14:Hematological parameters of rats after 14 days treatment with Valendraphola Chooranam. 
Parameters  
 
Group 1 
(Normal) 
Group 2 
(Anemic 
control) 
Group 3 
(100 mg/kg) 
Group 4 
(200 mg/kg) 
Group 5 
(400 mg/kg) 
Group 6 
(Heamatinic 
syrup) 
Hb (g/dl) 16.12 ±1.47** 9.78 ± 1.17 17.10 ± 0.68* 17.15 ± 0.56** 18.56 ± 0.54** 20.64 ±1.38** 
PCV (%) 44.38 ± 1.31 40.00±1.87 41.14±3.02 42.64±2.2 43.02±1.9 52.17 ± 1.82** 
RBC (x106/ml) 5.22±0.26** 3.28±0.50 4.00±0.37 4.81±0.34* 4.38±0.28 5.22±0.52** 
MCV (fl) 72.10±2.08** 87.56±2.85 80.16±2.40 75.10±1.61** 78.11±2.36* 73.21±2.46** 
MCH (pg) 29.24±2.85 32.19±2.24 30.00±1.48 28.54±1.74 28.13±1.27 29.65±2.17 
MCHC (g/dl) 34.26±2.88 31.05±1.34 32.02±1.33 32.89±0.68 33.74±2.58 34.10±3.02 
Values are mean ± S.E.M. (Dunnet’t' test). *P<0.05; **P<0.01 Vs Control N=6. 
 
 
 
 
 
 SPECIFIC INVESTIGATIONS FOR PANDU 
S.NO 
 
OP/IP NO 
 
AGE SEX 
HB 
[gm/dl] 
RBC 
[million/cu.mm] 
PCV 
[%] 
MCV 
[fL] 
MCH 
[pg] 
MCHC 
[gm/dl] 
 
HM 
ESR[mm] 
 
½ Hr 1 Hr 
 
BT 
 
AT 
 
BT 
 
AT 
 
BT 
 
AT 
   
BT 
  
AT 
   
 BT 
 
AT 
 
  BT 
 
AT 
 
BT 
 
AT 
 
BT 
 
AT 
  
BT 
 
AT 
1 C81998 52 F 9 9.7 5 5 31 31 61.8 61.3 18.5 19.2 30 30.1 HM HM 10 4 16 8 
2 C81264 39 F 6.4 7.8 3.9 4 23.6 25 59.6 58.2 16.2 16.2 27.1 27.8 HM HM 14 2 20 6 
3 C75674 55 F 9.3 11 4.7 5 31 33.4 65 65.9 19.5 20.9 30 31.7 HM N 12 6 32 12 
4 C83901 25 F 8.4 9.1 4.6 4.9 28.8 30.7 61.4 61.6 17.9 18.3 29.2 29.6 HM HM 10 4 14 8 
5 C82169 45 M 10 10 5.2 5.3 38.4 38.5 80.2 80.1 30.1 30.1 34.3 34.3 HM HM 8 6 20 18 
6 C69781 36 F 7.4 8.9 4.3 4.8 26.1 28.6 60.1 60.3 17.1 17.1 28.4 28.6 HM HM 6 2 14 10 
7 C91254 39 F 9.2 11 3.3 3.9 28.2 30.9 98 98.1 30 30.6 34.7 35.1 HM N 4 4 8 6 
8 C92794 33 F 8.6 11 3.8 4.7 25.8 30.3 88.3 88.2 29.7 29.7 31 31.2 HM N 12 10 24 20 
9 C91728 27 F 7.2 8.2 4.1 4.4 25.1 25.9 60.6 60.1 17.4 16.7 28.7 27.8 HM HM 4 6 8 12 
10 C92876 40 F 8.2 8.9 4.4 4.6 28.3 30 63.7 64.7 18.5 19.2 29 29.7 HM HM 4 2 10 8 
11 C92882 51 F 7.1 7.1 4.4 4.4 26.8 26.8 59.7 59.5 15.8 15.8 26.5 26.5 HM HM 4 4 8 10 
12 C82212 28 M 8.6 9.8 4.7 5 29.4 32.5 72.2 72.4 20.2 20.4 28.4 28.6 HM HM 10 6 18 12 
13 C93377 37 F 7.6 7.6 4.3 4.4 25.1 25.1 57.2 57.2 14.4 14.5 25.1 25.3 HM HM 20 14 42 22 
14 C91376 37 F 8.3 9.3 4.6 4.8 28.5 29.3 61 61.8 17.8 18 29.1 29.9 HM HM 16 6 22 12 
15 C94453 49 F 9.2 9.2 4.7 4.6 30.4 30.4 65.1 65.1 19.6 19.6 30.1 29.9 HM HM 6 2 20 4 
16 C89619 38 F 9.6 11 4 4.4 31.3 32.2 67.5 67.9 20.7 21 30.7 30.9 HM HM 8 4 16 12 
17 C94419 46 F 9 10 4.4 4.7 31.1 31.9 67.2 67.3 19.9 20 29.6 29.6 HM HM 4 4 12 10 
18 4248 48 F 8.5 10 3.7 3.9 32.2 30.4 79.5 77.6 25.7 25.5 32.3 32.9 HM HM 22 12 62 26 
19 D000707 47 M 8.9 10 5 5.4 28.3 32.5 67.6 67.9 20.3 20.4 29.4 29.6 HM N 12 6 20 12 
20 C90994 28 F 6.1 7.6 4.1 4.2 23.2 23.6 55.6 55.7 14.6 14.6 26.3 26.3 HM HM 18 14 24 20 
PANDU – BEFORE TREATMENT 
S 
NO 
OP/IP NO AGE SEX 
TC 
[cu.mm] 
DC PLT 
[Lak
hs/c
u.m
m] 
BLOOD 
SUGAR 
[mg/dl] URE 
[mg/
dl] 
CRE 
[mg/
dl] 
CHO 
[mg/
dl] 
 
LFT 
 
 CA[mg
/dl] 
 
P
H
O
[
m
g
/
dl
] 
 
 URINE 
 
U.A 
[mg/dl
] 
ALB 
SUGAR DEP 
p% L% E% 
M
% 
F PP 
OT 
[Iu/L
] 
PT 
[Iu
/L] 
ALP 
[Iu/L
] 
TP 
[mg/
dl] 
 
 F PP PUS EPI 
1 C81998 52 F 7700 58 33 6 3 3.6 107 127 15 0.6 136 14 15 140 6.7 11.2 3.4 4.4 nil nil nil 1-2 1-2 
2 C81264 39 F 6200 55 40 5 0 2.7 96 122 14 0.5 156 21 25 148 7.9 10.3 3.5 5 nil nil nil 2-3 2-3 
3 C75674 55 F 7400 55 35 10 0 4.2 89 106 15 0.5 140 33 16 150 7.4 10.5 3.2 3.6 nil nil nil 2-3 2-3 
4 C83901 25 F 6300 48 48 4 0 3.2 82 99 18 0.5 96 17 18 131 7 10.9 2.9 3.1 nil nil nil 6-8 3-4 
5 C82169 45 M 9000 63 32 5 0 3.1 103 138 14 0.5 211 37 40 220 7.6 11.3 4 3.6 nil nil nil 2-4 1-2 
6 C69781 36 F 4500 45 48 7 0 3.2 92 106 14 0.4 90 15 16 166 7.3 11.1 3.2 3.2 nil nil nil 2-3 2-3 
7 C91254 39 F 4700 64 30 5 1 2 102 116 14 0.4 105 35 36 245 6.5 11 3.1 3 nil nil nil 1-2 1-2 
8 C92794 33 F 8500 53 41 4 2 2.2 85 119 22 0.6 125 21 24 168 5.2 9.9 2.8 3.8 nil nil nil 1-3 2-4 
9 C91728 27 F 8200 63 34 3 0 3.2 92 101 25 0.7 115 14 15 147 7.2 9.8 2.9 2.9 nil nil nil 3-4 4-5 
10 C92876 40 F 6000 50 44 6 0 2.6 83 105 15 0.4 130 17 18 165 7.6 9.8 3 4 nil nil nil 2-3 1-2 
11 C92882 51 F 8900 68 28 4 0 4.9 99 134 20 0.6 147 14 13 166 7.2 11.3 2.9 5.2 nil nil nil 1-2 1-2 
12 C82212 28 M 9300 55 38 6 1 2.3 107 132 25 0.8 194 18 23 182 7 11.5 3 5.9 nil nil nil 2-4 1-2 
13 C93377 37 F 5300 50 42 6 0 3.1 94 121 14 0.4 146 22 23 164 7.2 10.5 3 3.7 nil nil Nil 3-4 1-2 
14 C91376 37 F 6500 53 42 4 1 4.3 94 104 17 0.5 128 10 11 130 7.6 11 3 4 nil nil Nil 1-2 2-3 
15 C94453 49 F 4700 54 39 5 2 2.5 86 116 15 0.4 168 16 18 173 5,8 10.5 3.1 4.2 nil nil Nil 2-4 2-4 
16 C89619 38 F 7700 58 40 2 0 2.9 103 127 14 0.4 153 16 20 186 5.9 10.8 3.2 3.4 nil nil Nil 1-2 3-5 
17 C94419 46 F 7000 59 36 4 1 4 89 118 15 0.4 135 15 17 161 6.2 11.6 3.4 3.6 nil nil Nil 2-3 2-3 
18 4248 48 F 10200 72 23 5 0 3.2 99 124 14 0.5 194 13 15 189 6.8 11.2 3.5 4.4 nil nil Nil 8-10 4-8 
19 D000707 47 M 6400 70 27 3 0 3.1 98 120 20 0.6 145 15 17 163 5 10.5 3.2 3.4 nil nil Nil 4-8 3-6 
20 C90994 28 F 7300 57 33 10 0 4 101 112 14 0.4 110 14 16 171 6.4 10.8 3.2 3.3 nil nil Nil 3-4 4-5 
 
 
PANDU – AFTER TREATMENT 
 
 
S.NO OP/IP NO      
AGE 
    
SEX 
 
TC 
[cu.mm] 
              
                DC 
PLT 
[Lakhs/ 
cu.mm] 
 
     BLOOD        
      SUGAR 
     [mg/dl] 
UREA 
[mg/dl] 
CREAT 
[mg/dl] 
CHOL 
[mg/dl] 
                       
                         LFT 
CA 
[mg/dl] 
 
PHOS 
[mg/dl] 
U.A 
[mg/dl] 
                       URINE 
          SUGAR DEP 
P% L% E% M% FBS PPBS SGOT 
[Iu/L] 
SGPT 
[Iu/L] 
ALP 
[Iu/L] 
TP 
[mg/ 
dl] 
ALB    F       PP PUS      EPI 
1 C81998 52 F 7700 65 30 5 0 3.3 110 120 18 0.5 140 22 23 166 7.2 10.1 3.2 3.5 Nil Nil nil 1-2 1-2 
2 C81264 39 F 7200 53 42 5 0 2.5 96 118 16 0.5 145 31 33 180 6.5 10.3 3.2 6.4 Nil Nil nil 2-4 2-4 
3 C75674 55 F 8000 65 26 9 0 4.1 92 112 14 0.4 150 14 15 175 5.5 10 3.5 2.9 Nil Nil nil 2-4 2-4 
4 C83901 25 F 6300 55 42 3 0 3.8 93 104 14 0.4 119 15 16 130 4.6 10.5 3.1 2.9 Nil Nil nil 2-4 2-4 
5 C82169 45 M 9400 59 36 4 1 2.9 84 120 15 0.4 200 20 22 152 7.1 11.9 3.2 5 Nil Nil nil 2-4 2-4 
6 C69781 36 F 5200 51 41 8 0 2.9 94 101 14 0.4 105 14 17 149 5.1 10.9 2.9 3 Nil Nil nil 2-4 2-4 
7 C91254 39 F 4500 58 38 4 0 2 95 108 18 0.5 115 30 32 196 6.5 10.8 3 3 Nil Nil nil 1-2 1-2 
8 C92794 33 F 9300 49 34 16 1 2.2 101 116 16 0.5 114 30 32 189 6.6 10.1 2.8 4 Nil Nil nil 1-2 1-2 
9 C91728 27 F 8900 70 26 4 0 4.1 98 116 23 0.7 143 11 12 155 6.6 11 3.4 3.5 Nil Nil nil 4-8 3-6 
10 C92876 40 F 5400 40 55 5 0 2.6 101 120 17 0.4 167 12 11 145 6.5 10.1 2.7 3.4 Nil Nil nil 1-2 2-3 
11 C92882 51 F 6100 63 35 2 0 4.7 102 136 14 0.4 178 14 16 154 6.7 10.7 2.9 3.7 Nil Nil nil 2-3 2-3 
12 C82212 28 M 9600 62 35 3 0 2.8 94 104 18 0.5 189 25 27 166 7.5 11.5 3 7.1 Nil Nil nil 2-4 2-4 
13 C93377 37 F 5500 42 55 3 0 2.8 97 120 14 0.4 150 19 21 170 7 10.8 2.9 3 Nil Nil nil 2-3 2-3 
14 C91376 37 F 6000 50 46 4 0 3.8 87 114 15 0.6 137 19 21 140 7 10 2.8 4 Nil Nil nil 1-2 1-2 
15 C94453 49 F 4800 56 39 5 0 2.7 91 140 14 0.5 161 19 21 175 6 10.4 2.9 4.3 Nil Nil nil 2-4 2-4 
16 C89619 38 F 7700 60 38 2 0 2.7 105 135 14 0.4 189 16 17 195 6 10 2.8 4 Nil Nil nil 1-2 2-3 
17 C94419 46 F 7200 53 44 3 0 4.1 92 114 14 0.4 180 20 22 183 5.5 10.6 2.8 4.3 Nil nil nil 1-2 1-2 
18 4248 48 F 5900 68 28 4 0 4.5 83 129 14 0.5 182 12 15 160 6.2 10.5 3.3 5 Nil nil nil 1-2 1-2 
19 D000707 47 M 5400 65 30 5 0 2.7 84 104 21 0.9 163 17 19 166 5.9 10.4 3 3.7 Nil nil nil 2-4 2-4 
20 C90994 28 F 7700 55 39 6 0 2.9 96 132 14 0.4 139 11 12 153 6.1 10.6 3 3 Nil nil nil 2-4 2-4 
IMPROVEMENT IN PROGNOSIS OF SYMPTOMS OF PANDU  
 
S.NO 
 
OP/IP NO 
 
AGE 
 
SEX 
 
PALLOR 
 
BREATHLESSNESS 
 
TIREDNESS 
 
GIDDINESS 
 
ANOREXIA 
 
PICA 
 
PALPITATIONS 
BT AT BT AT BT AT BT AT BT AT BT AT BT AT 
1 C81998 52 F        +         +         +         _         +         _         _         _         +         _         +         _         +         _ 
2 C81264 39 F        +         +         +         _         +         +         +         _         +         +         +         +         +         + 
3 C75674 55 F        +         +         +         _         +         _         _         _         +         _         _         _         _         _ 
4 C83901 25 F        +         +         +         _         +         _         +         _         +         _         +         _         +         _ 
5 C82169 45 M        +         +         _         _         _         _         _         _         _         _         _         _         +         _ 
6 C69781 36 F        +         +         +         +         +         _         +         +         +         _         +         +         +         _ 
7 C91254 39 F        +         _         +         _         +         _         _         _         +         _         _         _         _         _ 
8 C92794 33 F        +         _         +         _         +         _         _         _         +         _         +         _         +         _ 
9 C91728 27 F        +         +         +         _         +         _         +         _         +         +         +         +         +         _ 
10 C92876 40 F        +         +         +         +         +         _         +         _         +         _         +         _         +         _ 
11 C92882 51 F        +         +         +         +         +         +         +         +         +         _         +         _         +         + 
12 C82212 28 M        +         +         +         _         +         _         _         _         +         _         _         _         +         _ 
13 C93377 37 F        +         +         +         +         +         +         +         _         +         _         +         +         +         + 
14 C91376 37 F        +         +         +         _         +         _         +         _         +         _         +         _         +         _ 
15 C94453 49 F        +         +         _         _         +         _         +         _         +         _         _         _         _         _ 
16 C89619 38 F        +         +         +         _         _         _         _         _         _         _         _         _         _         _ 
17 C94419 46 F        +         +         +         _         +         _         _         _         +         _         +         _         +         _ 
18 4248 48 F        +         +         +         _         +         _         +         _         +         _         +         _         +         _ 
19 D000707 47 M        +         +          _         _         +          _         +         _         +          _         _         _         +         _ 
20 C90994 28 F        +         +         +         _         +         _         +         _         +         +         +         _         +         _ 
 
                   TABLES FOR TRAIL DRUG-2 SINGATHI CHOORNAM 
 
TRIAL DRUG II, TABLE 1: QUALITATIVE ANALYSIS: 
 
S.NO PARAMETERS RESULTS 
1. Phosphate Absent 
2. Sulphate Absent 
3. Magnesium Present 
4. Iron Present 
5 Aminoacids Present 
6. Starch Absent 
7. Flavonoids Absent 
8. Proteins Absent 
9. Tannic acid Present 
10. Glycosides Absent 
 
 
  
 TRIAL DRUG II, TABLE 2: PHYSICAL PROPERTIES 
                       
 
S.NO 
 
Characteristic test 
 
Results 
 
1. 
 
Ph 
 
5.52 
 
2. 
 
Ash Value 
 
0.85 
 
3. 
 
Water soluble ash 
 
0.11 
 
4. 
 
Acid insoluble ash 
 
0.13 
 
 
 
 
TRIAL DRUG II, TABLE 3: Preliminary acid, basic radicals screening of Singathi 
Chooranam 
S.No. Constituents SC 
1. magnesium + 
2. Iron (Ferric) + 
3. Iron (Ferrous) + 
4. sulphate _ 
5. Sodium + 
6. Starch _ 
7. Phosphate _ 
      
 
 
 
 
TRIAL DRUG II, TABLE 4: METAL CONTENT: 
 
 
SAMPLE 
NAME 
 
Fe (ppm) 
 
Zn (ppm) 
 
   K (ppm) 
  
  Na 
(ppm) 
 
  Ca 
(ppm) 
 
Mg (ppm) 
SINGATHI 
CHOORANAM 
 
 
    1.658 
 
      _ 
 
      _ 
 
    NA 
 
      _ 
 
     _ 
 
TRIAL DRUG II, GRAPH 1: FINGER PRINTING  
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TRIAL DRUG II, CHART 1 
 
 
  
 
TRIAL DRUG II, CHART 2 
           
 
 
 
         CLINICAL OBSERVATION 
 
 
TRIAL DRUG II, TABLE 15:AGE DISTRIBUTION 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
S.NO AGE(YEARS) PERCENTAGE 
1. 20-30 (8) 40% 
2. 31-40 (6) 30% 
3. 41-60 (6) 30% 
 
 
 
TRIAL DRUG II, TABLE 16: GENDER DISTRIBUTION 
 
 
S.NO GENDER NO OF PATIENTS PERCENTAGE 
1. MALE 9 45% 
2. FEMALE 11 55% 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
TRIAL DRUG II, TABLE 17: IMPROVEMENT SHOWING SIGNS AND 
SYMPTOMS BEFORE AND AFTER TREATMENT OF ERAIPPU PATIENTS. 
 
S.NO SYMPTOM 
NO OF PATIENTS WITH SYMPTOMS 
 
BT 
AT 
Improvement 
Percentage 
No 
improvement 
Improvement 
1. Wheeze 20(100%) 3(15%) 17(85%) 85% 
2. Dyspnoea 20(100)% 6(30%) 14(70%) 70% 
3. Cough 15(75%) 6(40%) 9(60%) 60% 
4. Expectoration 9(45%) 3(33.33%) 6(66.67%) 66.67% 
5. Chest tightness 17(85%) 2(11.77%) 15(88.23%) 88.23% 
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IMPROVEMENT IN PEFR 
 
 
S.NO OP/IP NO AGE SEX BT PEFR 
AT 
PEFR 
1 C71982 42 M 220 260 
2 C84528 47 F 200 240 
3 C83020 51 F 150 170 
4 C86752 38 F 230 230 
5 4042 29 F 200 240 
6 C87417 35 M 220 290 
7 C90579 47 F 220 260 
8 C77301 24 F 160 220 
9 4086 35 F 170 250 
10 C85121 21 M 220 270 
11 5043 23 M 220 340 
12 4097 36 F 230 280 
13 C91984 41 M 250 250 
14 C92779 27 F 200 260 
15 C92780 37 F 180 180 
16 5077 60 M 130 200 
17 C57806 39 M 230 300 
18 C97429 31 M 250 250 
19 C94448 39 F 180 260 
20 C74388 51 M 220 320 
 
 
 
 
 
 
 
 
 
 
STATISTICAL ANALYSIS 
 
All collected data were entered into MS Excel software using different columns as variables 
and rows as patients. SPSS software was used to perform statistical analysis. Basic 
descriptive statistics include frequency distributions and cross-tabulations were performed. 
The quantity variables were expressed as Mean ± Standard Deviation and qualitative data as 
percentage. A probability value of <0.05 was considered to indicate as statistical significance. 
Paired ‘t’ test was performed for determining the significance between before and after 
treatment. 
 
Paired t test for Symptoms before and after treatment: 
Variable Obs Mean Std.dev t.value P value 
Before symptoms 20 
 
4.05 
 
0.759 
 
12.990 P<0.0001 
After symptoms 20 1.00 0.973 
 
For Symptoms, the mean and standard deviation  before treatment is 4.05±0.759 and after 
treatment is 1.00±0.973, which is statistically significant(p<0.0001). 
 
Paired t test for AEC before and after treatment: 
Variable Obs Mean Std.dev t.value P value 
Before treatment 20 
 
524.65 
 
169.341 
 
4.283 P<0.0001 
After treatment 20 320.35 189.553 
 
For AEC, the mean and standard deviation  before treatment is 524.65±169.341 and after 
treatment is 320.35±189.553, which is statistically significant(p<0.0001). 
 
Paired t test for PEFR before and after treatment: 
Variable Obs Mean Std.dev t.value P value 
Before treatment 20 
 
204.00 
 
32.831 
 
-6.521 P<0.0001 
After treatment 20 253.50 42.212 
 
For  PEFR, the mean and standard deviation before treatment is 204.00±32.831 and after 
treatment is 253.50±42.212, which is statistically significant(p<0.0001). 
 
TOXICOLOGY TABLES 
      Trial drug II, Table 5: Dose finding experiment and its behavioural Signs of Toxicity 
No Dose 
mg/kg 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 
1. 500 + - - + - + - - - - - - - - - - - - -  - 
2. 1000 + - - + - + - - - - - - - - - - - - -  - 
3. 2000 + - - + - + + - - - - - + - - - - + + - 
1. Alertness 2. Aggressiveness 3. Pile erection 4. Grooming  5. Gripping  6. Touch Response 7. Decreased Motor Activity 8. Tremors 9. 
Convulsions 10. Muscle Spasm 11. Catatonia 12. Muscle relaxant 13. Hypnosis 14. Analgesia 15.Lacrimation 16. Exophthalmos 17. Diarrhoea 
18. Writhing 19. Respiration 20. Mortality 
 
Trial drug II, Table 6. Body wt (g) of rats exposed to Singathi Chooranam for 28days. 
Dose (mg/kg/day) Days 
1 7 14 21 28 
Control 120.19±4.00 122.10±3.44 125.19±4.34 128.14±5.11 130.04±3.56 
100 122.64±4.18 124.75±4.18 127.33±4.12 129.20±5.52 130.14±4.45 
200 127.10±4.00 129.50±3.55 124.15±3.88 126.12±4.84 128.16±4.34 
400 124.16±3.54 126.44±4.32 128.10±4.10 130.04±3.96 132.12±5.20 
Values are mean ± S.E.M. (Dunnet ’t' test). nsP>0.05; Vs Control N=6. 
 
Trial drug II, Table 7. Food intake of rats exposed to Singathi Chooranam for 28days. 
Dose (mg/kg/day) Days (gms/rats) 
1 7 14 21 28 
Control 42.46±2.88 45.11±2.50 50.74±2.38 50.14±2.62 52.40±3.00 
100 40.20±2.51 45.20±2.46 42.23±2.88 50.49±2.24 48.14±3.41 
200 41.15±2.17 42.56±2.34 44.50±2.64 45.53±3.00 46.30±3.12 
400 45.24±2.22 45.46±2.57 45.22±2.50 45.51±2.89 45.10±3.14 
Values are mean ± S.E.M. (Dunnet ’t' test). nsP>0.05; Vs Control N=6. 
 
    Trial drug II, Table 8. Water (ml/day) intake of rats exposed to Singathi Chooranam for 28days. 
Dose (mg/kg/day) Days(ml/rat) 
1 7 14 21 28 
Control 52.20±2.12 52.18±3.04 52.46±3.02 52.14±3.20 51.15±3.00 
100 51.11±2.36 52.12±2.88 55.00±3.12 54.22±3.05 55.12±2.41 
200 42.26±2.48* 44.10±3.00 42.73±3.10 42.20±2.31 42.10±3.50 
400 54.00±3.44 52.17±3.13 51.42±3.00 52.11±2.62 50.52±3.00 
Values are mean ± S.E.M. (Dunnet ’t' test). *P<0.05; Vs Control N=6. 
 
 
Trial drug II, Table 9. Hematological parameters after 28days treatment with Singathi Chooranam. 
Parameter Control 100 mg/kg 200 mg/kg 400 mg/kg 
RBC (millions/cu.mm) 5.01±0.32 5.12±0.35 5.15±0.52 5.44±0.36 
Hb (g/dl) 13.47±0.78 13.99±0.86 14.2±1.4 14.00±1.2 
PCV (%) 44.18±3.12 44.05±3.10 44.10±2.92 44.30±2.81 
WBC(cells/cu.mm) 7882±361.4 8324±312.4 8417±368.1 8542±225.2 
Neutrophil (%) 45.10±2.18 42.36 ±2.78  43.00±3.1 42.45±3.0 
Lymphocytes (%) 44.25±2.45 43.26±2.44  43.28±2.56 44.34±2.2 
Eosinophil’s (%) 3.7±0.42 3.2±0.50 3.4±0.41 3.5±0.38 
Monocytes (%) 4.2±0.30 4.1±0.31 4.2±0.4 4.1±0.4 
Basophils (%) 0±0 1.0±0 0±0 0±0 
Platelets (105 cells/cu.mm) 1.67±0.07 1.52±0.05 1.75±0.7 1.62±0.5 
MCV(Fl) 72.2±1.8 69.2±1.2 73.4±2.0 73.1±2.1 
MCHC (pg) 29.5±2.2 28.41±2.4 29.2±2.1 30.00±2.5 
Values are mean ± S.E.M. (Dunnet ’t' test). nsP>0.05; Vs Control N=6. 
 
 
 
 
 
Trial drug II, Table 10. Effect of Singathi Chooranam biochemical (LFT, RFT, Lipid Profile) Parameters 
Values are mean ± S.E.M. (Dunnet ’t' test). nsP>0.05; Vs Control N=6. 
 
       Parameter Control 100 mg/kg 200 mg/kg 400 mg/kg 
Glucose (mg/dL) 82.22±4.10 80.02±4.48 79.75±3.88 78.62±4.64 
Total Bilirubin (mg/dL) 0.210±0.03 0.212±0.05 0.214±0.05 0.212±0.04 
Bilirubin direct (mg/dL) 0.1±0.03 0.1±0.02 0.1±0.03 0.1±0.04 
Creatinine (mg/dL) 0.91±0.05 0.93±0.04 0.92±0.04 0.90±0.04 
BUN (mg/dL) 17.24±1.48 18.02±1.32 17.58±1.46 17.85±1.39 
AST (IU/L) 128.1±5.28 126.4±5.10 125.4±5.22 127.4±5.72 
ALT (IU/L) 35.14±3.15 34.48±2.99 35.00±2.46 34.92±2.75 
ALP (IU/L) 66.11±4.41 67.10±3.82 66.12±4.30 65.41±4.44 
Total cholestrol (mg/dL) 56.10±5.10 57.24±5.52 56.42±5.44 56.19±4.92 
Total protein (g/dL) 7.20±0.48 7.48±0.54 7.42±0.70 7.50±0.72 
Albumin (g/dL) 2.81±0.07 2.72±0.05 2.70±0.05 2.75±0.05 
Urea(mg/dL) 55.00±2.48 54.78±3.36 55.42±2.48 54.44±2.12 
Uric acid (mg/dL) 1.7±0.10 1.6±0.12 1.6±0.14 1.47±0.10 
Na m.mol 143.66±5.00 142.8±4.12 140.32±4.21 140.41±5.10 
K m.mol 20.24±2.56 19.00±1.05 20.14±1.78 20.47±1.86 
Cl m.mol 103.11±4.21 104.12±4.10 103.24±4.24 102.12±4.11 
HDL(mg/dL) 13.33±1.00 13.14±1.22 13.17±1.34 13.28±1.45 
LDL(mg/dL) 43.34±2.21 43.38±3.42 42.14±3.13 42.12±3.20 
VLDL(mg/dl) 15.45±2.62 15.90±2.60 15.48±2.35 15.96±2.12 
Triglycerides (mg/dl) 86.38±3.44 86.38±2.45 87.42±2.21 88.30±2.58 
Trial drug II, Table-11 Urine Analysis 
Parameters 
Control 100 mg/kg 200 mg/kg 400 mg/kg 
Colour Yellow Yellow Yellow Yellow 
Transparency Clear Slightly turbid Slightly cloudy Slightly turbid 
Specific gravity 1.010 1.010 1.010 1.010 
PH >7.2 >8.0 >8.0 >9.0 
Protein Nil 3+ 3+ 3+ 
Glucose Nil Nil Nil Nil 
Bilirubin -ve -ve -ve -ve 
Ketones -ve +ve +ve +ve 
Blood Absent Absent Absent Absent 
Urobilinogen Normal Abnormal Abnormal Abnormal 
Pus cells 0-cells/HPF 1-cell/HPF 2-cells/HPF 1-cell/HPF 
RBCs Nil Nil 0-1cells/HPF Nil 
Epithelial cells Nil 1-cell/HPF Nil 1-cell/HPF 
Crystals Nil Nil Nil Nil 
Casts Nil Nil Nil Nil 
 
 
 
 
 
Trial drug II, Table 12. Effect of Singathi Chooranam on organ weight 
Dose (mg/kg) Control 100 mg/kg 200 mg/kg 400 mg/kg 
Heart(g) 0.68±0.08 0.68±0.10 0.64±0.08 0.68±0.04 
Liver(g) 4.63±0.40 4.70±0.72 4.83±0.60 4.72±0.50 
Lung(g) 0.69±0.04 0.70±0.05 0.71±0.05 0.70±0.4 
Spleen(g) 0.69±0.04 0.68±0.04 0.70±0.05 0.69±0.05 
Kidney(g) 1.04±0.3 1.02±0.04 1.52±0.6 1.44±0.04 
Testis(g) 0.91±0.03 0.92±0.05 0.91±0.04 0.91±0.03 
Ovary(g) 0.04±0.01 0.04±0.02 0.04±0.02 0.04±0.02 
Brain 0.70±0.05 0.68±0.04 0.67±0.04 0.68±0.05 
Pancreas 1.42±0.04 1.44±0.06 1.48±0.12 1.50±0.10 
Uterus 0.78±0.04 0.84±0.07 0.80±0.04 0.80±0.05 
Values are mean ± S.E.M. (Dunnet ’t' test). nsP>0.05; Vs Control N=6. 
 
 
PHARMACOLOGICAL TABLES 
Trial drug II, Table-13: Effect of Singathi Chooranam on isolated Guinea pig ileum preparation  
 
Values are expressed in mean ± SEM, *p< 0.05: **P<0.01 compared with histamine alone induced contraction (41mm as 100%); n=3. 
 
 
 
Trial drug II, Table-14: Bronchodilator effect of Singathi chooranam on Histamine induced Bronchoconstriction. 
Treatment Pre-Treatment Exposition 
in seconds 
Post-Treatment Exposition in 
seconds 
Percentage Protection 
 
Singathi Chooranam 100mg/kg. p.o. 90.54 ±4.50 101.07±4.26 10.41% 
Singathi Chooranam 200mg/kg. p.o. 98.22±3.22 123.11±4.71** 20.21% 
Singathi Chooranam 400mg/kg. p.o. 94.28±3.46 127.52±4.66** 26.06% 
Promethazine (300mg/kg, p.o) 102.12±4.45 172.38±4.41** 40.75% 
 
N=6; Values are expressed as mean ± SEM; *Significant between pre and post treatment time (Student’s –‘t’) **P<0.01. 
 
S. No Dose of Histamine (μg/ml) 
Percent of maximum response 
Histamine alone 
Histamine+Singathi Chooranam 
(1mg/ml) 
1 10 2.4±0.7 1.8±0.5 
2 20 2.7±0.47 2.1±0.6* 
3 40 3.5±0.12 3.3±0.6* 
4 80 4.1±0.58 3.5±0.5** 
ERAIPPU - BEFORE INVESTIGATIONS 
 
S.
N
O 
OP/IP 
NO 
AGE SEX HB 
[g/ 
dl] 
TC 
[Cu. 
Mm] 
                DC TRBC 
[million/ 
Cu.mm] 
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Cu.mm 
    BLOOD   
     SUGAR 
[mg/dl] 
UREA 
[mg/ 
dl] 
 
CREAT 
[mg/ 
dl] 
CHOL 
[mg/ 
dl] 
                   LFT CA 
[mg
/ 
dl] 
 
PHOS 
[mg/ 
dl] 
 
U.A 
[mg/ 
dl] 
 
                                   URINE  
ALB SUGAR      DEP AF
B P% L% E% M%    F   PP SGOT 
Iu/L 
SGPT 
Iu/L 
ALP 
Iu/
L 
TP 
mg/d
l 
    F PP PU
S        
EPI 
1 C71982 42 M 15.8 10400 63 30 7 0 5.3 3.6 79 120 17 0.6 161 23 24 160 7.1 10.1 3.1 5.4 nil  nil nil 1-2 1-2 neg 
2 C84528 47 F 12.9 8200 60 23 16 1 4.2 3.7 91 108 17 0.5 224 18 19 138 6.5 10 3.5 6 nil  nil nil 2-3 2-3 neg 
3 C83020 51 F 12.1 6500 60 33 7 0 4.2 2.8 98 112 37 0.8 221 20 22 140 7 9.6 3.4 5.5 nil  nil nil 2-4 2-4 neg 
4 C86752 38 F 12.3 7800 58 30 12 0 4.2 1.8 103 125 17 0.5 142 14 15 156 7.6 9 3.2 5.3 nil  nil nil 2-4 1-2 neg 
5 4042 29 F 13.2 11400 74 22 4 0 4.5 2.6 73 89 22 0.6 145 22 27 168 7 10.2 2.6 4.4 nil  nil nil 3-4 3-4 neg 
6 C87417 35 M 15.1 8000 66 20 14 0 4.9 2.1 101 129 14 0.4 93 22 23 150 7.2 10.8 3.2 6.2 nil  nil nil 2-4 2-4 neg 
7 C90579 47 F 13.2 9400 65 30 6 0 4.7 3.7 107 119 15 0.4 162 26 27 147 6.9 10.5 3.2 5.6 nil  nil nil 2-4 2-4 neg 
8 C77301 24 F 14 12800 56 34 10 0 5.3 2.9 92 106 22 0.6 167 20 21 130 7.3 10.7 3 4.9 nil  nil nil 2-4 2-4 neg 
9 4086 35 F 12.1 9400 64 30 6 0 4.2 2.3 81 105 24 0.7 166 15 16 140 7.5 10.5 3.2 6 nil  nil nil 1-2 1-2 neg 
10 C85121 21 M 15.9 8500 70 20 10 0 5.4 2.9 94 114 14 0.4 91 20 21 176 6.6 11 3.6 3.2 nil  nil nil 1-2 1-2 neg 
11 5043 23 M 15.9 4800 56 37 7 0 5.6 2.4 75 89 18 0.5 83 27 24 166 5.7 11.6 3.4 7.6 nil  nil nil 2-3 2-3 neg 
12 4097 36 F 13 9400 52 43 5 0 4.4 2.3 73 95 16 0.5 108 11 10 135 6.9 10.8 2.9 5 nil  nil nil 1-2 1-2 neg 
13 C91984 41 M 16.3 6100 34 57 9 0 5.2 2 105 114 32 0.8 197 14 16 150 7.3 10.6 3.1 5.1 nil  nil nil 3-4 2-3 neg 
14 C92779 27 F 13 7200 70 20 9 1 4.3 3 89 117 24 0.6 151 11 12 175 5.7 10.1 2.9 3 nil  nil nil 1-2 2-4 neg 
15 C92780 37 F 13.4 8600 52 40 7 1 4.4 3.2 103 131 30 0.7 106 12 15 136 5.6 10.6 3 3.2 nil  nil nil 2-4 2-4 neg 
16 5077 60 M 12.4 6600 69 22 9 0 4.1 2.7 89 118 19 0.5 127 20 22 184 5.7 11 3.1 3.4 nil  nil nil 1-2 1-2 neg 
17 C57806 39 M 13.2 8800 59 30 10 1 6.2 2.5 90 123 23 0.6 163 20 22 179 6.5 10 2.9 5 nil  nil nil 4-5 3-4 neg 
18 C97429 31 M 16.8 6900 57 30 13 0 5.2 1.9 101 117 20 0.6 146 15 17 176 6.6 10 3.1 4.4 nil  nil nil 2-3 2-3 neg 
 C94448 39 F 12.3 4700 58 31 11 0 4.1 2.5 84 101 17 0.5 142 12 14 160 5.7 10.2 2.9 3 nil  nil nil 1-2 1-2 neg 
20 C74388 51 M 13.6 7900 54 35 10 2 4.8 2.3 83 108 18 0.5 171 30 33 148 7.1 10.6 3.5 5 Nil nil nil 1-2 2-3 neg 
ERAIPPU -AFTER INVESTIGATIONS 
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NO 
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E
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M
% 
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SGOT 
[Iu/L] 
 
SGPT 
Iu/L] 
 
ALP 
Iu/L] 
TP 
[m
g/ 
dl] 
 
F PP PUS EPI 
 
1 C71982 42 M 15.2 10100 65 30 5 0 5.2 3.5 81 100 15 0.5 153 35 25 194 6.1 12 3.5 6.8 nil nil nil 2-3 2-3 neg 
2 C84528 47 F 13 7900 59 31 10 0 4.2 3.9 100 112 15 0.4 220 14 15 141 7.5 10 3 3.9 nil nil nil 2-4 3-5 neg 
3 C83020 51 F 12.1 8600 57 39 4 0 4.2 2.7 100 120 21 0.6 181 29 30 166 6.6 10 3.2 3.7 nil nil nil 1-2 1-2 Neg 
4 C86752 38 F 13 8100 56 30 12 2 4.5 3.7 102 120 19 0.5 159 12 14 140 5.8 11 3.4 4.3 nil nil nil 2-3 2-3 Neg 
5 4042 29 F 13.2 10400 68 29 3 0 4.5 2.4 75 99 14 0.5 105 12 14 166 5.7 11 3.1 5 nil nil nil 1-2 1-2 Neg 
6 C87417 35 M 15 7600 61 34 5 0 4.5 2.1 81 100 19 0.5 101 32 39 197 6.6 11 3.1 5.1 nil nil nil 2-4 2-4 Neg 
7 C90579 47 F 14 8600 68 29 3 3 5.1 3.1 95 107 15 0.4 130 18 21 142 5.3 10 3.2 3 nil nil nil 1-2 2-3 Neg 
8 C77301 24 F 14 10900 63 30 6 1 5.2 3.2 86 100 23 0.7 146 16 18 136 7.4 11 3.1 3.1 nil nil nil 2-3 1-2 Neg 
9 4086 35 F 12.5 10500 64 32 4 0 4.4 3.8 82 107 19 0.6 152 21 22 160 5.6 10 2.9 3.5 nil nil nil 1-2 2-3 Neg 
10 C85121 21 M 15.6 7200 67 27 5 1 5.3 3 93 109 14 0.4 102 18 20 180 6.6 11 3.2 5.5 nil nil nil 3-4 2-3 Neg 
11 5043 23 M 16.8 9000 68 34 8 0 5.9 2.8 88 96 18 0.5 83 18 20 174 6.5 11 2.8 4.6 nil nil nil 1-2 2-3 Neg 
12 4097 36 F 13.5 7600 61 34 3 2 4.5 2.1 81 100 19 0.5 101 32 39 197 6.6 11 3.1 5.1 nil nil nil 2-4 2-4 Neg 
13 C91984 41 M 16.1 5800 66 24 10 0 5.1 1.7 88 106 26 0.7 253 20 21 179 7 11 3.1 4.1 nil nil nil 1-2 2-3 Neg 
14 C92779 27 F 11.9 7300 59 35 5 1 4.3 3 92 120 17 0.6 199 13 14 141 6.7 11 3 3.1 nil nil nil 4-8 4-8 Neg 
15 C92780 37 F 11.5 9300 63 30 7 0 4.1 2.8 102 126 14 0.5 126 16 17 139 6.5 11 3.2 3 nil nil nil 3-6 4-8 Neg 
16 5077 60 M 12.6 4900 59 36 5 0 4.2 2.7 100 118 30 0.8 104 27 28 172 6 11 3.2 3 nil nil nil 3-6 3-6 Neg 
17 C57806 39 M 13.6 7700 62 33 5 0 5.9 2.8 94 118 18 0.5 160 20 22 192 6 10 2.8 4.7 nil nil nil 2-4 2-4 Neg 
18 C97429 31 M 15 7200 60 27 13 0 5.2 1.9 105 124 18 0.6 152 20 22 175 6.1 10 3.1 4.5 nil nil nil 2-4 2-4 Neg 
19 C94448 39 F 12.4 7700 64 32 4 0 4.4 2.4 87 101 26 0.7 173 15 17 173 5.7 9.9 2.8 5 nil nil nil 2-3 2-3 Neg 
20 C74388 51 M 14.3 8000 61 33 6 0 5 2.4 98 116 14 0.4 163 31 33 215 7.5 9.9 2.9 5.5 nil nil nil 2-4 2-4 Neg 
 
 
SPECIFIC INVESTIGATIONS FOR ERAIPPU 
 
 
S.NO OP/IP NO AGE 
SEX 
 
           E[%] ½  Hr ESR             [mm] 
1 Hr ESR 
               [mm] 
        AEC 
[cellc/cu.mm] PEFR 
   BT   AT    BT      AT       BT      AT     BT    AT      BT      AT 
1 C71982 42 M 7 5 8 2 14 8 480 260 220 260 
2 C84528 47 F 16 10 8 4 18 8 670 480 200 240 
3 C83020 51 F 7 4 14 2 22 8 463 370 150 170 
4 C86752 38 F 12 12 12 10 26 20 600 600 230 230 
5 4042 29 F 4 3 4 8 8 12 650 500 200 240 
6 C87417 35 M 14 5 6 2 18 4 411 256 220 290 
7 C90579 47 F 6 3 12 4 26 12 333 111 220 260 
8 C77301 24 F 10 6 4 2 8 10 866 166 160 220 
9 4086 35 F 6 4 8 6 26 8 644 56 170 250 
10 C85121 21 M 10 5 12 2 16 4 633 88 220 270 
11 5043 23 M 7 8 2 2 4 4 277 280 220 340 
12 4097 36 F 5 3 2 2 8 4 644 178 230 280 
13 C91984 41 M 9 10 12 12 16 16 536 580 250 250 
14 C92779 27 F 9 5 10 6 22 10 578 460 200 260 
15 C92780 37 F 7 7 8 4 16 10 400 400 180 180 
16 5077 60 M 9 5 8 4 28 14 122 64 130 200 
17 C57806 39 M 10 5 14 4 22 10 430 200 230 300 
18 C97429 31 M 13 13 12 12 20 22 696 706 250 250 
19 C94448 39 F 11 4 16 4 24 8 600 346 180 260 
20 C74388 25 M 10 6 10 4 18 8 460 306 220 320 
IMPROVEMENT IN PROGNOSIS OF SYMPTOMS OF ERAIPPU 
 
 S.NO OP/IP NO AGE SEX 
WHEEZE DYSPNOEA COUGH EXPECTORATION CHEST TIGHTNESS 
BT AT BT AT BT AT BT AT BT AT 
1 C71982 42 M         +       _       +        +       +        _         _         _         +          _ 
2 C84528 47 F         +       _       +        +       +        _          +         _         +          + 
3 C83020 51 F         +       _       +         _       _        _          _         _         +          _ 
4 C86752 38 F         +       _       +       _       +        +          +         _         _          _ 
5 4042 29 F         +       +       +       _       +        +          +         +         +          _ 
6 C87417 35 M         +       _       +       +       +        +          _         _         +          _ 
7 C90579 47 F         +       _       +       +       _        _          _         _         +          _ 
8 C77301 24 F         +       _       +       _       +        _          _         _         +          _ 
9 4086 35 F         +       _       +       _       +        +          _         _         +          _ 
10 C85121 21 M         +       _       +       _       +        _          _         _             +          _ 
11 5043 23 M         +       _       +        _       +        +          +         _         +          _ 
12 4097 36 F         +       _       +       _       +        _          +         +         +          _ 
13 C91984 41 M         +       _       +       _       +        +          +         +         _          _ 
14 C92779 27 F         +         _       +       _       +        _          _         _         +          _ 
15 C92780 37 F         +       +       +       +       _        _          _         _         +          + 
16 5077 60 M         +       _       +        +       +        _          +         _         +          _ 
17 C57806 39 M         +       _       +       _       +        _          +         _         _          _ 
18 C97429 31 M         +       +       +       _       +        _          +         _         +          _ 
19 C94448 39 F         +       _       +        _       _        _          _          _         +          _ 
20 C74388 51 M         +       _       +       _       _        _          _         _         +          _ 
BIBILIOGRAPHY 
1. http://health.nytimes.com/health/guides/disease. 
2. Medical Journal Armed Forces, India,Vol.68,issue 4,Oct 2012. 
3. http://www.who.int/vmnis/anaemia/prevalence/en/. 
4. Indian Journal Medical Research 130, November 2009. 
5. Indian Journal of Haematology and Blood Transfusion,2012. 
6. Journal Of Siddha,Vol.2,Jan-June 2009, issue.I. 
7. Dr.M.Shanmugavelu,H.P.I.M., Noi Naadal Noi Muthal Naadal thirattu, Part II,2003, 
Department of Indian Medicine and Homeopathy. 207, 149.  
8. Murugesa Mudaliar,Gunapadam Mooligai Vaguppu, Part I, Dept., of Indian Medicine 
and Homeopathy,7th Edition,2003,808-809. 
9. Saraku Suthi Sei Muraigal, Department of Indian Medicine and Homeopathy, 
Chennai-106, 1st Edition, 2008, Dr.Aanaivaari Ananthan,Ph.D. 4, 6, 7, 13. 
10. Kannusamy Parambarai Vaithiyam, B.Rathina nayagar and Sons, Chennai-79, 2006, 
155,215,116,243,169,195,239,173,133,107,244,238,330. 
11. Dr.A.K.Nadkarni, Indian Materia Medica, Volume I, Ramdas Bhatkal for Popular 
Prakashan Pvt. Ltd, Mumbai.2005, 170. 
12. USDA(United States of Department of Agriculture) Plants Database. 
13. Kuppusamy Mudhaliyar,H.P.I.M., Siddha Marurhuvam Pothu, Department of Indian 
Medicine and Homeopathy,6th Edition, 2004,345-350, 241-245. 
14. KV Krishna Das,Textbook of Medicine, 5th Edition,Jaypee Brothers Medical 
Publishers (P) Ltd,2008,984, 989, 990. 
15. R Alagappa, Manual of Practical Medicine,Fourth edition,Jaypee Brothers Medical 
Publishers (P) Ltd, 2011,347. 
16. P.C.Das,Textbook of Medicine,4th Edition,Current Book Inernational, 
Calcutta,2007,270-271. 
17. Thomas M.Delvin, Text Book of Biochemistry with Clinical correlations,Kaye pace-
2011,1086. 
18. http://www.medicinenet.com 
19. Dr.Uththamarayan,H.P.I.M., Thotra Kirama Araichiyum Siddha Maruthuva 
Varalarum, Department of Indian Medicine and Homeopathy,3rd Edition,2003, 345-
350.  
20. http://www.thoracomedicine.org/article,2008. 
21. D Behera Foreword VK Vijayan,Bronchial Asthma 2nd Edition,2005,Jaypee Brothers 
Medical Publishers (P) Ltd. 
22. http://en.wikipedia.org/wiki/asthma. 
23. Kumar and Clark, Clinical Medicine, 5th Edition, 2002, Parveen kumar, Michael 
clark, WB Saunders, 874. 
24. Indian Journal Medical Research, Aug 2011. 
25. Harrison’s Principles Of Internal Medicine, Volume II, 16th Edition, 2005, Mc Graw 
Hill, Medical Publishing Division, 1508. 
26. http://times of India.indiatimes.com/topic/asthma, 2012. 
27. http://en.wikipedia.org/wiki/siddha-medicine. 
28. Journal Of National Remedies, Vol.3, issue 2, June 2003. 
29. Agathiyar Mani ennum Vaithiya Chinthamani Venba 4000, 1st Edition, 1996, 
Dr.S.Prema, M.D(S), Thamarai Noolagam, Chennai 26, 183, 252, 254, 269, 365. 
30. C.Kannusami pillai, Sigicha Rathna Deepam ennum Vaithiya nool, 1st Edition, 2007, 
B.Rathina nayagar and Sons, Chennai-79, 28, 29, 30, 35. 
31. Dr.R.Thiyagarajan, Gunapadam Thathu Jeeva Vaguppu,Part 2 & 3, 4th Edition, 2004, 
Department of Indian Medicine and Homeopathy, Chennai-106,  369-371. 
32. Siddha Marunthugalin Seimurai, India Maruthuvargal Kooturavu Marunthu Sei 
Nilayam matrum Pandagasaalai, Chennai-41, 14th Edition, 2003, 175, 177, 224, 284. 
33. Agathiyar Vaithiya Kaviyam-1500, 1st Edition, 1994, Tamil PalKalai Kazhagam, 
Thanjavur-613005,  790. 
34. Database On Medicinal Plants Used in Ayurveda, Central Council For Research in 
Ayurveda and Siddha Jawahar Lal Nehru Bharatiya Chikista Avum Homeopathy 
Anusandhan Bhawan, New Delhi. Volume I - 73-75, Volume III – 158 & 160, 282 & 
284, 472, 474 & 475, Volume IV – 122 & 124, 269, 272 & 273, Volume V – 187, 189 
& 190, 315, 317 & 319, Volume VII – 135 to 138, 169 to 171. 
35. http://www.phcogrev.com/article, Role of herbs in the management of Asthma, 
Review Article, 2009, Volume 3, issue 6. 
36. Journal of Complementary and Integrative Medicine. Volume 7, Issue 1, Pages –, 
ISSN (Online) 1553-3840, DOI: 10.2202/1553-3840.1401, September 2010 
37. Indian journal of Medical Research 
38. Journal of Scientific and Industrial Research, Volume 69, Oct. 2010. 
39. Indian journal of Pharmacology, 1994 
40. International Journal of Herbal Drug Research, Vol I, Issue 1, 15-18, 2011 
41. International journal of pharmacology, 2012, volume 8, issue 3  
42. Screening of Indian plants for biological activity. 
43. Indian herbal remedies, Rational Western Therapy, Ayurvedic and Traditional Usage, 
Botany, edited by C.P.Khare, 2004 
44. http://en.wikipedia.org/org/wiki/halite. 
45. Dr.A.K.Nadkarni, Indian Materia Medica, Volume II, Ramdas Bhatkal for Popular 
Prakashan Pvt. Ltd, Mumbai.2005, 108. 
46. Siddha Materia Medica (Mineral and Animal Kingdom), Department of Indian 
Medicine and Homeopathy, Chennai-106, 1st Edition, 2008, Dr.Anaivari 
Ananthan,Ph.D., Dr.M.Thulasimani,M.D.(Pharmaco). 303 & 304. 
47. http://www.medscape.com 
48. K Sembulingam Prema Sembulingam, Essentials of Medical Physiology, 5th Edition, 
2007, JAYPEE Brothers Medical publishers (P) Ltd,78. 
49. http://www.botanical-online.com/alkaloids 
50. www.medscape.com 
51. www.medind.nic.in, Review article, Nutririon and Asthma, 2007, K.B.Gupta, Manish 
verma. 
 
 PHARMACOLOGICAL REFERENCES-DRUG I 
1. Bowman WC, Rand MJ (1980). Textbook of Pharmacology. Blackwell Scientific 
publication, New York pp. 21-31.  
2. Clemens MR, Remmer H, Waller HD (1984). Phenylhydrazine-induced lipid 
peroxidation of red blood cells: in vitro and in vivo monitoring by the production of 
volatile hydrocarbons. Biochem. Pharmacol. 33: 1715-1718. 
3. Dacie JV, Lewis SM (1994). Practical Haematology 8th ed. ELBS, Churchill, 
Livingstone. pp. 49-59. 
4. Diallo A, Gbeassor M, Vovor A, Eklu-Gadegbeku K, Aklikokon K, Agbonon A, 
Abena AA, de souza C, Akpagana K (2008). Effect of Tectona grandis on 
phenylhydrazine-induced anaemia in rats. Fitoterapia 79(5): 332-336. 
5. Dina OA, Adedapo AA, Oyinloye OP, Saba AB (2000). Effect of T.occidentalis 
extract on experimentally induced anaemia in domestic rabbits. Afr. J. Biomed. Res. 
3: 181-183. 
6. Duff S (2008). Types of Anaemia. www,innvista.com.  
7. Erah OP, Asonye CC, Okhamafe OA (2003). Response of Trypanosoma Brucei 
brucei induced anaemia to a commercial herbal preparation. Afr. J. Biotechnol. 2 (9): 
307-311. 
8. Muriel C, Jean-Yves LH (1998). Prevalence of and Risk Factors of Anaemia in young 
children in Southern Cameroon. Am. J. Trop. Med. Hyg. 58 (5): 606-611. 
9. Nelson C, Erikson K, Pinero DJ, Beard JL (1997). In Vivo dopamine metabolism is 
altered in iron deficient anaemic rats. J. Nutr. 127(12): 2282-2288. 
10. Oma NU (1991). Iron Deficiency anaemia. Clin. Pharm. Herbal Med. 7 (116): 12-15. 
11. Orna NU (1991). Iron deficiency anaemia. Clin. Pharm. Herb. Med. 7: 12-16. 
12. Ramzi SC, Vinay K, Stanley LR (1994). Pathologic Basis of Disease, 5th edn. Pub. 
W.B. Saounders Company. pp. 586-590.  
 
PHARMACOLOGICAL REFERENCES-DRUG 2 
1. Abe, T. Yoshida, K. Omata, I. Segawa, Y.Mastuda, K.and Nagai, H. Effects of ZCR 
2060 on allergic airway inflammation and cell activation in guinea pigs, J. Pharm. 
Pharmacol., 46,876 (1994). 
2. Abraham, E. Deodhar, M.M. Natu, M.V.A comparative study of the bronchodilator 
activity of the calcium antagonists on histamine induced bronchospasm in guinea 
pigs, Indian J. Pharmacol., 24,231-232, (1992). 
3. Anilkumar D, Ramu P. (2002). Effect of Methanolic extract of Benincasa hispida 
against histamine & acetycholine induced bronchoplasm in Guinea pigs. Indian J. 
Pharmacology, 34, pp. 365-366. 
4. Anilkumar, D. and Ramu, P. Effect of methanolic extract of Benincasa hispida 
against histamine and acetylcholine induced bronchospasm in guinea pigs, Indian J. 
Pharmacol,. 34,365-366, (2002). 
5. Babe, K.S. and Serafin, W.E. “Goodman and Gilman’s The Pharmacological basis of 
Therapeutics”. In; Histamine, Bradykinin and their antagonists, Hardman, J.G. 
Limdird, L.E. Molinoff, P.B. Ruddon, R.N. and Gilman, A.G. (eds), 9th Edn, Mc 
GrawHill, New York, 587-588 (1996). 
6. Bhujbal SS, Kumar D, Deoda RS, Deore TK, Patil MJ. (2009). Antiasthmatic activity 
of roots of Hemidesmus indicus R. Br. Pharmacologyonline, 1, pp. 209-216. 
7. Ghosh, M.N. “Fundamentals of Experimental Pharmacology”, Singha.J. (Ed), 
Calcutta Scientific Book Agency,. Calcutta, 177-82, (1984). 
8. Gokhale, A.B. and Saraf, M.N. Bronchoprotective effect of ethanolic extract of 
Tephrosia purpurea invivo, Indian Drugs., 37(7), 346-347, (2000). 
9. Govindan SS, Viswanathan S. (1999). A Pilot Study on Clinical Efficacy of Solanum 
xanthocarpum and Solanum trilobatum in Bronchial Asthma. Journal of 
Ethnopharmacology, 66, pp. 205-210. 
10. Kumar D, Bhujbal SS, Deoda RS, Mudgade SC. Bronchodilator activity of aqueous 
extract of stem bark of Ailanthus excelsa Roxb. Phcog Res., 2, 102-106. 
11. Nair, A.M. and Saraf, M.N. Inhibition of antigen and compound 48/80 induced 
contractions of guinea pig trachea by the ethanolic extract of leaves of Virtex negundo 
Linn, Indian J. Pharmacol., 27, 230-233, (1995). 
12. Saraf MN, Patwardhan BK. (1988). Pharmacological studies on Sarcostemma 
brevistigma Whight part II. Bronchodilator activity. Indian Drugs, 26, pp. 54-57. 
13. Singh S. Agrawal S. (1990). Bronchorelaxant activity of Belamcanda chinensis 
(Adans).; Ind. J. Pharmacol., 22, pp. 107-109. 
 
 
 
 
ACKNOWLEDGEMENT 
 
 I feel immense awe and colossal gratitude in my heart of hearts to God Almighty 
for making this dissertation have its present form. 
 I express my sincere thanks to the Vice-Chancellor, The Tamilnadu Dr.MGR 
medical university Chennai-32. 
 I express my sincere thanks to Prof. Dr.K.Manickavasakam M.D(S), Director  
National Institute of Siddha, Tambaram sanatorium,Chennai-47. 
I express my gratitude to  Dr.M.Rajasekaran M.D.(S)., Associate Prof., Head of 
the Department of Gunapadam i/c, National Institute of Siddha, Tambaram sanatorium, 
Chennai-47, for his encouragement, suggestions and valuable guidance in this dissertation 
work. 
 I express my sincere thanks to Dr. A.Rajendra kumar M.D.(S)., Associate 
professor, Gunapadam department, NIS,Chennai-47, for his suggestions. 
I express my sincere thanks to Dr .S.Visweswaran M.D.(S)., Lecturer, 
Gunapadam department, NIS,Chennai-47, for his suggestions. 
 I express my sincere thanks to Dr.S.Sivakumar M.D.(S)., Lecturer, Gunapadam 
department, NIS,Chennai-47, for his suggestions. 
 I express my sincere thanks to Dr.A.Mariappan M.D.(S)., Lecturer, Gunapadam 
department, NIS,Chennai-47, for his suggestions. 
I express my grateful thanks to Dr.J.Anbu Ph.D.,Vels college of pharmacy, 
Pallavaram, Chennai. 
I express my sincere thanks to Dr.D.Aravind M.D.(S) M.Sc., Assistant Professor, 
Medicinal Botany,NIS,Chennai-47. 
I express my sincere thanks to Dr.V.Suba M.Pharm, P.hD., Assistant Professor in 
Pharmacology, NIS, Chennai-47. 
I express my sincere thanks to Dr.Muthuvel, Assistant Professor, Biochemistry 
Dept.,NIS,Chennai-47. 
 I express my sincere thanks to Mr.M.Subramanian MSc,SRO,NIS,Chennai-47, for 
his guidance in statistical analysis. 
 I express my grateful  thanks to Dr.C.Saravana babu, M.Pharm.,Ph.D., SRMC, 
Porur, Chennai. 
  
 







